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Summary 
Skeletal metastases are the most common form of secondary tumour associated with 
prostate cancer (PCa). Aberrant function of bone cells neighbouring these tumours leads to 
the development of osteolytic or osteoblastic lesions, with the latter being most commonly 
seen with PCa. Communication between PCa cells and bone cells at these secondary sites 
governs both the formation/development of the associated lesion, as well as growth of the 
secondary tumour. 
We isolated small extracellular vesicles (sEVs), known to facilitate intercellular 
communication, from PC3 cells and examined their effect on cells of the bone 
microenvironment.  
Using Next Generation Sequencing (NGS), we profiled the miRNA content of sEVs from PC3 
cells, showing that miR-221-3p and miR-16-5p were highly expressed. We then showed these 
PC3 sEVs are able to stimulate increased differentiation of 7F2 osteoblast cells, with 
Ingenuity® Pathway Analysis (IPA®) revealing miR-16-5p as likely involved in this signalling.  
Using the NGS data, miR-16-5p targets in 7F2 cells, possibly facilitating the increased 
osteoblastogenesis, were selected; AXIN2, PLSCR4, ADRB2 and DLL1. We then confirmed the 
targeting of these genes by sEV miR-16-5p, and subsequently developed 7F2 cell lines 
overexpressing them. Overexpression of PLSCR4, ADRB2 and DLL1 lead to decreased 
osteoblastogenesis, whereas AXIN2 overexpression lead to increased osteoblastogenesis.  
We then examined the effect of PC3 sEVs on RAW 264.7 cells (osteoclast precursors), 
showing that the addition of PC3 sEVs decreased the osteoclastogenesis of RANKL treated 
RAW cells. 
These results indicate that PC3 sEVs induce osteoblastogenesis and inhibit 
osteoclastogenesis, mirroring, and potentially partially explaining the tendency of PCa 
secondary tumours to produce osteoblastic lesions.  
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1 Introduction 
1.1 Prostate: 
The prostate is a chestnut sized gland, belonging to the organs of the male reproductive 
system. The prostate surrounds the urethra immediately inferior to the bladder and is 
posterior in relation to the rectum, allowing its inspection rectally. The ducts of the prostate 
feed into the urethra, where prostatic secretions along with sperm from the testis make up 
roughly 1/3 of the fluid component of semen. The function of these secretions are to aid 
sperm survival and delivery to the ovum; for example, prostate specific antigen (PSA) thins 
the fluid to aid sperm motility, citrate acts as an energy substrate for sperm and zinc prevents 
the oxidation of citrate (Verze et al., 2016).   
1.1.1 Structure:  
1.1.1.1 Microanatomy: 
The prostate is comprised of three main cell types; exocrine glandular cells, smooth muscle 
cells and fibrous cells. The glandular tissues of the prostate are responsible for the 
production and secretion of the prostatic secretions found in semen. The fibrous component 
of the prostate provides support via large amounts of connective tissue, rich in dense, 
irregular collagen fibres. The expulsion of prostatic secretions is aided by the abundance of 
smooth muscle both within and around the prostate, which are strongly stimulated during 
ejaculation.  
1.1.1.2 Zones:  
The prostate is made of three zones (figure 1.1). The central lies furthest from the rectum 
whereas the peripheral zone is closest to the rectum and therefore is the area felt during a 
digital rectal examination (DRE). The transition zone lies between the central and peripheral 
zones and is commonly associated with an enlargement of the prostate known as benign 
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prostate hyperplasia (BPH). Some texts also refer to the stroma, a surrounding capsule of 
connective tissue and smooth muscle, as a zone of the prostate.  
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Figure 1.1: Anatomical diagram of the prostate showing distribution 
of the three zones: the central zone (red), the transition zone (green) 
and the peripheral zone (blue) (image curtesy of Shutterstock) 
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1.1.2 Lobes 
Whilst zones are often used to describe the prostate in the context of pathology, the lobe 
description is often favoured in terms of anatomy. The prostate is made of 5 lobes; anterior 
lobe (lying in front of the urethra), median lobe (found between the two ejaculatory ducts), 
two lateral lobes (the lateral sections of the gland, together make up the majority of the 
gland) and posterior lobe (the posterior portion of the gland).  
1.1.3 Prostate Morphogenesis  
Prostate morphogenesis originates within the embryonic urogenital sinus (UGS), an area 
present during the early development of the urinary and reproductive organs. Here, 
interactions between the stroma and epithelia drive the development of the mature prostate 
gland. Androgen-dependant signals from the UGS mesenchyme guides the early prostatic 
epithelium to form buds from the UGS which elongate and form canals characterised by an 
epithelium rich in tall columnar luminal cells (Cunha et al., 1983). The mesenchymal cells 
then form the adjacent smooth muscle, the patterning of which is determined by the 
interactions with the recently formed, adjacent epithelia (Hayward et al., 1996).  
1.1.4 Prostate Cancer 
Prostate cancer (PCa) is the most common form of cancer to occur in men with around 
382,000 cases in Europe a year. PCa is also the third leading cause of cancer related mortality 
in men behind lung and colorectal cancers (Ferlay et al., 2010). Prostate cancer is unique due 
to its often slow growing nature and the fact it almost exclusively presents in men over 50. 
Over 95% of primary prostate cancers present as adenocarcinoma, with the remaining cases 
being rare tuours such as small cell, intralobular and ductal tumours (Nelson et al., 2003). 
Although only 1 in 14 men will be diagnosed with prostate cancer at some point in their life, 
autopsy studies show that 50% of 50 year olds and 75% of 85 year olds present with prostate 
cancer related histological changes (Sakr et al., 1993).  
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1.1.4.1 Symptoms 
PCa symptoms are usually urinary in nature, due to the expansion of the prostate pressing 
on the urethra. These include difficulty urinating, urinating more frequently and the feeling 
that the bladder is not being fully emptied (NHS, 2014).  
1.1.4.2 Risk Factors 
As discussed PCa almost exclusively affects those over 50. A study by the American Cancer 
Society in 2007 found that incidence and mortality is higher in African-Americans compared 
to European Americans, and that conversely incidence is lower in Hispanic, Asian-American 
and Pacific Island men. Twin studies have shown that the genetic risk of PCa accounts for 
around 42% of total familial PCa risk (Lichtenstein et al., 2000), higher than the genetic risk 
of any other cancer.  
Lifestyle and dietary factors can also influence an individual’s chances of developing PCa. 
Salem et al. (2011) found that a diet high in fat increases the chances of developing PCa 
whereas diets high in tomato or garlic negatively correlate with PCa risk. A review by Allott 
et al. (2013) showed that although obesity appeared to be linked to decreased incidence of 
PCa, it was also linked to higher incidence of aggressive PCa, PCa related death, biochemical 
failure following radical prostatectomy and external-beam radiotherapy and complications 
following androgen deprivation therapy.   
Studies have also found that an increase in frequency of ejaculation, particularly between 
the ages of 20-30, can be linked to a decreased risk of developing prostate cancer (Giles et 
al., 2003; Leitzmann et al., 2004). 
1.1.4.3 Diagnosis 
Before a diagnosis can be made, biomarker levels are tested to determine a patient’s 
likelihood of having PCa. The most frequently tested biomarker in PCa is prostate specific 
antigen (PSA), with a PSA level of >4ng/ml being indicative of PCa risk (Crawford & DeAntoni, 
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1993; Moore et al., 1992; Pepe & Aragona, 2011). However PSA levels can be unreliable with 
an alarmingly high number of false negatives (15%) and false positives (66%) (Kang et al., 
2015). 
A patient with a PSA level of >4ng/ml is often given a digital rectal examination (DRE), this 
often unpleasant procedure involves feeling the prostate via the rectum for any 
abnormalities in size or shape. In the early stages of prostate cancer DRE can be unreliable if 
tumours have originated in zones distal from the rectum i.e. the central or transition zones 
(Green, 1993).   
If the PSA and DRE tests point towards an abnormality, a transrectal-ultrasound (TRUS) 
guided needle biopsy is performed. TRUS has been the guidance technique of choice since 
its discovery by Hodge et al. (1989). Again this procedure has a high false-negative rate, 
estimated at around 25% (Daneshgari et al., 1995).  
There are also a number of imaging techniques that can help in the diagnosis of PCa. TRUS 
has already been discussed, as a method of biopsy guidance rather than PCa imaging. TRUS 
can also be used to calculate the volume of the prostate for measuring PSA density (Terris & 
Stamey, 1991). Computerised tomography (CT) scanning has a limited role in prostate 
cancer, only being used in very advanced, high-grade, nodal tumours due to the fact CT scans 
can only pick up tumours of >1cm3 (O'Dowd et al., 1997). Magnetic resonance (MR) imaging 
can be effective if used at a high enough resolution, allowing the detection of PCa in zones 
of the prostate often missed by TRUS-biopsy such as the transition zone (Zakian et al., 2003). 
PET scanning can also be useful in PCa, not in diagnosis of primary PCa but in the locating of 
bone metastases or recurrent disease (Vali et al., 2015). 
1.1.4.4 Staging 
The most widely used staging system for prostate cancer is the The American Joint 
Committee on Cancer (AJCC) and International Union Against Cancer (UICC) tumour, node 
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and metastasis (TNM) system, where T= Primary tumour, N= Regional lymph nodes and M= 
Distant metastasis (Cheng et al., 2012).  
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1.1.4.5 Grading 
PCa tumours are also given a grade based on how much of the biopsy looks like healthy or 
cancerous tissue. A grade of 1-5 is given, with 1 representing healthy tissue, and 5 
representing the most poorly differentiated cancerous tissue. Gleason scores are given in 
two parts, one is the score for the largest representative area of the biopsy, and the second 
is for the second largest area. For example, if the largest part of the biopsy is grade 4, and 
the second largest is grade 3, the score is given as “4+3=7”. Alternatively, these two scores 
can be the same.  
1.1.4.6 Tumour frequency by Zone 
The three zones of the prostate (see section 1.1.1.2) each have their own independent 
incidence of tumour development, shown in table 1.1: 
Table 1.1: Frequency of prostate tumour development per zone displayed as a percentage 
of all tumours found in the study (Cohen et al., 2008). 
Zone 
% of total Prostate 
tumours 
Central 2% 
Transitional 34% 
Peripheral 64% 
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1.1.4.7 Tumour Characteristics by Zone 
Tumours of the central zone have much higher rates of ejaculatory duct and seminal vesicle 
invasion than peripheral zone or transition zone tumours which is unsurprising given the 
close proximity of the central zone to these areas. Central zone tumours also displayed the 
highest Gleason score and were consistent with the worst outcomes with a considerably 
lower failure-free probability and shorter time to failure than peripheral or transitional 
zones. However central zone tumours are the rarest form, and failure-free survival and time 
to failure of peripheral and transitional zone tumours was similar (Cohen et al., 2008).   
1.1.4.8 Localised PCa 
Localised PCa is defined as not extending beyond the capsule of the prostate (Akduman & 
Crawford, 2006).  
1.1.4.9 Localised PCa Treatments 
For low risk localised prostate cancers where the patient has a life expectancy in excess of 
20 years, the primary course of action is “watchful waiting”. This emphasises monitoring of 
the tumour with bi-annual or annual DRE and PSA testing with biopsies dependant on the 
results (Mohler et al., 2014).  
Localised PCa is relatively low risk, with the main treatment option being radical 
prostatectomy. This involves the complete removal of the prostate, seminal vesicles and 
pelvic lymph nodes. PSA should be undetectable 4-6 weeks post-surgery and levels of more 
than 0.2ng/mL can indicate a recurrence (Mohler et al., 2014). (Bill-Axelson et al., 2011) 
showed that radical prostatectomy can reduce “disease-specific mortality, overall mortality, 
and the risks of metastasis and local progression” in prostate cancer patients compared to 
watchful waiting. Since the discovery of the location of the cavernous nerves by Dr Patrick 
Walsh in 1981, nerve sparing radical prostatectomy has become common practice in order 
to maintain a patient’s post-operative erectile function and quality of life. With the 
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development of nerve sparing radical prostatectomy came the concerns that this method 
would involve higher risks of positive surgical margins and biochemical progression. These 
concerns were tested by Alkhateeb et al. (2010) who found that in properly selected patients, 
the risk of positive surgical margins and biochemical progression was no greater in nerve 
sparing procedures compared to non-nerve sparing procedures.  
Radiation therapy is also used in low risk patients in an attempt to stop tumour growth 
through the fatal damaging of malignant cell DNA. For prostate cancer, there are two 
radiation therapies commonly used; interstitial brachytherapy or external beam 
radiotherapy (EBRT). Interstitial brachytherapy involves inserting rods of radioactive isotopes 
such as palladium 103 or iodine 125. The rods are implanted under the perineum into the 
prostate gland via unltrasonograph guidance (Simmons et al., 2011). Two main types of 
interstitial brachytherapy are currently in use; low-dose permanent (LDR-BT), a slow release 
system that sits within the prostate indefinitely and high-dose temporary (HDR-BT) which 
has a higher release of radioactivity but over a shorter period of time. LDR-BT is a more cost 
effective option and preferred in early prostate cancers (Skowronek, 2013). EBRT involves 
the delivery of ionising radiation from an external source using a linear accelerator (Vanneste 
et al., 2016). Via the use of imaging and beam manipulation, EBRT can be used to target the 
prostate whilst minimising collateral tissue damage. Newer ERBT techniques involve the use 
of heavier particles such as protons which due to their ability to arrest within the target (in 
this case the prostate tumour), can deliver higher doses of treatment whilst minimising off 
target effects (Wisenbaugh et al., 2014). The main benefits of ERBT are that it is non-invasive 
and painless. However, treatments last for several weeks and require multiple visits to a 
speacialist unit a week. For more advanced localised cases with higher risk, ERBT and 
brachytherapy can be combined (Zaorsky et al., 2017).   
Chapter I: Introduction 
12 
 
However, these treatments can often be associated with significant morbidity and reduced 
quality of life. Furthermore, overtreatment is frequently seen in prostate cancer and often a 
close monitoring approach may avoid unnecessary treatments and allow more personalised 
treatment options at a later date (Klotz, 2013). 
1.1.4.10 Metastatic PCa  
Like all cancers, PCa can metastasise to distal sites. Cancers of different origins have 
individual metastatic tendencies, in the case of the prostate the most common metastatic 
locations (in order) are the bone (84%), distant lymph nodes (11%), liver (10%) and the thorax 
(9%) (Gandaglia et al., 2014). Other less common metastatic sites include the brain, digestive 
system, kidneys and adrenal glands (Gandaglia et al., 2014). Metastases are associated with 
considerably higher mortality rates (Sieh et al., 2013; Tangen et al., 2003). 
Diagnosis of metastatic disease is dependent firstly on imaging techniques. For example, for 
the past 35 years the detection of bone metastases has been primarily done by radioisotope 
bone scintigraphy (RBS), with a technetium 99m- labelled diphosphonate (Pollen et al., 
1981). RBS works by visualising high metabolising areas, thus are most effective at detecting 
metastases that hypermetabolise the bone, which are commonly seen in PCa (Heindel et al., 
2014). X-rays are a simple way to view the damage caused by bone metastases and CT scans 
are useful for viewing bone metastases in cortical bone. Whereas CT scans are useful for 
viewing metastases of the cortical bone, MRI can be useful in detecting metastases within 
the bone marrow. PET scanning is used to detect areas of high metabolic activity, and can be 
used to detect multiple metastatic locations, including the bone with high accuracy (Fujimoto 
et al., 2006).  
Biopsy of the metastatic site can sometimes be extremely effective in diagnosis of primary 
tumour location. For example, case reports from Nakata et al. (2005) and Ueda et al. (2007) 
state that in their patients, no primary tumour could be found from two separate prostate 
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biopsies. However, biopsy of metastases in the pubic bones of these patients revealed poorly 
differentiated prostate cancer or general adenocarcinoma, likely to be of prostatic origin.  
1.1.4.11 Bone Metastasis 
As discussed, the most common secondary site of prostate cancer is the bone (Bubendorf et 
al., 2000), this occurrence is known as metastatic bone disease. Common complications of 
metabolic bone disease include spinal compression which leads to paresis or hemiparesis, or 
an increase in mechanical/chemical activation of periosteal and endostial pain receptors 
leading to a constant sense of dull pain (Msaouel et al., 2008).  
1.2 Formation of Metastatic Bone Disease 
PCa metastasis to the bone is a multi-step process (for overview of the process see figure 
1.2) that begins with tumour formation within the prostate. Over time, growth of the tumour 
results in spreading to the prostate stroma, the first step in the development of an invasive 
tumour (Koutsilieris, 1993).  
Chapter I: Introduction 
14 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: An overview of the metastatic process from the PCa to the bone. The primary tumour develops and 
induces angiogenesis, tumour cells then use this new vasculature to disseminate, eventually extravasating at the 
secondary site. Commonly for PCa this is the bone (adapted from de Groot et al., 2017). 
Chapter I: Introduction 
15 
 
As the tumour becomes more advanced it invades the surrounding tissues such as the 
seminal vesicle and the bladder (Msaouel et al., 2008). As the tumour becomes larger, simple 
diffusion is insufficient to supply all cancerous cells with enough nutrients, thus angiogenesis 
occurs to increase the blood flow to all parts of the tumour. Angiogenesis is the de novo 
formation of capillaries from post-capillary venules, stimulated by growth factors such as 
hypoxia-inducable factor (HIF)-1α which modulates the expression of vascular endothelial 
growth factor (VEGF), angiopoietin-2 and several others (Pugh & Ratcliffe, 2003). The 
development of this vasculature increases the chances of metastasis due to the now close 
proximity of malignant cells to the bloodstream. Furthermore, the vasculature at cancerous 
sites is highly permeable to cancer cell extravastation (Garcia-Roman & Zentella-Dehesa, 
2013). 
In order for cells to travel to distal sites, they must enter the bloodstream. The first hurdle in 
the process is a phenomenon known as ‘Anoikis’, a process of fatty acid synthase (FAS)-
induced apoptosis that occurs in epithelial cells that detach from the extracellular matrix 
(Rennebeck et al., 2005). In order to metastasise, cancer cells must develop Anoikis 
resistance.  
A major hurdle in the migration of PCa cells is survival within circulatory systems, protection 
systems still pose threats to cancer cells after the evasion of Anoikis. Approximately 85% of 
tumour cells that enter the circulation will undergo a rapid phase of intravascular cell death 
(Msaouel et al., 2008). A survival advantage can sometimes be gained by PCa cells by 
circulating withinin platelet aggregates, protecting them from the shear forces of the 
circulatory system. Furthermore PCa cells have been known to down-regulate major 
histocompatibility complex (MHC) class I molecules from their surface, resulting in a 
decrease in their degradation by cytotoxic T cell killing. Complete loss of human leukocyte 
antigen (HLA) I is seen in 34% of primary PCa tumours and 80% of prostate derived lymph 
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node tumours, wheras downregulation of HLA I is seen in 84% of primary tumours and 100% 
in the metastases (Blades et al., 1995). 
PCa cells show tendencies for metastasising to particular parts of the skeletal system. 
Notably, PCa cells frequently infiltrate trabecular bones of the axial skeleton such as the 
pelvis, ribs and lumbar spine as well as the proximal ends of the femurs (Msaouel et al., 
2008), although the reason for this preference is still under debate. Stephen Paget’s “Seed 
and Soil” hypothesis states that distal sites (soil) contain/secrete factors that provide a 
habitable environment for a specific cell type (seed) (Paget, 1989). Another theory may be 
explained by the close relationship shared between the marrow of the vertebral column and 
a network of veins called the Batson plexus first detailed in 1967. These veins drain blood 
from the lower vertebral column which receives blood from the prostate (Batson, 1967).   
PCa cells extravasate to the marrow, but bone metastases are found on the bone surface 
(Suva et al., 2011). The first step in gaining entry to the bone marrow is the arrest of PCa cells 
in the microvasculature within. This occurs in the sinusoids of the skeletal vascular beds, here 
the large diameter and reduced velocity aid cell bedding (Msaouel et al., 2008). Lehr and 
Pienta (1998) showed that PCa cells preferentially adhere to bone marrow endothelium 
compared to other endothelial cell types, at least partly through their interaction with 
epithelial galectin-3 and lymphocyte function associated antigen 1 (LFA-1) receptors. Here 
the cells secrete proteolytic enzymes which aid the traversal of PCa cells through the 
endothelial basement membrane and enables extravasation into the bone 
microenvironment (Koutsilieris, 1995). Once in the bone microenvironment, the PCa cells 
stimulate their own vascular supply via angiogenesis which facilitates their migration to the 
bone surface (Suva et al., 2011). The bone surface is covered in lining cells, therefore when 
the PCa cells move to within close proximity of the endosteal bone surface they release 
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agents that stimulate the motility of lining cells and trigger bone resorption. This crucial step 
provides the PCa cells with access to the demineralised bone surface.  
1.3 Bone 
Bone is a dynamic tissue with many functional roles including providing structural support, 
protection of vital organs and permitting movement in conjunction with the muscular 
system. Bone also plays a role in the homeostasis of minerals such as calcium (Bronner, 
1992). Roughly 80% of the human skeleton is cortical bone (Eriksen, 1994), dense bone that 
surrounds the marrow and forms the outer surface of bones, providing protection and 
strength. The remaining 20% of the human skeleton is trabecular (or cancellous) bone, 
located at the ends of long bones and within flat and irregular bones such as the spine, 
sternum and pelvis (Keaveny et al., 2001). Trabecular bone is formed of open porous space, 
filled with bone marrow and cells. A directional grain within the porous structure of 
trabecular bone increases its load bearing strength, whilst still having a reduced weight 
compared to cortical bone.  
1.3.1 Bone Matrix 
Bone matrix represents the extracellular component of bone which consists of around 60% 
inorganic component, formed of primarily hydroxyapatite (HA), 10% water and 30% organic 
material, formed of various bone matrix proteins (Morgan et al., 2013; Zhu et al., 2008). 
1.3.1.1 Inorganic Component 
HA [Ca5(PO4)3(OH)] is the major component of crystallised inorganic bone matrix (Fujisawa & 
Tamura, 2012). HA contains vast amounts of both calcium and phosphate, therefore 
formation and degradation of HA is key to the homeostasis of these minerals. Impurities 
within HA are common, such as the substitution of phosphate groups with carbonate ions, 
substitutions of calcium groups with potassium, sodium and magnesium and substitution of 
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chloride and fluoride with hydroxyl groups (Morgan et al., 2013). The inclusion of these 
impurities into HA crystals means the inorganic bone matrix is also involved in the 
homeostasis of these minerals. 
1.3.1.2 Organic Component  
The organic component of bone matrix is made up of various proteins. Collagenous proteins 
make up 90% of the organic matrix, of which most is type I collagen (Viguet-Carrin et al., 
2006). However, small amounts of other collagens such as type III and V are also present in 
bone. Collagen provides much of the strength and load bearing qualities of bone. Collagen 
molecules are organised in the same orientation to form long fibrils, with overlapping 
collagen molecules to provide additional strength. These molecules are then crosslinked by 
lysyl oxidase enzymes to form collagen fibrils, which in turn group together to form collagen 
fibres. Collagen fibres are organised according to the load bearing direction of the bone and 
are responsible for the incredible directional strength seen in bones such as the femur 
(Martin et al., 2015). Nudelman et al. (2010) implicated collagen I fibrils in the process of HA 
mineralisation, linking the functions of the organic and inorganic phases. In this study, they 
showed that the positive charge close to the C-terminal end of collagen molecules facilitates 
the invasion of negatively charged non-collagenous protein and amorphous calcium 
phosphate (ACP) complexes into the collagen fibril.  
 As well as collagens, a wide variety of non-collagenous proteins (NCPs) and growth factors 
also exist within the bone matrix. Proteins such as osteocalcin (OCN), bone sialoprotein 
(BSP), osteopontin (OPN), osteonectin (ON) and bone morphogenetic proteins (BMPs) are 
abundant within the matrix and are generally involved in guiding cells as well as modulating 
cellular functions and the mineralisation process as a whole (Al-Qtaitat, 2014). Similarly, 
numerous growth factors and cytokines are present within the bone matrix such as 
transforming growth factor β (TGFβ), fibroblast growth factors (FGFs), insulin-like growth 
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factors (IGFs), platelet-derived growth factors (PDGFss), colony stimulating factor (CSF), 
tumour necrosis factor (TNF) interleukin (IL) 1, 4, 6 and interferon-γ. Again the role of these 
growth factors is to tightly control cell function within the bone matrix, a process which is 
under constant, dynamic feedback modulation.  
1.3.2 Bone Cells 
Within bone, three principle cell types exist that perform tightly regulated roles; osteoblasts, 
osteoclasts and osteocytes. The cells arise from various stem cell lines and are involved in a 
number of processes such as bone remodelling and mineral homeostasis.  
1.3.2.1 Osteoblasts 
The primary role of osteoblasts is the creation and deposition of fresh bone matrix. This 
matrix deposition is key to maintaining skeletal integrity. Osteoblasts are cuboidal in shape 
and have very distinctive intracellular features such as basal PAS-positive granules containing 
bone matrix precursor glycoproteins (Del Fattore et al., 2012) and membranes enriched in 
alkaline phosphatase (Morris et al., 1992), an enzyme crucial for mineralisation (Sugawara et 
al., 2002). Active osteoblasts also display a prominent Golgi apparatus and abundant rough 
endoplasmic reticulum (Caetano-Lopes et al., 2007), typical of a high protein synthesising 
cell.  
1.3.2.1.1 Osteoblast Function 
As discussed, the primary function of osteoblasts is the deposition of bone matrix. The initial 
step in the process is the production of uncalcified matrix termed osteoid (Del Fattore et al., 
2012), which forms the organic phase of mature bone matrix. This is achieved through the 
secretion of a number of proteins, primarily type I collagen, but also contain non-collagenous 
proteins such as BSP, ON and osteocalcin as well as the proteoglycans biglycan and decorin. 
Osteoid is subsequently mineralised by osteoblasts. This process is partially mediated by the 
action of osteoblast associated matrix vesicles (Anderson et al., 2005). Matrix vesicles are 
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around 50-200nm in size and bud from the osteoid-facing surfaces of osteoblasts. HA crystals 
initially form within the vesicles, which occur because of excessive concentrations of Ca2+ 
(Genge et al., 1992) and PO4 (Montessuit et al., 1995), which leads to the deposition of CaPO4 
in the form of HA (Anderson et al., 2005). These HA crystals are then released through the 
membranes of the matrix vesicles, which, due to high levels of local Ca2+ and PO4, grow by a 
process of nucleation. These HA crystals can interact with collagen molecules as described 
earlier, and after continuous nucleation, are able to fill the gaps between collagen fibres 
within the skeletal matrix. The activity of non-collagenous proteins are also largely 
responsible for the overall process of mineralisation. For example, BSP is able to bind gap 
zones within the collagens, thus mediating mineral deposition from ions in solution 
(Glimcher, 1984). Some non-collagenous proteins, such as OPN contribute to the inhibition 
of matrix mineralisation (Yuan et al., 2014), whereas others, such as MMP3 indirectly 
increase mineralisation by degrading inhibitory proteins such as OPN (Boukpessi et al., 2008). 
1.3.2.1.2 Osteoblast Differentiation 
Osteoblasts differentiate from mesenchymal stem cells (MSCs). Commitment of MSCs 
towards an osteo/chondroprogenitor lineage is the first step in osteoblastogenesis (figure 
1.3), a pathway under the control of BMP and Wingless (Wnt) signalling pathways 
(Grigoriadis et al., 1988). Osteo/chondroprogenitors now have high expression of crucial 
osteoblast differentiation genes such as Runt-related transcription factors 2 (Runx2), the 
master osteoblast differentiation gene, as well as Distal-less homeobox5 (Dlx5) and osterix 
(Osx) (Capulli et al., 2014; Ducy et al., 1997). Osteoprogenitor cells then undergo a 
proliferative stage, during which Alkaline Phosphatase (ALP) activity increases, these cells are 
now deemed preosteoblasts and express Collagen Type I Alpha 1 Chain (COL1A1) which is 
upregulated by runx2 (Capulli et al., 2014). From the immature osteoblast stage onwards, 
the function of runx2 becomes inhibitory (Komori, 2006). It is therefore believed that the 
function of runx2 lies in maintaining the supply of immature osteoblasts, at which point, 
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other genes may take over in driving maturation to mature osteoblasts. For example, 
maturation from preosteoblasts to mature osteoblasts is characterised by a further increase 
in the expression of Osx as well as the secretion of organic matrix proteins such as type I 
collagen, osteocalcin and BSP (as described in section 1.2.2.1.1) (Nakashima et al., 2002). 
Furthermore, during this final stage, there is a morphological shift towards the large cuboidal 
shape characteristic of a mature osteoblast.  
When osteoblasts reach the end of their lifespan, which in humans is up to 8 weeks 
(Sommerfeldt & Rubin, 2001), they have a number of potential fates; such as apoptosis, or 
becoming bone lining cells (BLCs). BLCs are quiescent osteoblasts displaying a flat 
morphology. As their name suggests, BLCs line the surface of bone and have a number of 
roles in bone physiology. Firstly the act as a physical barrier, preventing interactions between 
osteoclasts and bone matrix (Florencio-Silva et al., 2015). BLCs also modulate the maturation 
of osteoclasts via differential expression of both receptor activator of nuclear factor kappa-
Β ligand (RANKL) and osteoprotegrin (OPG) (a decoy receptor for RANKL). Finally it is 
hypothesised that BLCs can regain an active osteoblastic phenotype and through this, extend 
their lifespan (Matic et al., 2016).  
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Figure 1.3: Differentiation of MSCs into mature Osteoblasts. BMP and Wnt signalling drives MSCs down the 
oseo/chondroprogenitor lineage, while Wnt signalling also prevents MSCs from maturing into preadipocytes. Expression of runx2, 
and dlx5 is crucial for driving further maturation of the osteo/chondroprogenitor cells. Osteoprogenitor cells then proliferate and 
mature into preosteoblasts, characterised by a rise in the expression of ALP and COL1A1. These cells then mature into osteoblasts, 
characterised by further increases in ALP and COL1A1 expression, increased secretion of matrix proteins such as BSP and OCN as 
well as a morphology change to a large cuboidal shape (adapted from Del Fattore et al., 2012; Komori, 2006). 
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1.3.2.2 Osteocytes 
Another potential differentiation avenue for osteoblasts occurs when they become trapped 
in the mineralised bone matrix and become osteocytes. Osteocytes make up 95% of the cells 
within bone (Dallas et al., 2013). Osteocytes are found within lacunae, located within the 
mineralised matrix, and have a dendritic phenotype (Florencio-Silva et al., 2015). Osteocytes 
have many dendritic processes (around 40-100 per cell) (Beno et al., 2006) that spread 
through canaliculi within the bone, allowing communication with nearby osteocytes as well 
as the bone surface and surrounding vasculature (Dallas et al., 2013). Osteocytes are also 
able to communicate with osteoblasts and osteoclasts, relaying mechanical loading and 
pressure information to orchestrate effective rebuilding of the local bone (Bonewald, 2007).  
1.3.2.3 Osteoclasts 
Osteoclasts are giant multinucleated cells responsible for the resorption of mineralised bone 
matrix. Osteoclasts are highly specialised cells, able to polarize and segregate plasma 
membrane domains for a more specific pattern of resorption (Szewczyk et al., 2013).  
1.3.2.3.1 Osteoclastogenesis  
Osteoclasts originate from haematopoietic stem cells which become colony forming unit-
granulocyte monocyte cells (CFU-M) upon initiation of osteoclastogenesis (figure 1.4). The 
initial commitment of a precursor cell to the osteoclast lineage is governed by PU.1, a 
transcription factor of the Ets (E26 transformation-specific or E-twenty-six) transcription 
factor family (Tondravi et al., 1997). PU.1 is activated by M-CSF signalling, which along with 
RANKL signalling, upregulates another transcription factor; nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 1 (NFATc1) (Asagiri & Takayanagi, 2007; Ishiyama et al., 
2015). A third transcription factor, Melanocyte Inducing Transcription Factor (MITF), is also 
involved in this stage of osteoclastogenesis. Initially, MITF was found to work with PU.1 to 
recruit NFATc1 into a complex able to promote osteoclastic genes (Sharma et al., 2007), 
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although further work has since revealed a role for MITF downstream of NTFATc1 during 
RANKL signalling to further promote NTFATc1 dependent osteoclastogenesis (Lu et al., 2014).  
The next step in osteoclastogenesis is the fusion of mononuclear cells to form mature, 
multinucleated osteoclasts. Fusion of osteoclast precursors relies on a small subset of cells 
with a “fusion founder” competence (Levaot et al., 2015), these cells generally represent 
<10% of a cell population in vitro and fuse with multiple “fusion follower” cells. Numerous 
molecules have been identified as being involved in osteoclast fusion such as cluster of 
differentiation (CD)47 (Han et al., 2000), E-cadherin (Mbalaviele et al., 1995) and Meltrin-α 
(Abe et al., 1999). Two key molecules in osteoclast fusion are dendritic cell-specific 
transmembrane protein (DC-STAMP) and osteoclast stimulatory transmembrane protein 
(OC-STAMP). DC-STAMP is up-regulated by RANK-NFATc1 and knockdown of DC-STAMP 
completely abrogates osteoclast precursor fusion (Yagi et al., 2005), indicating DC-STAMP as 
the master regulator of osteoclastogenesis. OC-STAMP, another transmembrane protein, 
also results in abrogated osteoclastogenesis when blocked (Chiu & Ritchlin, 2016). However 
the mechanism by which DC and OC-STAMP mediate osteoclastogenesis remains largely 
unknown due to the lack of characterised ligands. 
Multinucleated osteoclasts are then recruited to the bone surface by the action of CSF-1 and 
RANKL, at which point the cells adhere to the bone and undergo cytodifferentiation to form 
bone resorbing osteoclasts. The activity of genes such as c-Src (Proto-oncogene tyrosine-
protein kinase Src), capicua transcriptional repressior-7 (CIC-7) and cathepsin K are crucial 
for the development of a bone resorbing phenotype (Kornak et al., 2001; Lowe et al., 1993; 
Troen, 2004). Throughout differentiation, continuous RANKL stimulation is required for 
osteoclast survival (Park et al., 2017). 
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Figure 1.4: Osteoclast Differentiation Lineage and Affecting Factors: Osteoclasts originate as haematopoietic precursors which are stimulated to 
begin osteoclastogenesis by the PU.1 transcription factor, becoming CFU-GM cells. M-CSF and RANKL are crucial for driving further differentiation 
whilst OPG inhibits osteoclastogenesis at multiple stages. CFU-GM cells then fuse to form a polykaryon, termed a multinucleated osteoclast, which 
then mature and gain resorbing activity, becoming activated bone resorbing osteoclasts. Above and below the image are the genes of which 
mutations are known to increase and decrease osteoclastogenesis (respectively) (blue boxes refer to the effects of these genes in mouse 
overexpression models) (adapted from Boyle et al., 2003). 
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1.3.2.3.2 Osteoclast Bone Resorption 
For resorption to occur, polarisation of the osteoclasts is crucial. Once polarised, four distinct 
membrane domains can been seen. The “ruffled border” describes the plasma membrane 
domain facing the bone surface where bone resorption occurs, and is characterised by 
numerous membrane folds (Stenbeck, 2002). The adhesion domain describes the area 
immediately surrounding the ruffled border, responsible for attaching the osteoclast to the 
bone surface and creating a sealed off area for bone resorption to occur in, known as the 
“Howship’s Lacunae” (Del Fattore et al., 2012). The apical domain is located opposite the 
ruffled border and the basolateral domain is located between the adhesion and apical 
domains. These domains are responsible for ion transport and transcytosis of products 
internalised from the lacunae into the extracellular space.  
As discussed, bone matrix has two main components; an organic phase, consisting of largely 
type 1 collagen and a HA containing inorganic phase. Breakdown of the bone is therefore a 
two-step process specifically designed for the degradation of each component. The first step 
involves acidification of the lacunae and is carried out by H+ATPase pumps within the ruffled 
membrane (Blair et al., 1989). This releases calcium and phosphate, leaving the organic 
component vulnerable to proteolytic degradation. The proteolytic enzymes utilised by 
osteoclasts are cathepsin K and Matrix metalloproteinase-9 (MMP9) (Reponen et al., 1994; 
Troen, 2004). Cessation of osteoclast activity is primarily orchestrated by OPG, which can 
directly inhibit osteoclast activity (Hakeda et al., 1998), cause detachment of osteoclasts 
from the bone surface (O'Brien et al., 2001) and even promote osteoclast apoptosis (Liu et 
al., 2015). 
1.3.2.4 Bone Remodelling 
Bone remodelling describes the dynamic process by which bone is simultaneously degraded 
and synthesised. Bone remodelling takes place within specialised units, called basic 
Chapter I: Introduction 
27 
 
multicellular units (BMUs), where various bone cell types including the crucial osteoblasts 
and osteoclasts, are active and cooperate in a coordinated manner. The bone remodelling 
process has 5 stages; activation, resorption, reversal, formation and termination (Raggatt & 
Partridge, 2010). An overview of the bone remodelling process is shown in figure 1.5. 
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Figure 1.5: An overview of the bone remodelling process. Activation stimulates osteoclastogenesis, resorption involves 
osteoclastic degradation of the bone, the reversal phase terminates osteoclast function and stimulates osteoblastogenesis, 
the formation phase involves the osteoblastic deposition of new bone and the termination phase halts bone remodelling by 
suppressing osteoblast function (adapted from Abdelgawad et al., 2016; Kapinas & Delany, 2011). 
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The activation phase begins with the detection of an initiating signal, such as mechanical 
strain, damage or hormone signalling. Bone damage causes nearby osteocyte apoptosis, 
resulting in a reduction in local TGF-β, an osteoclastic inhibiting hormone produced by the 
osteocytes (Heino et al., 2002). Parathyroid hormone (PTH) is produced by the parathyroid 
glands in response to low serum calcium levels and binds PTH receptors on osteoblasts, 
which in turn activates pro osteoclastic signalling, resulting in osteoclastogenesis (Swarthout 
et al., 2002).  
The resorption phase is activated by pro osteoclastic signals, originating from osteoblasts as 
discussed, as well as from stromal and bone lining cells (Proff & Romer, 2009). Monocyte 
chemoattractant protein 1 (MCP-1) secreted by these cells acts as a strong chemotactant for 
osteoclast precursors. Osteoblasts also increase their expression of CSF-1 and RANKL whilst 
subsequently reducing their OPG expression, resulting in a heavily pro osteoclastic 
environment (Ma et al., 2001). At this stage, osteoblasts also produce MMP-13, which 
degrades the fresh, unmineralised surface of the bone, revealing arginine-glycine-aspartic 
acid (RGD) adhesion sites (McHugh et al., 2000). RGD adhesion sites act as anchoring points 
for osteoclasts by their interaction with osteoclastic αvβ3 integrin, creating the adhesion 
domain described previously. Once attached and fully differentiated, mature osteoclasts 
begin the process of bone resorption (described in section 1.3.2.3.2).  
The reversal phase is primarily orchestrated by ‘reversal cells’, mononuclear cells of 
osteoblastic lineage (Andersen et al., 2013). Reversal cells have a flat phenotype, similar to 
that of a bone lining cell, albeit less elongated (Delaisse, 2014). Their role is proposed to be 
smoothening of the reversal surface, the area of bone that remains post resorption before 
osteoblastic deposition (Andersen et al., 2013). This smoothening is facilitated by the 
secretion of MMPs from reversal cells that degrade remaining collagens left over from 
resorption, and interestingly, blocking this demineralised collagen degradation can prevent 
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the deposition of fresh bone matrix, highlighting the importance of the reversal process 
(Everts et al., 2002). Early reversal cells interact with neighbouring osteoclasts and perform 
smoothening of the reversal surface, as discussed, but as bone lining cells mature, they gain 
a more osteoblastic phenotype (Abdelgawad et al., 2016). 
The formation phase is the osteoblastic phase of bone remodelling, where new bone is 
synthesised in response to formation signals. The formation phase is key to maintaining 
skeletal density and integrity by replacing bone removed by osteoclasts. The signalling 
relationship between osteoclasts and osteoblasts is therefore crucial to maintaining bone 
homeostasis, and this signalling relationship is known as coupling. The exact origin of these 
coupling signals is still unclear although data suggests a multitude of potential signal sources. 
Matrix derived signals, released by the action of bone resorption, were originally thought to 
trigger formation (Howard et al., 1981), specifically TGFβ and insulin like growth factors. 
However, in an environment containing functionally redundant osteoclasts, these formation 
signals still persist, suggesting a potential osteoclastic origin for these signals separate from 
resorption (Lotinun et al., 2013). In this model sphingosine-1-phosphate (S1P) is the primary 
osteogenic signal, although studies have also implicated other coupling molecules such as 
collagen triple helix repeat containing 1 (CTHRC1) (Takeshita et al., 2013) and afamin (Kim et 
al., 2012). Formation signals can also arrive from other sources such as macrophage derrived 
oncostatin M (OSM) which can enhance osteoblast differentiation (Guihard et al., 2012). 
Once signalled to differentiate, mature osteoblasts begin to deposit fresh bone matrix as 
described in section 1.2.2.1.1.  
The termination phase concludes the remodelling process once the resorbed bone has been 
sufficiently replaced. Sclerostin, produced by local osteocytes suppresses osteoblastic 
activity and prevents matrix deposition (van Bezooijen et al., 2004). To inhibit further bone 
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resorption, osteoblasts produce OPG through Notch and Wnt signalling (Matsuo & Irie, 
2008).  
1.3.3 Effects of Bone Metastases on Bone Remodelling 
Interplay between cancer and bone cells drives both the progression of the tumour and 
modulates the remodelling of the surrounding bone. The effects of bone metastases on the 
remodelling of the bone can be broadly divided into two main categories; osteolytic and 
osteoblastic, representing the excess resorption and deposition of bone respectively. Breast 
and prostate cancer both commonly metastasise to the bone, with breast cancer 
predominantly forming osteolytic lesions and prostate cancer metastases forming 
predominantly osteoblastic lesions (Ye et al., 2007).   
1.3.3.1 Osteoblastic Lesions 
As the name suggests, an osteoblastic bone metastatic lesion is characterised by a relative 
over activity of osteoblasts within the surrounding area. This results in nodules formed by 
excess bone deposition, often seen on X-rays as bright areas representing increased bone 
density. Osteoblastic lesions account for roughly 85% of PCa bone metastases with 12% 
being mixed lesions and only 4% being osteolytic (Charhon et al., 1983; Roudier et al., 2004). 
The most common complication with osteoblastic lesions is pain (Coleman, 2001), caused by 
either stimulation of the local nerves by tumour released cytokines or chemical mediators or 
by mechanical stimulation from the tumour mass itself (Selvaggi & Scagliotti, 2005). Epidural 
spinal cord compression is another complication of metastatic lesions, but is not specific to 
osteoblastic phenotypes. Compression of the spinal cord by the metastatic tumour causes 
demyelination and axon damage and leads to vascular compromise (Cole & Patchell, 2008), 
which becomes a significant source of pain. 
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1.3.3.1.1 Osteoblastic PCa Bone Metastasis 
Upon the arrival of PCa cells to the bone there is an initial lytic stage, resulting in the 
debulking of the bone surface which subsequently aids the seeding of the PCa cells (Msaouel 
et al., 2008), a process carried out by bone resorbing osteoclast cells. To initiate this 
osteoclastic stage, the tumour cells chemotactically recruit pre-osteoclasts whereupon their 
maturation is subsequently triggered. This maturation is initiated by local increases in 
osteoblastic factors, including RANKL, which triggers osteoclastogenesis as described in 
section 1.3.2.3.1 PCa cells themselves also express several factors capable of further 
regulation of osteoclastogenesis including M-CSF, parathyroid-hormone-related protein 
(PTHrP), interleukin (IL)-1/6 and TGF-β.  
Osteoclastic activity then stimulates osteoblastic activity through the mechanisms described 
in the formation stage of bone remodelling (section 1.3.2.4). This triggering of osteoblast 
activity is a precursor to the following stage of PCa related metastatic bone disease, which 
displays as predominantly osteoblastic, favouring bone deposition (Ibrahim et al., 2010). As 
discussed, during the early stages of bone metastasis, PCa cells secrete a number of factors 
that act on the bone microenvironment, such as IL-6 and PTHrP that can stimulate pro-
osteoclastic pathways (Axmann et al., 2009; Kudo et al., 2003). However, in the later stages 
of bone metastasis, PCa cells express large amounts of OPG, thus reducing the activity of 
local osteoclasts via a reduction in RANK-RANKL signalling. Additionally, OPG acts as a pro-
survival factor for PCa cells by binding to TNF related apoptosis-inducing ligand (TRAIL) and 
preventing TRAIL induced apoptosis (Holen et al., 2002). Furthermore PCa cells also secrete 
factors such as BMPs, TGF-β and IGF (Logothetis & Lin, 2005). These bind a range of receptors 
on osteoprogenitor cells triggering a number of pathways such as the mitogen-activated 
protein kinase (MAPK), protein kinase C (PKC) and SMAD signalling pathways. These activate 
genes including RUNX2 and osterix, inducing osteoblastogenesis. Metastatic PCa cells are 
also responsible for a rise in local levels of urokinase-type plasminogen activator (uPA) 
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(Koutsilieris, 1993). uPA promotes osteoblastic activity in number of ways; firstly uPA is 
responsible for the lysis of IGF binding proteins (IGFBPs) . IGFBPs sequester IGFs, therefore 
uPA indirectly increased the activity of IGFs resulting in proliferation of osteoblasts and PCa 
cells via IGF-R (Koutsilieris & Polychronakos, 1992). uPA can also cleave and activate TGF-β 
as well as binding osteoblasts and triggering activation directly (Ibrahim et al., 2010). This 
osteoblastic shift in signalling results in the formation of nodules , characteristic of PCa bone 
metastases. 
In addition to the signalling network changes induced by PCa cells, excess bone deposition 
can occur directly from the action of PCa cells through a process called osteomimicry. This 
describes the ability of PCa cells within the metastatic niche to increase their expression of 
osteoblastic genes such as ALP, BMPs, COL1A1, OPN and OCN (Knerr et al., 2004).  
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Figure 1.6: Signalling network shared between PCa and bone cells. PCa cells secrete factors that act to increase 
osteoclast function (PTHrP & IL-6), decrease osteoclast function (OPG) and increase osteoblast function (IGFs, TGF-
βs, ET-1 & BMPs) (adapted from Msaouel et al., 2008).  
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1.3.3.1.2 Osteolytic Lesions 
Osteolytic lesions are characterised by a relative over activity of osteoclasts within the 
surrounding area of the metastasis. As discussed, osteolytic lesions only represent 4% of PCa 
related bone metastases. However, osteolytic lesions are markedly more common from lung 
and renal cancer metastases as well as breast cancer, where 48% of metastatic lesions 
present as osteolytic (Harvey, 1997). Osteolytic lesions appear on X-rays as dark areas within 
the bone representing reduced bone density as a result of the increased osteoclastic activity.  
The increased osteoclast activity seen in osteolytic bone metastases are predominantly the 
result of increased osteoclast stimulation by RANKL (Boyce & Xing, 2008). This RANKL is 
produced by local osteocytes and osteoblasts and is upregulated in response to stimulation 
with PTHrP, produced by tumour cells (Soki et al., 2012).  
Pain is also a common complication of osteolytic lesions (Coleman et al., 2014), this is again 
linked to mechanical stimulation from the tumour itself but is also stimulated in other ways 
such as a general increase in local acidity due to overproduction of hydrochloric acid (HCl) by 
osteoclasts (Yoneda et al., 2015). Hypercalcaemia is another complication of osteolytic 
lesions, caused by calcium release during excessive bone resorption (Stewart, 2005). 
Hypercalcaemia can cause nausea and vomiting as well as impair cognition, and is also able 
to stimulate pain (Tsuzuki et al., 2016). Unsurprisingly, bone fractures are common in 
patients with osteolytic bone metastases and usually appear within the long bones 
(Sarahrudi et al., 2006). These fractures are painful and show poor healing, often requiring 
surgery (Harrington, 1995). This leads to a significantly reduced quality of life. 
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1.3.3.2 Treatment of metastatic PCa 
The primary treatment option for metastatic PCa is androgen deprivation therapy (ADT). This 
involves reducing the circulating levels of testosterone, thus reducing androgen receptor 
(AR) activity, a prominent driver of PCa progression. The most abundant androgen in males 
is testosterone, which can be lowered in a two main ways; removal of the testis (the main 
site of testosterone production) known as surgical castration or pharmacological 
intervention leading to reduced function of the testis, known as medical castration. However 
in the majority of cases, advanced PCa develops an androgen independent phenotype, where 
growth and development can occur in the absence of testosterone. This process is thought 
to occur via multiple mutations including the acquisition of the 3q12-q13 and loss of the 
6q24-qter and 21q chromosomal regions (Hyytinen et al., 1997). For castration resistant 
metastatic prostate cancer, a breakthrough came in 2004 in the form of Docetaxel, a 
chemotherapy drug (Tannock et al., 2004), which was followed over the next decade by 
sipuleucel-T (immunotherapy), cabazitaxel (taxane), abiraterone (CYP17 inhibitor), radium 
223 (α-emitter), and enzalutamide (androgen receptor antagonist) (Park & Eisenberger, 
2015).  
Treatment options for bone metastases are also very limited. Currently, no curative options 
are available for bone metastases, instead treatment options look to reduce symptomatic 
issues associated with the tumour. For example, bisphosphonates are able to disrupt 
osteoclast function and are the standard treatment for tumour-induced hypercalcaemia 
(Body et al., 1996). Denosumab, a monoclonal antibody able to inhibit RANKL signalling is 
also used to inhibit osteoclast function and prevent bone loss, and has been shown to 
improve the outcome of patients with castration-resistant PCa (Smith et al., 2015). Bone 
metastasis associated pain is treated in a number of ways, with varying degrees of success. 
Radiotherapy provides pain relief, although the mechanism for this is not understood 
(Maisano et al., 2001). Analgesia for bone metastases comes in a number of forms and 
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depends on the severity of the pain. These range from NSAIDs and paracetamol to mild 
opioids such as codeine and even stronger opioids such as morphine and oxycodone (Marras 
& Leali, 2016). Surgery is only indicated for the repair of fractured bones or relieving nerve 
compression (Selvaggi & Scagliotti, 2005).  
1.3.3.3 The Importance of Cell Signalling in PCa Bone Metastases 
As discussed in section 1.3.3.1.1 and in figure 1.6, the network of signalling molecules 
governing the function of bone cells within a PCa secondary site is extremely complex. Cell 
signalling can occur in a number of ways, including paracrine, autocrine endocrine and 
synaptic signalling. Frequently, in cancer, cellular signalling pathways become dysregulated. 
For years, cell signalling was focussed on the release of ligands, commonly proteins or 
hormones and their interactions with receptors on the target cell. However, the recent 
discovery of several small nucleic acid molecules has challenged the definition of what is/is 
not a signalling molecule (Cech & Steitz, 2014). Nucleic acid signalling functions without the 
need for receptors and can deliver/alter genetic information within the target cell. One of 
these recently discovered groups of nucleic acis are the microRNAs. 
1.4 miRNAs: 
MicroRNAs (miRNAs, miRs) are 19-25nt single stranded RNAs that regulate gene expression 
at the post-transcriptional level, targeting the 3’untranslated region (UTR) of protein coding 
mRNAs utilising a complementarity dependant mechanism.  
1.4.1 miRNA Biogenesis 
miRNA biogenesis is a complex multistep process, of which certain aspects are still not fully 
understood. miRNA synthesis has two main processing stages; the nuclear and cytoplasmic 
stages (figure 1.7). 
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Figure 1.7: miRNA biogenesis pathway showing both the nuclear and cytoplasmic stages. (Nuclear stage) Pri-miRNAs are transcribed from DNA 
by RNA Polymerase II. Pri-miRNAs are cleaved to pre-miRNAs by the enzyme drosha. Pre-miRNAs are exported out of the nucleus by exportin 5. 
(Cytoplasmic stage) premiRNAs are cleaved by the enzyme dicer to form mature miRNAs, which associate with RNA-induced silencing complexes 
(RISCs) which fascilitate their mRNA regulatory effects (adapted from Ryan et al., 2015). 
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1.4.1.1 Nuclear Processing 
In terms of processing pathways, two types of miRNA exist; intergenic (exonic) miRNAs and 
coding-intronic miRNAs. The most commonly documented pathway of miRNA synthesis 
follows the lineage of intergenic miRNAs. Intergenic miRNAs are transcribed by RNA 
polymerase (pol) II or III. The resulting RNA product is a primary miRNA (pri-miRNA), a hairpin 
structure several kilobases (sometimes >10 kilobases) in length that features lower stem, 
miRNA duplex, upper stem and terminal loop sections (Han et al., 2006) (figure 1.8). Within 
the nucleus, pri-miRNAs undergo a cleavage process known as “cropping”, catalysed by the 
ribonuclease (RNase) III member; Drosha (Lee et al., 2003a). For cropping to occur, Drosha 
requires the activity of a cofactor; DiGeorge syndrome critical region gene 8 (DGCR8) which 
binds Drosha to form a complex known as the microprocessor (Denli et al., 2004). The stem 
of a pri-miRNA (the total section between the basal single stranded tails and apical terminal 
loop) contains 3 helical turns (Han et al., 2006). The microprocessor recognises the basal 
single stranded segment junction and facilitates cleavage of pri-miRNAs on the stem ~11bp 
(roughly one helical turn) away from this, forming precursor miRNAs (pre-miRNAs). 
Occasionally, cleavage can also occur ~11bp from the apical junction on a pri-miRNA, 
resulting in cleavage of the miRNA sequence, a process known as “unproductive processing” 
or “abortive processing”.  
Although also transcribed by RNA pol II, coding-intronic miRNAs are processed differently 
within the nucleus. Due to their location within the intron of a protein coding gene, these 
miRNAs are transcribed as part of a pre-mRNA (Rodriguez et al., 2004). From here two main 
hypotheses exist as to how miRNAs are excised from these pre-mRNAs. The first involves 
splicesomal components that excise and debranch the introns from the pre-mRNAs (Lin et 
al., 2003). Within this a number of potential sub steps may occur, the exact nature of which 
is still unclear. The splicesome may release pri-miRNAs, which subsequently acquire a stem 
loop structure and are processed by Drosha and DGCR8 as intergenic miRNAs do. Conversely 
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they may produce pre-miRNAs directly. Furthermore a third molecule may be produced, a 
small 50-200nt intronic section able to support hairpin formation, termed a mirtron 
(Macfarlane & Murphy, 2010). Although the subsequent pathway of mammalian mirtrons 
have not yet been studied, it is suggested based on invertebrate mirtrons that they bypass 
microprocessor cleavage and are exported similar to pre-miRNAs (Ruby et al., 2007). The 
second hypothesis is that the microprocessor directly liberates pre-miRNAs from pre-mRNAs 
(Kim & Kim, 2007), these pre-miRNAs follow the same lineage as pre-miRNAs produced from 
pri-miRNA cleavage from both intronic and exonic sources.  
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Figure 1.8: Pri-miRNA structure.  Structure of pri-miRNA showing two mature miRNA 
strands  (green & red) released during later processing (adapted from Zhu et al., 2013) 
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1.4.1.2 Nuclear Export 
Further processing of pre-miRNAs occurs within the cytoplasm and thus pre-miRNAs must 
translocate the nuclear envelope. This translocation occurs through nuclear pore complexes 
(NPCs). NPCs are tube like structures that connect the nucleoplasm to the cytoplasm and are 
around 100-150nm in diameter, with an internal diameter of 9nm and a cut off weight for 
free diffusion of 60-100kDa (Wang & Brattain, 2007). Pre-miRNA export through NPCs is 
mediated by the nucleocytoplasmic transport factor; Exportin 5 (Exp5) in a RanGTP 
dependent manner. Exp5 recognises the 3’ 2nt overhangs on pre-miRNAs (Wang et al., 2011), 
however in free solution, the inner surface of Exp5 is distorted and residues within Exp5 
“lock” the entrance of the 3’ overhang binding site. Binding of Ras-related nuclear protein 
(Ran)GTP rigidifies the Exp5 in a tight curved conformation, aiding pre-miRNA binding (Wang 
et al., 2011). Binding of the pre-miRNAs to Exp5 begins with the pre-miRNA 3’ 2nt overhang 
adopting a fully closed state, which reduces steric barriers, allowing easier entry of the pre-
miRNA into the Exp5 pocket. As the pre-miRNA reaches the bottom of the pocket, the Exp5 
facilitates the movement of negative phosphodiester groups on the 3’ end of the pre-miRNA 
forming an extended state. This extended state eases the binding of the pre-miRNA to the 
Exp5 pocket. Widening of the minor groove within the double helix stem of the pre-miRNA 
also aids Exp5 binding. Furthermore, phosphate residues within the pre-miRNA major 
grooves form H-bonds with the basic area of Ran, increasing the stabilisation of the 
Exp5/GTP/RNA complex.  
The Exp5/GTP/RNA complex then translocates through the NPC utilising weak interactions 
between the complex and FG repeats within the NPC lumen (Katahira & Yoneda, 2011).  
After reaching the cytosol, Ran binding protein (RanBP1) binds the molecule causing the 
dissociation of RanGTP and RanBP1 from the remaining Exp5 whilst also releasing the pre-
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miRNA (Bischoff & Gorlich, 1997). Once removed from the complex, RanGTP is hydrolysed 
by RanGAP to form RanGDP, which then dissociates from RanBP1.  
1.4.1.3 Cytoplasmic Processing 
Cytoplasmic processing of miRNAs is centred around the removal of the hairpin loop from 
pre-miRNAs by the RNase III Dicer. This process occurs in conjunction with the loading of the 
pre-miRNA onto the RNA induced silencing complex (RISC).  
1.4.1.4 RISC Loading 
The process of mRNA regulation by miRNAs is facilitated by the guiding of an associated 
group of proteins known as the RISC. RISC is the term given to a family of heterogeneous 
molecular complexes capable of silencing a multitude of genes (Pratt & MacRae, 2009). The 
minimal requirements of a RISC capable of gene recognition and silencing are an Argonaute 
(Ago) protein and a small RNA (Rivas et al., 2005), with the RNA providing the guidance and 
specificity, and the Ago protein exerting the silencing effect. However RISC isolations display 
vast variability due to the extensive list of potential Ago protein binding partners. The human 
genome encodes four different Ago proteins, of which only Ago2 is capable of catalytic RNA 
slicing (Liu et al., 2004). Ago proteins have four distinct domains; the N-terminal, PAZ, Mid 
and PIWI domains. The PAZ domain recognises the 3’ end of miRNAs and siRNAs and is able 
to bind these in a sequence independent manner (Lingel et al., 2004; Ma et al., 2004). The 
PIWI and Mid domains are responsible for binding and anchoring the 5’-phosphate, which 
binds to a divalent cation at the interface between the two domains (Ma et al., 2005; Parker 
et al., 2005). 
RISC assembly in mammals is still relatively unclear, Drosophila RISC assembly is 
characterised much more clearly and early mammalian RISC hypotheses were often based 
on this. Early work from Maniataki and Mourelatos (2005) suggested the requirement of a 
RISC loading complex (RLC) consisting of Ago, Dicer and TRBP. They hypothesised the binding 
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and cleavage of pre-miRNAs was carried out by Dicer in association with Ago and that the 
cleaved product was then oriented by DICER-TRBP heterodimers and transferred to Ago. 
However miRNA mediated RNA interference (RNAi) still takes place in Dicer KO cells 
transfected with small RNA duplexes, indicating the role of Dicer is at least cleavage and 
handover based rather than being involved in small RNA delivery to Ago alone 
(Kanellopoulou et al., 2005). Subsequent work by Liu et al. (2012) has since shown that 
expression of non-functional Dicer mutants causes a build-up of RLC, indicating that Dicer 
processing of pre-miRNAs and loading may trigger the dissociation of Ago from the RLC. The 
findings of Liu et al. (2012) are consistent with those of Maniataki and Mourelatos (2005) 
suggesting Dicer is involved in the handover of cleaved small RNA duplexes from pre-miRNAs 
to Ago proteins, but at the same time do not exclude the possibility of Dicer independent 
loading of small RNA duplexes shown by Kanellopoulou et al. (2005).  
Cleavage of pre-miRNA begins with the recognition of the 3’ 2nt overhang on pre-miRNAs by 
the PAZ domain of Dicer, which initiates binding (Zhang et al., 2004).  Intermolecular 
dimerisation of two RNase III domains within Dicer create a catalytic centre that cleaves the 
pre-miRNA using the distance between the PAZ and RNase III domains as a guide (Zhang et 
al., 2004).  
As discussed, after processing by Dicer in the RLC, miRNAs exist as duplexes consisting of the 
guide strand; which is essential for guiding the RISC, and the passenger strand; which is 
degraded once released from the guide strand. These duplexes have characteristic 5’ 
monophosphates and 3’ 2-nucleotide overhangs, crucial for Ago loading as discussed 
(Nakanishi, 2016). These characteristic 5’ and 3’ groups aid the docking of the RNA duplex 
within the Ago protein at the PAZ and PIWI domains as mentioned previously. Furthermore 
the ‘seed’ region of the guide strand, located between nucleotides 2 and 8, is recognised by 
the nucleic acid binding channel via the 2’ hydroxyl groups and phosphate backbone (Schirle 
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& MacRae, 2012). The loading of RNA duplexes into the Ago proteins is an ATP-dependant 
process requiring the action of chaperone machinery consisting of Heat shock cognate 
(Hsc)70/90 (Iwasaki et al., 2010). The energy from adenosine triphosphate (ATP) hydrolysis 
is used to ‘stretch’ the Ago protein so as to allow entry of the bulky RNA duplex, often 
referred to as the “rubber band model” (Kawamata & Tomari, 2010). It is suggested that 
unwinding of the duplex RNA is performed by RNA helicase A (RHA), a DEAH-box protein 
capable of unwinding RNA duplexes with 3’overhangs (Robb & Rana, 2007).  
Interestingly, pre-miRNAs can also directly bind Ago2 without prior processing. The pre-
miRNA-Ago complex is termed the miRNA precursor deposit complex (miPDC). Ago2 cleaves 
the middle of the 3’ strand, generating a small “ac-pre-miRNA” fragment (Diederichs & 
Haber, 2007), a process that is believed to aid in removal of the 3’ passenger strand. 
Furthermore, pre-miR-451 actually bypasses Dicer-dependant biogenesis altogether 
(Cheloufi et al., 2010). Instead, pre-miR-451, which is shorter than other pre-miRs, binds 
Ago2, upon which its 3’ strand is cleaved. From here a process of uridylation and trimming 
of the 3’ end produces a mature 23nt miRNA bound to Ago2, capable of acting as a functional 
RISC.  
1.4.2 miRNA Mediated Gene Regulation 
1.4.2.1 miRNA Binding  
miRNA mediated gene regulation is achieved through binding of the miRNA and the RISC to 
protein coding mRNAs. These interactions are thought to be dependent on the level of 
complementarity between the two strands. Metazoan miRNA targets often show a high level 
of complementarity to a 6-8 nucleotide section at the 5’ end of the miRNA, known as the 
‘seed region (Brennecke et al., 2005). miRNAs can bind to a number of areas on a target 
mRNA (figure 1.9) The main mechanism for this interaction is the binding of the miRNA/RISC 
to the 3’ UTR of its target mRNA. In animals this interaction generally results in the 
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translational repression or degradation of the target mRNA, however in some rare cases it 
can result in the endonucleolytic cleavage of the mRNA (reviewed by Ameres & Zamore, 
2013).   
As well as binding the 3’ UTR of their mRNA targets, miRNAs are able to bind the 5’ UTR 
(figure 1.9). miRNAs binding to the 5’ UTR of their mRNA targets also leads to translational 
repression (Lytle et al., 2007) but binding here can also enhance translation of the gene in 
some cases (Orom et al., 2008). Tay et al. (2008) showed an additional ability of miRNAs to 
bind to the coding sequence of an mRNA target (figure 1.9) whereupon translational 
repression again occurred.  
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Figure 1.9: Mechanism of miRNA and RISC binding to target mRNAs and the associated outcome. miRNA/RISC can either bind to the 
3’UTR, resulting in mRNA degradation or translational repression, the 5’UTR, resulting in translational repression of translational 
activation, or to the coding sequence, resulting in translational repression (adapted from Ling et al., 2013). 
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1.4.2.2 Non-Cleavage Mediated Regulation 
The majority of human miRNA gene regulation is carried out in a non-cleavage mechanism. 
This is due to, amongst other factors, the fact that of the four human Ago proteins, only Ago2 
is capable of catalysing mRNA cleavage (Liu et al., 2004). Non-cleavage mechanisms of gene 
regulation are namely translational repression and miRNA degradation.  
1.4.2.2.1 Translational repression  
Translational repression is described as an observation of decreased protein that is greater 
than the decrease in the level of the associated mRNA. Translation consists of three main 
steps; ribosome initiation, elongation and termination (Gu & Kay, 2010). Initial studies were 
conflicting on which stage of translation the repression occurred at, with some arguing it 
occurred at the post initiation stage (Petersen et al., 2006) and some arguing it occurred 
during translation initiation (Mathonnet et al., 2007). Furthermore, multiple molecules such 
as translation initiation factors were proposed as being crucial (Chendrimada et al., 2007; 
Kiriakidou et al., 2007). These findings, along with reports suggesting that the protein GW182 
is crucial for miRNA mediated translational repression (Eulalio et al., 2008; Iwasaki et al., 
2009), lead Gu and Kay (2010) to propose a model for translational repression (figure 1.10 A-
D). This model suggests translational repression may occur in multiple different ways, 
mediated by GW182. These include; 
 GW182 and poly a binding protein (PABP) competing with eukaryotic translation 
initiation factor-4G (eIF4G) to prevent circularisation of the mRNA required for 
translation (figure 1.10A) 
 Preventing association of 60s and 40s ribosomal subunits (figure 1.10B 
 Slowing of ribosomes along the mRNA (Figure 1.10C) 
 Initiating premature termination of translation (Figure 1.10D)
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Figure 1.10: Proposed mechanisms for miRNA mediated translational repression. (A) GW182 and PABP competing with eIF4G 
to prevent circularisation of the mRNA required for translation, (B) Preventing association of 60s and 40s ribosomal subunits, (C) 
Slowing of ribosomes along the mRNA, (D) Initiating premature termination of translation. (E) Mechanism of mRNA degradation 
(Gu & Kay, 2010). 
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1.4.2.2.2 mRNA Degredation 
mRNA degredation, in a mechanism separate from endonucleolytic cleavage, represents 
>84% of miRNA mediated mRNA repression in mammals (Guo et al., 2010). mRNA 
degradation is also mediated by GW182. GW182 first mediates deadenylation of the mRNA 
followed by de-capping before negative on TATA (NOT)/ carbon catabolite repressor 4 
(CCR)4/ chromatin assembly factor-1 (CAF1) complexes degrade the mRNA (figure 1.10E) (Gu 
& Kay, 2010).   
Djuranovic et al. (2012) and Bazzini et al. (2012) have subsequently shown that translational 
repression may actually precede mRNA degradation. This balance between repression and 
degradation of the mRNA is dependent on the interactions of the miRNA with 3’ UTR proteins 
as well as local translational regulators/mRNA decay machinery (Hu & Coller, 2012).  
1.4.2.3 Endonucleolytic Cleavage 
Endonucleolytic cleavage of target mRNAs is rare in animals. As discussed, only AGO2 has 
cleavage capability whereas Ago1, Ago3 and Ago4 do not (Liu et al., 2004). For cleavage to 
occur, complementarity must be extremely high between the miRNA and its target mRNA. 
One example of this is miR-196a and its ability to cleave HoxB8 mRNA (Yekta et al., 2004). 
miRNA-196a and HoxB8 are complementary on 20/22 base pairs, and as frequently occurs in 
plants, cleavage of the mRNA occurs opposite nucleotides 10 and 11 on the miRNA (Ameres 
& Zamore, 2013). This cleavage then leaves the mRNA open to exonucleic degradation from 
both 5’-3’ and 3’-5’ directions by exoribonuclease 1 (XRN1) and the exosome complex 
respectively.  
1.4.2.4 Translational Activation 
As discussed, although miRNAs are generally known as repressors of gene expression, they 
are also able to activate genes. Usually this activation occurs in an indirect manner, via the 
repression of a gene repressor, thus increasing the expression of a particular gene. miR-128 
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for example, targets nonsense-mediated decay machinery in the brain during mammalian 
neuronal differentiation, therefore increasing the amount of local mRNAs involved in neuron 
and brain function (Bruno et al., 2011).  
Interestingly Place et al. (2008) showed that miR-373 is able to directly induce expression of 
its target genes, namely E-cadherin and cold shock domain containing C2 (CSDC2). This 
activation is triggered by miR-373 binding to a complementary site within the promotor of 
these gene and functioning similar to a transcription factor. 
The action of some miRNAs appears to be dependent on cell cycle status. In proliferating 
cells miR-369-3 represses tumour necrosis factor alpha (TNFα). However, during G1/G0 arrest 
miR-369-3 activates TNFα translation by recruiting fragile X mental retardation–related 
protein 1 (FXR1) and Ago2 to AU-rich elements within the 3’UTR of the TNFα mRNA 
(Vasudevan et al., 2007). This change in miR-369-3 function at different cell cycle states is 
thought to be dependent on differential subcellular localisations of Ago2-FXR1 complexes 
during different stages of cell cycle (Vasudevan & Steitz, 2007). 
1.4.3  GW-Bodies 
Many components of the RNAi pathway such as Ago proteins are concentrated in GW-
bodies, distinct foci within eukaryotic cytoplasm (Jakymiw et al., 2005). Furthermore, 
knockdown of GW182, another crucial component of RNAi prevented the formation of GW-
bodies (Yang et al., 2004), further emphasising a link between RNAi and GW-bodies. miRNA 
induced RNAi is therefore believed to occur within these bodies (Jakymiw et al., 2005) 
however there is still an abundance of non GW-body associated RNAi components (Leung et 
al., 2006). miRNA function is now believed to occur not only in GW-bodies, but in other 
cellular compartments such the nucleus and mitochondria (Leung, 2015). 
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1.4.4 miRNA Isoforms 
It is now known that many miRNAs may comprise multiple isoforms (Westholm et al., 2012). 
These isoforms, or isomiRs have mostly the same sequence as the original miRNAs, with 
modifications at either the ends or to internal nucleotides, allowing them to be identified as 
isomiRs and not different miRNAs. Three main mechanisms exist for generating isomiRs; 
internal A to I editing, 5’ modifications and 3’ modifications.  
1.4.4.1 Internal miRNA Isoforms 
Internal A to I editing is rare and is carried out by adenosine deaminase acting on RNA (ADAR) 
(Hundley & Bass, 2010). Editing of miRNAs in this way can affect RISC loading (Iizasa et al., 
2010) and if editing occurs within the seed sequence, can also affect target 
recognition/binding (Gandy et al., 2007).  
1.4.4.2 3’miRNA Isoforms 
3’ modifications to miRNAs can be either trimming (removing nucleotides) or tailing (adding 
nucleotides). Because the seed region, used for target recognition, is measured from the 5’ 
end of the miRNA, adaptations to the 3’ end are proposed to produce miRNAs with the same 
targets but different repression capabilities. Trimming in Drosophila requires the 3’-5’ 
Exoribonuclease Nibbler (Liu et al., 2011) which removes 2nt from the 3’ end of 24nt Ago1 
loaded miRNAs. A similar process of 3’ trimming of Ago bound miRNAs in mammals has been 
seen (Juvvuna et al., 2012) although as yet the protein that facilitates this remains unknown.   
The monouridylation of pre-miRNAs by the terminal nucleotidyl transferases (TNTases) 
ZCCHC11 and ZCCHC6 can enhance Dicer activity on miRNAs (Heo et al., 2012), and if 
uridylation occurs on the 3’ arm, this will be propagated into the mature miRNA. Addition of 
an adenosine to a mature miRNA by Germ line development 2  (GLD2) can also occur, 
increasing miRNA stability (Katoh et al., 2009). 
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1.4.4.3 5’ Isoforms 
As discussed, the seed region of miRNAs is measured from the 5’ end, therefore any 
alteration to the length of the 5’ end will result in a change in the seed sequence and 
subsequently alter the miRNAs targeting. 5’ isomiRs can be formed from the processing of 
different paralogous pre-miRNAs or from the imprecise trimming of pre-miRNA 5’ extensions 
(Chiang et al., 2010). 
1.4.5 Regulation of miRNA Expression 
DNA methylation is a substantial mechanism of miRNA regulation. Methylation 
predominantly occurs within the promotor of miRNAs and is correlated with decreased 
expression of the associated miRNAs (Deneberg et al., 2014; Jimenez-Wences et al., 2016; 
Qin et al., 2015). In these cases, aberrant methylation and subsequent changes in miRNA 
expression are associated with poor prognosis in multiple forms of cancer.  
Regulation of miRNA levels can also occur through changes in the levels of miRNA processing 
proteins. For example, Dicer and Drosha are both elevated in the dorsolateral prefrontal 
cortex of Schizophrenia patients, resulting in an overall increase in miRNA levels (Santarelli 
et al., 2011).  
Other factors such as hormone levels and exposure to xenobiotics such as carcinogens, 
including cigarette smoke and even alcohol can alter miRNA levels (Most et al., 2016; Shi et 
al., 2016; Zhang et al., 2012). Furthermore, due to the global expression of miRNAs and their 
role in a multitude of signalling pathways, it is likely that countless additional regulators of 
miRNA function will discovered in the future.  
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1.4.6 miRNAs in Prostate Cancer 
miRNAs play a role in most biological functions and their aberrant expression is linked to 
numerous diseased states, including multiple forms of cancer (Ardekani & Naeini, 2010; Li & 
Kowdley, 2012).  
In PCa, alterations to miRNA biogenesis machinery are common. However, these alterations 
tend to show a pattern of increased expression, with the opposite being rarely seen in PCa. 
Table 1.2 details the findings of a review by Kumar and Lupold (2016) linking overexpression 
of miRNA processing machinery to PCa: 
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Table 1.2 The effect of miRNA processing protein overexpression on PCa. 
Gene/Protein 
Overexpressed 
Details Reference 
DGCR8 (Drosha Cofactor) 
DGCR8 is overexpressed in 
primary tumours, knockout 
of DGCR8 caused decreased 
PCa progression 
(Ambs et al., 2008; Belair 
et al., 2015) 
DEAD box protein 5 (DDX5) 
(helicase component of 
Drosha complex) 
Overexpressed in PCa, 
related to AR signalling and 
possible hormone-
refractory disease. 
(Clark et al., 2008; Clark et 
al., 2013) 
EXP5 
Up-regulated in metastatic 
vs organ-confined PCa 
(Chiosea et al., 2006) 
Dicer* 
Up-regulated in metastatic 
vs organ-confined PCa and 
correlated to PCa staging 
(Chiosea et al., 2006) 
AGO1 
Up-regulated in metastatic 
vs organ-confined PCa 
(Chiosea et al., 2006) 
AGO2 
Not present in prostate 
gland basal or alveolar cells 
but present in 57% of 
prostate carcinoma samples 
(Yoo et al., 2010) 
Trinucleotide Repeat 
Containing 6A (TNRC6A) 
(GW body component, 
involved in RISC induced 
mRNA silencing) 
Not present in prostate 
gland basal or alveolar cells 
but present in 64% of 
prostate carcinoma samples 
(Yoo et al., 2010) 
*Although Dicer is upregulated in human PCa samples, lower Dicer levels are seen in 
recurring primary PCa tumours compared to non-recurrent tumours (Zhang et al., 2014). This 
indicates multiple roles of Dicer in PCa development and sustenance, a relationship that is 
not yet understood.  
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1.5 miRNA Therapeutics 
miRNA based therapeutics can be split into two main forms; treatments that utilise miRNA 
based gene silencing such as exogenous miRNAs and miRNA mimics, and treatments that 
decrease miRNA based gene silencing such anti-miRNA oligonucleotides (AMOs). The crux of 
miRNA therapeutics is centred around the simple idea of attempting to reduce the effect of 
tumour promoting miRNAs, or increasing the activity of tumour suppressive miRNAs.  
One of the biggest hurdles in the development and use of RNA based cancer therapies is the 
effective delivery of the RNA to target cells. Methods including conjugation of small RNAs to 
cholesterol or association with polymers (to create nanoparticles) are effective in increasing 
the delivery of RNA therapies and have been utilised in mouse studies (Hu-Lieskovan et al., 
2005; Krutzfeldt et al., 2005).  
Currently there is one miRNA based therapeutic in clinical trials. Phase I clinical trials of the 
miR-34 mimic MRX34 are underway after animal studies using MRX34 were able to show 
safety and reduced tumour growth (Daige et al., 2016). In Phase I trials, MRX34 showed 
several adverse effects (AEs) (Beg et al., 2017), most likely due to the multitude of 
downstream miR-34 targets. However these AEs are tolerable under dexamethasone pre-
treatment. Responses to MRX34 were mixed but some anti-tumour activity was seen in 
particular subsets of patients (Beg et al., 2017; Hong et al., 2016).  
1.6 Extracellular Transport of miRNAs 
1.6.1 Free transport  
Ribonucleases (RNases) are abundant in circulation and are elevated further in certain 
pathologies including cancer (Reddi & Holland, 1976). Therefore, it was hypothesised that 
miRNAs are not exported as naked RNA molecules. This was confirmed by Tsui et al. (2002) 
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who showed that >99% of synthetic RNA in plasma was degraded within 15 seconds. Since 
then, a number of molecules have been discovered that are known to shuttle extracellular 
miRNAs. Arroyo et al. (2011) showed that Arganaut2 (Ago2), the catalytic component of the 
miRNA RISC is present in human serum and is associated with miRNAs. Vickers et al. (2011) 
found that purified HDL contained miRNA and that the level of miRNA associated with HDL 
changes during a diseased state. They also showed that HDL molecules can associate with 
exogenous miRNA in culture and are capable of delivering miRNAs to co-cultured cells.  
1.6.2 Vesicular Transport 
miRNAs are also exported in extracellular vesicles (EVs). Three types of EV are involved in 
exportation; microvesicles (MVs), exosomes and apoptotic bodies. miRNAs within EVs may 
be considered more likely signalling molecules than non-vesicular miRNAs due to the 
protective effects of vesicle encapsulation (Turchinovich et al., 2013). Exosomes and MVs are 
formed as a part of regular cell processes, although their production can be stimulated under 
the influence of stress and/or exogenous stimuli. Converesely, apoptotic bodies, as their 
name suggests, are only formed during programmed cell death (Akers et al., 2013). Thus MVs 
and exosomes often attract more attention in terms of their ability as signalling molecules.  
Although biological definitions exist for individual vesicle subtypes, the increasingly apparent 
difficulty in isolating specific vesicle subtypes has prompted a shift in vesicle nomenclature. 
When referring to isolated vesicles throughout this thesis, intracellular/endosomal vesicles, 
including exosomes, as well as some smaller membrane derived vesicles, will be referred to 
as small extracellular vesicles (sEVs). Conversely, larger membrane derived vesicles, such as 
microvesicles and apoptotic bodies, will be referred to as large extracellular vesicles (lEVs). 
This is except for when referencing papers which specifically refer to exosomes, 
microvesicles or apoptotic bodies by name.  
Chapter I: Introduction 
58 
 
1.6.3 MVs 
MVs are around 100-1000nm in size. MVs are formed by a process known as membrane 
blebbing, where membrane budding and fission occurs to release cytosolic contents into the 
extracellular space (Cocucci et al., 2009). This fission resembles that of the abscission step of 
cytokinesis where contractile machinery brings opposing membranes together and cuts 
within the cleavage furrow (Schweitzer & D'Souza-Schorey, 2004). MVs are abundant within 
the circulation of healthy individuals, with the majority of these MVs being platelet derived 
(Horstman & Ahn, 1999). Furthermore it is now well known that MV levels are often elevated 
in diseased states (Galindo-Hernandez et al., 2013; Harms et al., 2015; VanWijk et al., 2003). 
1.7 Exosomes 
Exosomes are 40-100nm lipid-bilayer vesicles first described in 1981 (Trams et al., 1981) as 
extracellular vesicles with 5’-nucleotidase activity. Shortly after, Harding et al. (1983) 
redefined exosomes as vesicles of an endosomal origin released during rat reticulocyte 
maturation as a method of releasing transferrin receptors.  
1.7.1 Exosome Biogenesis   
Exosome biogenesis begins with the invagination of the plasma membrane (PM), budding to 
form endosomal compartments in a clathrin-dependent manner or by clathrin-independent 
pathways such as calveolae or lipid raft endocytosis (figure 1.11) (Doherty & McMahon, 
2009). These endosomes are then directed to the sorting endosomes (SEs); highly specialised 
comparements that act to accept and sort internalized cargo from the PM (Gruenberg et al., 
1989). SEs are responsible for sorting cargo destined for a variety of cellular destinations such 
as late endosomes or recycling to the PM. Within SEs, vacuolar regions exist, where inward 
budding of the limiting membrane generates intraluminal vesicles (ILVs) of around 50nm in 
size (Mari et al., 2008). Generation of ILVs depends on the actions of a number of proteins 
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such as Endosomal Sorting Complex Required for Transport (ESCRT) proteins and ESCRT 
associated proteins such as ALG-2-interacting protein X (ALIX) and tumour susceptibility gene 
101 protein (TSG101) which are involved in cargo sorting as well as membrane budding and 
abscission (reviewed by Kowal et al., 2014). Other non-ESCRT proteins are also involved in 
ILV generation such as phospholipase D2 (PLD2) and CD63 (Laulagnier et al., 2004; van Niel 
et al., 2011) as well as the sphingolipid ceramide (Trajkovic et al., 2008). These vesicle rich 
regions of the SE can either mature or detach to form multivesicular endosomes (MVEs) 
(Bissig & Gruenberg, 2013). If the content of these ILVs is destined for degradation, MVEs 
can mature into lysosomes or interact with lysosomes already present in the cytosol (Luzio 
et al., 2007).  
1.7.2 Exosome Secretion 
If the ILV cargo is destined for extracellular release, the MVE must fuse with the PM. The 
process of MVE trafficking to the PM is complex and is known to involve multiple proteins 
including the Rab family of small GTP-ases. Rab proteins are involved in multiple steps of 
membrane organisation including budding, trafficking, docking and fusion (figure 1.11). 
Rab11 and Rab35 are both believed to be involved in the sorting of early ILV containing 
endosomes (Kowal et al., 2014). In more mature MVEs, Rab27a and Rab27b are responsible 
for extracellular exosome release. Ostrowski et al. (2010) showed that silencing of Rab27a 
or Rab27b resulted in a build-up of intracellular MVEs indicating that both are involved in PM 
docking. However differing MVE size and subcellular clustering proved that RAB27a and 
Rab27b are responsible for different aspects of MVE trafficking and PM docking. Ostrowski 
et al. (2010) also showed that Rab2b, Rab5a and Rab9a were involved in exosome secretion.  
Release of the exosomes requires the fusion of the PM and MVE membrane. This process is 
mediated by another GTPase; RAL-1 (Hyenne et al., 2018), which activates complexes 
consisting of the target soluble NSF-attachment protein receptor (t-SNARE) protein syntaxin 
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5 (Syx5) and vesicle (v)-snares on the surface of the MVE. Vaculolar H+-ATPases (V-ATPases) 
are also involved in MVE-PM tethering and fusion (Liegeois et al., 2006), knockdown of VHA-
5, part of the transmembrane V0 subunit of the V-ATPase resulted in a decrease in MVE 
tethering/fusion and subsequent exosome release. However whether V-ATPases affect 
membrane fusion by creating a H+ gradient or creating a fusion pore remains unknown 
(Maxson & Grinstein, 2014).  
Although knowledge of these factors and pathways has grown dramatically in recent years. 
The full repertoire of endogenous factors responsible for exosome biogenesis, trafficking and 
exocytosis are still completely understood and may indeed be prone to change by external 
stimuli. 
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Figure 1.11: Intracellular exosome trafficking pathways. ESCRT proteins, lipids (including ceramide) and 
tetraspanins are involved in ILV formation. RAB11 and RAB35 are involved in sorting early ILV containing 
endosomes. RAB27a and RAb27b are involved in the extracellular release of MVEs (adapted from Kowal et al., 
2014). 
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1.7.3 Exosome Content  
Exosomal contents have been widely studied and a plethora of molecules have been found 
both internally and within exosomal membranes. Full characterisation of exosomal 
molecules is difficult due to the differential expression of molecules between exosomes of 
different cell types (Griffiths et al., 2017). This characterisation is further complicated by 
variation in exosomal molecules between cells of the same type. For example exosomes 
released from apical or basolateral surfaces of the same cell can even exhibit differences in 
the expression of exosomal molecules (van Niel et al., 2001; Willms et al., 2016). 
Whilst exosomes vary dramatically in the levels of certain molecules, there are a set of 
molecules associated with what is currently believed to be most, if not all exosomes 
(highlighted in figure 1.12). Of the ~2,400 proteins found in exosomes (Mathivanan & 
Simpson, 2009) heat shock protein (Hsp)70, Hsp90 and MHC molecules are present in most 
(Blanchard et al., 2002; Thery et al., 2002). The tetraspanins CD9, CD63, CD81 and CD82 are 
the proteins most commonly associated with exosomes, and as a result are often used in the 
characterisation of exosomal isolations (Jorgensen et al., 2013). Other proteins such as ALIX 
and TSG101, involved in exosome biogenesis (see section 1.7.1) are also present in 
exosomes. 
As well as proteins, a number of nucleic acids are present within exosomes. Vast quantities 
of tRNA, rRNA and mRNAs are present along with a number of small non-coding RNAs (Huang 
et al., 2013; Li et al., 2014). Of all the small RNAs, miRNA is the most abundant in exosomes, 
making up around 76% of all sequences in exsosomal short RNA libraries (Huang et al., 2013).  
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Figure 1.12: Exosomal intracellular and surface contents. Exosomes contain crucial surface molecules such as the tetraspanins, lipids 
such as ceramide and MHC molecules. Exosomes also contain a wide range of intracellular cargo such as miRNAs, mRNAs, HSPs as well 
as proteins such as ALIX and TSG101 involved in MVE formation (adapted from Gupta & Pulliam, 2014). 
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1.7.3.1 Sorting of Exosomal miRNAs 
Due to the way exosomes are synthesised, by inward budding of the endosomal membrane, 
it could easily be assumed that they simply randomly sample the nearby cytoplasm. 
However, studies have subsequently found that concentrations of molecules such as miRNAs 
are found at different levels in exosomes than in whole cells (Montecalvo et al., 2012; Valadi 
et al., 2007) These stoichiometric differences suggest a selective packaging mechanism for 
exosomes, further indicating their potential as dedicated signalling molecules.  
Current evidence points toward four potential methods for miRNA packaging into 
exosomes (outlined by Zhang et al., 2015): 
1. Kosaka et al. (2013) showed that overexpression of neural sphingomyelinase 2 
(nSMase2) increased the quantity of exosomal miRNA and conversely, inhibition of 
nSMase2 had the opposite effect.   
2. Heterogenous nuclear ribonucleoprotein (hnRNP)A2B1 recognises a GGAG motif in 
the 3’ end of the miRNA. This recognition targets specific miRNAs for exosomal 
packaging (Villarroya-Beltri et al., 2013). 
3. Koppers-Lalic et al. (2014) demonstrated a role for 3’ end motifs in the sorting of 
miRNAs. Adenylated miRNAs were predominantly found in RNA samples from 
whole B cells, whereas uridylated miRNAs were found to be overexpressed in 
isolated B cell exosomes.  
4. Ago2 has also been linked to exosomal miRNA sorting. Knocking out Ago2 resulted 
in a decrease in the abundance of miRNAs that are preferentially exported in EVs 
by HEK294T cells such as miR-451, mIR-150 and miR-486 (Guduric-Fuchs et al., 
2012).  
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1.7.4 Exosome Internalisation 
A number of exosome internalisation mechanisms have been described in the literature. 
Some result in cellular responses whilst others result in exosome degradation and a 
termination of any signalling potential. Internalisation can occur in four main ways; fusion, 
phagocytosis, micropinocytosis and receptor/raft mediated endocytosis (figure 1.13) 
(McKelvey et al., 2015; Mulcahy et al., 2014).  
 
 
 
 
 
Chapter I: Introduction 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: Mechanisms of EV uptake. The main mechanisms of EV uptake are fusion, 
phagocytosis, micropinocytosis and receptor/raft mediated endocytosis (Mulcahy et al., 
2014). 
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Fusion of exosomes with target cells has been seen in the uptake of exosomes by melanoma 
cells, and is mediated by the lipid composition of the target cell membrane (Parolini et al., 
2009). Internalisation of exosomes by phagocytosis has also been proven (Feng et al., 2010). 
Phagocytosis of exosomes requires the action of opsonin receptors such as Fc receptor (FcR) 
and complement receptors, and subsequently this process occurs more efficiently in 
phagocytic cells. Phagocytosis is primarily a mechanism of lysosomal clearance, however, 
whether this can also be a route of exosomal genetic transfer remains unclear. 
Macropinocytosis, stimulated by phosphatidylserine on the surface of exosomes is a method 
of internalisation for non-antigen-presenting cells (Fitzner et al., 2011). This process is often 
mediated by NA+ and phosphoinositide 3-kinase (PI3K) within the target cell (Tian et al., 
2014). Finally, receptor/raft mediated endocytosis can internalise exosomes by utilising 
interactions between exosomal ligands and cellular receptors. These interactions result in in 
clathrin mediated endocytosis, whereas caveolae mediated endocytosis is not involved in 
exosome uptake (Svensson et al., 2013; Tian et al., 2014).  
Internalisation of exosomes represents the majority of mechanisms that allows transfer of 
internal exosomal genetic material such as miRNAs, along with direct fusion of the vesicle 
and cell membranes. However, non-internalisation based signalling of exosomes can occur 
via interactions between target cell receptors and membrane bound or soluble exosomal 
ligands (McKelvey et al., 2015). FasL and TRAIL can all be cleaved from exosome surfaces to 
form soluble ligands and can also interact with target cells in their membrane bound form. 
Exosomal MHC molecules can also interact with target cell plasma membrane receptors, 
triggering signalling pathways (McKelvey et al., 2015).  
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1.8 Study Aims 
In this study we look to uncover the signalling relationship between PCa cells and bone cells, 
hopefully uncovering some of the mechanisms at play in the development of PCa bone 
metastases. Cancer cell sEVs have shown an ability to educate pre-metastatic sites including 
the bone, even in cancers with low bone metastatic tendencies (Peinado et al., 2012). 
Furthermore, sEV miRNAs have displayed an ability to alter key processes involved in bone 
metastatic development (Valencia et al., 2014). Osteoclast sEV miRNAs have also shown an 
ability to alter the function of bone cells, a crucial factor in the development of metastatic 
lesions (Sun et al., 2016). 
As discussed, sEVs and their associated miRNAs can have a multitude of effects on metastatic 
sites and the function of the cells within. Therefore, our hypothesis is as follows: 
Prostate cancer cells use small extracellular vesicles to deliver miRNAs to cells within the 
bone microenvironment during the development of bone metastases, thus altering the 
delicate balance of bone remodelling. 
To do this, our aims are: 
 To assess the miRNA content of PCa sEVs, looking at which are most abundant and 
whether miRs are being selectively packaged 
 To explore the effect of sEV treatment on the function of cells of the bone 
microenvironment 
 To implicate the sEV miRNAs in any changes seen in sEV treated bone cells
Chapter II: Materials and Methods 
69 
 
 
 
 
 
 
Chapter II: 
Materials 
and Methods 
  
Chapter II: Materials and Methods 
70 
 
2 Methods 
 Cell Lines 
The PC3, DU145 and LNCaP prostate cancer cell lines, the PZ-HPV-7 prostate epithelial cell 
line and the 7F2 osteoblast cell line used throughout this research project were all obtained 
from the American Type Culture Collection (ATCC, Middlesex, UK). Origin, characteristics and 
culture medium for all cell lines used are detailed in table 2.1.   
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Table 2.1 Cells, Characteristics and Culture medium 
 
Cell Line Species Morphology Origin Additional Information Culture Medium 
Prostate Cell Lines     
PC-3 
Homo sapiens 
Epithelial 
 
Caucasian male, aged 62 
Derived from bone metastasis from 
grade IV prostate adenocarcinoma. 
DMEM/F12 
DU145 
Homo sapiens Epithelial Caucasian male, aged 69 
Derived from prostate cancer brain 
metastasis. 
DMEM/F12 
LNCaP 
Homo sapiens Epithelial Caucasian male, aged 50 
From metastatic site; left 
supraclavicular lymph node 
RPMI-1640 
PZ-HPV-7 
Homo sapiens Epithelial Caucasian male, aged 70 
Derived from prostate epithelial cells 
harvested from the peripheral zone of 
the prostate. HPV-18 Transformed. 
keratinocyte media + 
bovine pituitary extract 
and human 
recombinant 
epidermal growth 
factor 
Bone Cell Lines     
7F2 Mus musculus Fibroblast 
(Osteoblast)  
Male mouse, aged 5-6 
weeks 
Isolated from p53-/- mouse. 
MEM + 10mL 200mM 
L-Glutamine 
RAW 264.7 Mus musculus 
Macrophage Adult male mouse 
Abelson murine leukaemia virus 
transformed 
DMEM/F12 
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 Primers 
Both Taqman® and SYBR® Green quantitative polymerase chain reaction (qPCR) was 
performed during this research project. Taqman® primers used are detailed in table 2.2 and 
SYBR® Green primers used are detailed in table 2.3. 
 Antibodies 
2.3.1 Primary Antibodies 
Primary antibodies used throughout this research project are detailed in table 2.5 including 
supplier, host species and dilution used. 
2.3.2 Secondary Antibodies 
For western blot, secondary antibodies were used to match primary antibody species and 
were either horseradish peroxidase (HRP) conjugated anti-mouse IgG (A5278) or anti-rabbit 
IgG (A6154) antibodies (Sigma-Aldrich, Dorset, UK).   
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Table 2.2 Taqman® primers used  
 
 
 
 
 
 
 
 
 
 
 
Primer Species Assay ID 
HPRT Mouse Mm03024075_m1 
β-Actin Mouse Mm02619580_g1 
AXIN2 Mouse Mm00443610_m1 
ACP5 (TRAP) Mouse Mm00475698_m1 
miR-16-5p Human 477860_mir 
miR-423-3p Rat rno478327_mir 
miR-423-5p Human 478090_mir 
miR-221-3p Rat rno481005_mir 
mIR-93-5p Human 478210_mir 
miR-222-3p Human 477982_mir 
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Table 2.3 SYBR® Green primers used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 
ACVR1 
F: TCTCCCTTGGAGCAGTCAGT 
R: CCTGGATCCATTCATCCCTGT 
MMP3 
F: TAAAGACAGGCACTTTTGGCG 
R: GGAGACCCAGGGTGTGAATG 
COL1A1 
F: GAGAGGTGAACAAGGTCCCG 
R: AAACCTCTCTCGCCTCTTGC 
DLX5 
F: TATGGCAAAGCGCTCAACCC 
R: TTCTTTCTCTGGCTGGCTGGT 
GAPDH 
F:  TGCACCACCAACTGCTTACG 
R:  GGCATGGACTGTGGTCATGAG 
RPL-19 
F: AGCGAGCTCTTTCCTTTCG 
R: GAGCCTCTTCTGAAGCCTGA 
DLL1 
F: ACCAAGTGCCAGTCACAGAG 
R: TCCATCTTACACCTCAGTCGC 
PLSCR4 
F: AAATGTCAGGTCTGGTCCCCA 
R: ACAAGGAGAGGCAACTGGTC  
ADRB2 
F: TGGTGGGCTACGTCAACTC 
R: TCCGTTCTGCCGTTGCTATT 
OSCAR 
F: TCGCTGATACTCCAGCTGTC 
R: CTAGGGGCGCTGTTGGTG 
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Table 2.4 Primers used for amplifying coding regions 
 
 
 
 
 
 
Primer Sequence 
AXIN2 
F: ATGAGTAGCGCCGTGTTAGTG 
R: TCAGTCGATCCTCTCCACTTTG 
DLL1 
F: ATGGGCCGTCGGAGCG 
R: TTACACCTCAGTCGCTATAACAC 
PLSCR4 
F: ATGTCAGGTCTGGTCCCCA 
R: CTATCTTGACATACGTCGCGG 
ADRB2 
F: ATGGGGCCACACGGGAAC 
R: TTACAGTGGCGAGTCATTTGTACTA 
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Table 2.5 Primary Antibodies used for Western Blot and Immuno-Phenotyping 
 
 
 
 
 
 
 
 
 
Antibody Code Company Dilution 
ALIX 3A9 Cell Signalling 1 in 1000 
CALNEXIN C5C9 Cell Signalling 1 in 1000 
AXIN2 Ab109307 abcam 1 in 1000 
RANKL Sc9073 Santa-Cruz 1 in 1000 
GAPDH 6C5 Santa-Cruz 1 in 500 
CD9 MAB1880 R&D Systems 1µg/mL 
CD63 MCA2142 AbD Serotec 1µg/mL 
CD81 MCA1847EL BioRad 1µg/mL 
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 Reagents and Solutions 
2.4.1 Solutions for General Laboratory Work 
2.4.1.1 Diethylpyrocarbonate (DEPC) water  
500µL of DEPC was topped up to 500mL using distilled water and left for 24 hours at RT 
before being autoclaved.  
2.4.1.2 Phosphate-Buffered Saline (PBS) 
A 10x PBS stock (Sigma-Aldrich) was diluted to a 1x solution using distilled water. PBS was 
then aliquoted and stored at room temperature.   
2.4.2 Solutions for Tissue Culture  
2.4.2.1 Trypsin-Ethylenediaminetriacetic Acid (EDTA) 
10x Trypsin-EDTA stock (Sigma-Aldrich) was diluted to a 1x solution with PBS. 
2.4.2.2 Antibiotic Antimycotic Solution (Abx) 
A 100x antibiotic antimycotic solution (10,000U/mL penicillin, 10mg/mL streptomycin, 
25µ/mL amphotericin B) (Sigma-Aldrich) was diluted to a 1x solution with distilled water. 
2.4.3 Solutions for Western Blot 
2.4.3.1 Lysis Buffer 
For 100mL 0.87g 150mM NaCl + 0.19g 5mM EGTA + 0.61g 50mM Tris + 1mL 1% (v/v) Triton 
X-100 was combined with dH2O. For use, one protease inhibitor tablet (Roche) was added. 
The solution was then aliquoted and stored at -20°C. 
2.4.3.2 Tris-Buffered Saline (TBS) 
10X TBS (Sigma-Aldrich) was diluted to a 1x soltuion using dH20. 
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2.4.3.3 10% w/v Ammonium Persulphate (APS) 
1g of APS (Melford Laboratories Ltd, UK) was dissolved in 9mL dH2O. The solution was the 
aliquoted and stored at -20°C. Once opened, APS was stored at 4°C for no longer than 2 
weeks.  
2.4.3.4 0.1% v/v TBS/Tween (TBST)  
1mL of Tween20 (melford Laboratories Ltd, UK) was added to 1L of TBS and mixed 
thoroughly.  
2.4.3.5 Running Buffer 
1L of 10x Tris Glycine SDS Buffer (Sigma-Aldrich) was added to 9L dH2O 
2.4.3.6 Transfer Buffer 
1L of 10x Tris/Glycine Concentrate Buffer (Sigma-Aldrich) and 2L of Methanol (Fisher 
Chemical) was added to 7L of dH2O. 
2.4.3.7 10% Sodium Dodecyl Sulfate (SDS) 
10g of SDS (Melford Laboratories Ltd, UK) was dissolved in 100mL of dH2O. 
2.4.4 Solutions for Bacteriology 
2.4.4.1 Lysogeny Broth (LB) 
8g of low salt LB (Melford Laboratories Ltd, UK) was added to 400mL dH2O and mixed until 
fully dissolved. The solution was then autoclaved. Before use and once cooled, 400µL of 
100mg/mL ampicillin (Sigma-Aldrich) was added. 
2.4.4.2 LB-Agar Ampicillin Plates 
8g of low salt LB (Melford Laboratories Ltd, UK) was added to 400mL dH2O and mixed until 
fully dissolved. 5g agar (Melford Laboratories Ltd, UK) was added, prior to sterilisation by 
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autoclaving. Once cooled, but still liquid, 400µL of 100mg/mL ampicillin (Sigma-Aldrich) was 
added. The solution was then poured into 10cm2 dishes to cool and solidify. 
2.4.5 Specialised Solutions 
2.4.5.1 RANKL 
Recombinant mouse RANKL (R&D Systems) was diluted to 10µg/mL in sterile PBS + 0.1% 
(w/v) bovine serum albumin (BSA).  
2.4.5.2 1x Reporter Lysis Buffer 
5x reporter lysis buffer (Promega) was diluted to a 1x solution with dH2O and stored at room 
temperature. 
 Cell Culture 
2.5.1 Cell Culture Medium 
Keratinocyte Serum Free Medium (Gibco) was supplemented with bovine pituitary extract 
and human recombinant EGF (Gibco). Mimimum essential medium eagle (MEM) (Sigma-
Aldrich) was supplemented with 1% v/v Abx, 2mM L-glutamine (Sigma Aldrich), 1mM sodium 
pyruvate (Thermo Fisher Scientific, Massachusetts, USA) and 10% (v/v) Foetal Bovine Serum 
(FBS). Dulbecco’s Modified Eagle’s Medium DMEM/F12 with L-glutamate (Sigma-Aldrich) 
was supplemented with 1% v/v Abx. RPMI-1640 was supplemented with 1% (v/v) antibiotics 
(penicillin-streptomycin 10,000U/mL) and 10% (v/v) FBS. 
2.5.2 Cell Passaging 
Cells were grown in 25cm2 or 75cm2 tissue culture flasks (Greiner Bio-One Ltd, 
Gloucestershire, UK), incubated at 37°C with 5% CO2 and 95% humidity. All tissue culture was 
performed using aseptic techniques within a class II laminar flow cabinet using autoclaved 
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equipment. Cells were passaged upon reaching 80-90% confluency, gauged visually using a 
light microscope. Once 80-90% confluency was met, medium was removed and cells were 
washed with PBS. 1-2mL of Trypsin:EDTA (0.01% trypsin and 0.05% EDTA in PBS buffer) 
(depending on cell type and flask size) was added to the cells and flasks were left at 37°C for 
5 minutes. Once detached, 5mL of serum containing medium was added to neutralise the 
effects of the trypsin. Cells were decanted into a universal container and pelleted by 
centrifugation at 1700xg for 5 minutes. The Trypsin:EDTA and medium mixture was aspirated 
and cells were resuspended in pre-warmed media. The required amount of cells were then 
placed in a fresh tissue culture flask to continue growing. 
2.5.3 Cell Counting 
10µL of cells in suspension were added to a 0.100mm depth haemocytometer (Neubauer). 
Cells were counted within the squares of the haemocytometer a minimum of 3 times 
before an average was taken.  
2.5.4 Freezing Cells 
Cells were trypsinised and pelleted according to section 2.2.3. Cell pellets were resuspended 
in 1mL FBS + 10% (v/v) dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Cell suspension was then 
transferred to a Cryo-tube (Grenier Bio-one), wrapped in tissue and stored at -80°C overnight 
before being transferred to liquid nitrogen.  
2.5.5 Revival of Cells 
Cells were thawed quickly using a 37°C water bath. Cell suspension was transferred to a 
sterile universal container and 5mL of fresh medium was added. Cells were pelleted at 
1700xg for 5 minutes and supernatant was removed. Cells were resuspended in fresh 
medium, transferred to fresh cell culture flasks and placed in a 37°C incubator.  
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2.5.6 Mycoplasma Test 
Cells were checked for mycoplasma using an EZ-PCR Mycoplasma Test Kit (Biological 
Industries). Media from cell culture flasks was centrifuged for 5 minutes at 250xg. 
Supernatant was removed and centrifuged again for 10 minutes at 15000xg. Supernatant 
was discarded and the pellet was resuspended in 25µL of buffer solution and heated to 95°C 
for 3 minutes. A 35 cycle specific PCR was conducted using the supplied reaction mix, 
including supplied positive controls and results were visualised on a 2% agarose gel (positive 
product= 270bp). 
2.5.7 Co-Culture 
0.4µm pore size 24 well inserts (Sigma-Aldrich) were used for co-culture experiments. 7F2 
cells were seeded at 80% confluency and left overnight to settle. The following day, the 
media was changed to 1mL of control or osteogenic media. Inserts were added above the 
7F2 cells and PC3 cell pellets, containing the required cell number were resuspended in 
200µL of control or osteogenic media and  added into the inserts. 7F2 cells were then left to 
mineralise.
 sEV Isolation 
For collection of sEVs PC3 cells were cultured in Bioreactor Flasks; CELLine AD 1000 (Integra). 
Bioreactor flasks are dual chamber flasks, allowing large quantities of cells to grow in a 
compartment separated by a 10kDa membrane. This compartment holds a maximum of 
20mL of media, allowing for extremely concentrated media to be collected. Above the cell 
compartment, a media compartment holds 0.5-1L of medium. These two chambers ensure 
delivery of fresh nutrients to the cells through the semi-permeable membrane, whilst 
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allowing a build-up of larger molecules within the cell compartment, in this case, sEVs.  An 
overview of these compartments and their surrounding membranes is shown in figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Overview of the chambers within the bioreactor flask. The cell compartment 
holds large quantities of cells. The 10kDa membrane above allows free movement of 
nutrients from the media above and smaller waste products from the cells. The 10kDa limit 
of this membrane traps large products produced by the cells, such as sEVs. The lower silicone 
membrane allows efficient gas exchange between the cells and the surroundings (The Lab 
Depot, 2018)  
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2.6.1 Bioreactor Flask Setup 
1% (v/v) antibiotics (penicillin-streptomycin 10,000U/mL) was added to a fresh bottle of 
medium. 15mL was removed and 5% (v/v) FBS was added to the remaining medium. 50mL 
of this medium was added to the inside of the bioreactor flask for 5 minutes to wet the semi-
permeable membrane and allow it to equilibrate. According to the protocol, 25x106 cells 
were collected from T75 flasks and resuspended in the 15mL of serum free medium decanted 
prior. 5% (v/v) exosome depleted FBS (Thermo Fisher Scientific, Massachusetts, USA) was 
added to the cell suspension and all 15mL was added to the cell compartment using a 
serological pipette. The remaining media (roughly 500mL) was then added to the media 
compartment and cells were left for 10 days. 
2.6.2 Media Collection 
Cell compartment media was collected weekly. Outer chamber media was also changed 
weekly in coordination with collection chamber media.  
For collection of inner chamber and changing of outer chamber media, a fresh bottle of 
DMEM/F-12 was pre-warmed to room temperature. All media from the collection chamber 
was removed using a 20mL serological pipette and added to a sterile 20mL universal 
container. 1% (v/v) antibiotics (penicillin-streptomycin 10,000U/mL) was added to the bottle 
of medium and 45mL was decanted into a sterile 50mL falcon tube. Ten millilitres of this was 
then used to wash the inner chamber 3 separate times using a fresh 20mL serological pipette, 
leaving 15mL. 5% (v/v) of exosome depleted FBS (Thermo Fisher Scientific, Massachusetts, 
USA) was added to the remaining 15mL of media. A final fresh 20mL serological pipette was 
used to add this 15mL of media into the collection chamber. The outer chamber was then 
emptied and discarded. 5% (v/v) of regular FBS was added to the remaining 455mL of media. 
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This media was then carefully poured into the outer chamber of the bioreactor flask, and 
both lids were tightened.   
The universal container, containing the collected media was span twice at 2000xg for 5 
minutes, and finally at 4000xg for 15 minutes to remove debris, pouring into fresh universal 
containers between each centrifugation. The media was then filtered through a 0.8µm filter 
and subsequently a 0.22µm filter using a 20mL syringe under sterile conditions and stored in 
a universal container at -80°C. 
For the sEV isolation, media was defrosted in a 37°C water bath and the ultracentrifuge 
(Beckmann Coulter, Optima LE-80K) was cooled to 4°C. Media was then transferred to 
QuickSeal 33mL centrifuge tubes (Beckmann Coulter). 3-5mL of 30% sucrose/D2O cushion 
consisting of 7.5g sucrose and 22.5g D2O was carefully added to the bottom of the QuickSeal 
33mL centrifuge tubes using a spinal needle pouring under gravity, underneath the media, 
being careful not to disturb the separate layers. Once all air was removed from the tube, the 
tips of the tube were sealed using a soldering iron and casting dye to create a uniform, air-
tight seal. Media then underwent ultracenrifugation at 100,000xg for 60 minutes on a 
Beckmann Coulter SW32 swing arm rotor at 4°C. The sucrose cushion was then removed 
from the ultracentrifuge tubes using a syringe and spinal needle and diluted in enough PBS 
to fill another ultracentrifuge tube. The sucrose cushion/PBS mix was then added to a fresh 
ultracentrifuge tube using a spinal needle under gravity. Media was then ultracentrifuged 
again at 100,000xg for a further 60 minutes at 4°C on a 70Ti fixed arm rotor to pellet the 
sEVs. The sEV pellet was then resuspended in 500µL of PBS.  
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2.6.3 sEV Validation 
2.6.3.1 Nano Particle Analysis  
Nanoparticle Tracking Analysis (NTA) is a technique used to measure nanometre sized 
particles of 10-2000nm in liquids, under flow. NTA uses a high powered 488nm LM14 laser 
module which is scattered by nanoparticles flowing through the sample chamber in 
suspension. This scattering is recorded by a highly sensitive digital camera (OrcaFlash 2.8, 
Hamamatsu C11440, Hamamatsu City, Japan). NTA (Malvern Instruments, Malvern, UK).  
utilises the scattering of this light to determine the size of the nanoparticle over multiple 
frames as well as Brownian motion; the random motion of nanoparticles in suspension 
dependant on the temperature and viscosity of the liquid. The NanoSightTM NS300 machine 
was calibrated using 100nm latex nanobeads (Malvern Instruments, Malvern, UK). For NTA, 
particles were suspended in particle free water (Fresenius Kabi, Runcorn, UK) to a 
concentration of 2x108 and 9x108 particles/mL. Samples were administered under a constant 
speed using a NanoSight syringe pump set to 50, and temperatures were kept at a constant 
25°C. Tracking videos of 30 seconds were used and each sample had a total of 6 replicates. 
Videos were analysed using NTA software (version 3.1), with the camera sensitivity and 
detection threshold set to 14-16 and 1-3 respectively.  
2.6.3.2 Protein Concentration Assay 
The protein concentration of sEV samples was assessed using a Bio-Rad DCTM Protein Assay 
kit (Bio-Rad Laboratories, Hemel-Hempstead, UK). Samples were diluted 1:8 in PBS and 
compared to a standard curve from 0-2000µg/mL of BSA. (see section 2.11.2 for assay 
details).  
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2.6.3.3 Immuno-Phenotyping Assay 
SEVs were diluted in PBS and 1µg was added to each well of a High Protein Binding enzyme 
linked immunosorbent assay (ELISA) Strip 96 well plate (Greiner Bio-One, Germany). SEVs 
were incubated in the wells at 4°C overnight. Wells were washed 3 times using TRIS-wash 
buffer (Kaivogen, Finland). 1% BSA (w/v in PBS) blocking solution was added for 2 hours at 
room temperature and wells were subsequently washed 3 times. Primary antibodies 
(1µg/mL) were added and incubated for 2 hours at room temperature and subsequently 
washed 3 times. Bioatinylated secondary antibody (Perkin Elmer, USA) was diluted to 
200ng/mL in 0.1% BSA (w/v in PBS) and incubated in wells for 1 hour at room temperature. 
Wells were washed again 3 times and a Europium-Streptavidin conjugate (Perkin Elmer) in 
assay buffer (Kaivogen) was added and incubated at room temperature for 45 minutes. Well 
were finally washed 6 times and enrichment intensifier (Kaivogen) was added and incubated 
at room temperature for 5 minutes. Time-resolved fluorescence (TRF) was measured using a 
PHERAstar FS Microplate Reader (BMG Labtech, UK) 
2.6.3.4 Western Blot  
PC3 sEV lysate (20µg) was analysed alongside PC3 cellular lysate (20µg) via western blot. See 
section 2.11 “methods for protein detection”.
 Methods for Gene Expression Detection 
2.7.1 RNA Extraction  
2.7.1.1 Cellular RNA 
RNA extraction was carried out following the TRI Reagent protocol from Sigma-Aldrich as 
detailed below. When cells were ready, media was aspirated and washed with PBS before 
TRI Reagent was added (1mL per 5-10x105 cells). TRI Reagent was mixed around the 
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well/flask thoroughly and passed multiple times through a pipette to ensure all cells were 
lysed. Cell lysate was then transferred to a sterile 1.5mL microcentrifuge tube and left at 
room temperature for 5 minutes. Two hundred microlitres of 1-bromo-3-chloropane is 
added to each tube and samples are vortexed for 15 seconds to ensure thorough mixing. 
Samples were then left for 15 minutes at room temperature before being centrifuged at 
12,000g for 15 minutes at 4°C. The upper aqueous, RNA containing layer was carefully 
removed and 500µL of 2-propanol was added (500µL per mL of TRI Reagent). The mixture 
was vortexed and left to stand at room temperature for 10 minutes before centrifugation at 
12,000g for 10 minutes at 4°C. The supernatant was discarded and RNA pellets were washed 
in 75% (v/v) ethanol before being centrifuged at 7,500xg for 5 minutes at 4°C. The ethanol 
was then removed and pellets were resuspended in 20µL of DEPC water.  
2.7.1.2 RNAs in Media 
For RNA extraction, 1mL of media was transferred to a sterile 1.5mL microcentrifuge tube 
and centrifuged at 2,000g for 5 minutes at 4°C. Eight hundred microlitres of media was taken 
from the top of the centrifuged media and transferred to a fresh 1.5mL microcentrifuge tube. 
This was then centrifuged at 16,000g for 15 minutes at 4°C. Five hundred microlitres was 
taken from the top of the newly centrifuged media and placed in a final 1.5mL sterile 
microcentrifuge tube and stored at -80°C until required.  
RNA harvested from media was often too dilute to accurately quantify by Nanodrop (Thermo 
Fisher Scientific, Massachusetts, USA). Because of this, for media RNA extractions, C. elegans 
miR-39 was used as a housekeeping gene to control for changes in RNA extraction efficiency 
between samples. A constant volume was added before RNA extraction and samples were 
normalised to this C. elegans miR-39 level at the qPCR stage. Sufficient Trizol® LS (Thermo 
Fisher Scientific, Massachusetts, USA) for all current samples was added to a universal 
container along with a C. elegans miR-39 spike in control (1µL/mL of Trizol® LS). Seven 
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hundred and fifty microlitres of Trizol® LS was added to 250µL of media (prepared as 
described in section 1.3.2) in a sterile 1.5mL microcentrifuge tube and vortexed to mix 
thoroughly. Two hundred microlitres of 1-bromo-3-chloropane was then added and the 
reagents were vortexed again and left at room temperature for 2 minutes. The homogenate 
was then centrifuged at 12,000g for 15 minutes at 4°C. Three hundred microlitres of the 
upper aqueous, RNA containing layer was then carefully removed and transferred to a fresh 
sterile 1.5mL microcentrifuge tube and 2µL of Glycoblue (Thermo Fisher Scientific, 
Massachusetts, USA) was added to allow greater visualisation of the RNA pellet later. Five 
hundred microlitres of 100% 2-propanol (Fisher Chemical) was added to each tube, and the 
samples were left to incubate at room temperature for 10 minutes. Samples were then 
centrifuged at 12,000g for 25 minutes at 4°C. At this point a very small blue pellet was visible. 
All supernatant was carefully removed and the pellet was washed with 100µL of 75% 
ethanol:DEPC water. Samples were then centrifuged again at 12,000g for 5 minutes at 4°C 
and the supernatant was carefully removed. Samples were centrifuged briefly at 12,000g for 
1 minute at 4°C and the remaining supernatant was very carefully removed with a 10µL tip 
and pipette. The pellet was then air dried for 2-5 minutes, dissolved in 20µL of DEPC water 
and stored at -80°C until use.  
2.7.2 RNA Quantification 
RNA quantity and purity was measured using an Implen Nanophotometer (Implen, Munich, 
Germany) set to detect single strand RNA. Absorbance was measured at 260nm and 
compared to a DEPC water blank.  
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2.7.3 Reverse Transcription  
2.7.3.1 Advanced miRNA Reverse Transcription 
Reverse transcription was carried out using the TaqMan® Advanced MicroRNA Assay kit 
following the supplied protocol (Thermo Fisher Scientific, Massachusetts, USA) as detailed 
below. The TaqMan® Advanced MicroRNA Assay is a 4 step process involving 4 separate 
mastermixes and thermal cycling runs (protocol dictates that all mastermixes contain an 
extra 10% to account for “variations in pipetting”). 
Guidelines dictated a maximum of 10ng of total RNA per reaction. Therefore RNA was diluted 
to a maximum of 5ng/µL, as 2µL of sample was to be used.  
Step 1 Poly(A) Tailing Reaction:   
The following mastermix was prepared in a sterile 1.5mL microcentrifuge tube; 
Component Per Reaction 
10X Poly(A) Buffer 0.5µL 
ATP 0.5µL 
Poly A Enzyme 0.3µL 
RNase-Free Water 1.7µL 
Total Volume 3µL 
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The mastermix was vortexed and 3µL was combined with 2µL of sample in a sterile PCR tube 
(5µL total). The tube was then sealed, vortexed and centrifuged briefly to spin down the 
contents before being placed in a SimpliAmp Thermal Cycler (Thermo Fisher Scientific, 
Massachusetts, USA) under the following conditions: 
Step Temperature Duration 
Polyadenylation 37°C 45 minutes 
Stop Reaction 65°C 10 minutes 
 
We then proceeded immediately to the Ligation Reaction. 
Step 2 Ligation Reaction: 
The following mastermix was prepared in a fresh sterile 1.5mL microcentrifuge tube; 
Component Per Reaction 
5X DNA Ligase Buffer 3µL 
50% PEG 8000 4.5µL 
25X Ligation Adaptor 0.6µL 
RNA Ligase 1.5µL 
RNase-Free Water 0.4µL 
Total Volume 10µL 
 
The mastermix was vortexed thoroughly and 10µL was combined with all 5µL from the 
Poly(A) Tailing reaction (15µL total). Tubes were vortexed briefly and centrifuged to spin 
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down contents. Tubes were then placed in a SimpliAmp Thermal Cycler (Thermo Fisher 
Scientific, Massachusetts, USA) under the following conditions.    
Step Temperature Duration 
Ligation 16°C 60 minutes 
 
We then proceeded immediately to the Reverse Transcription Reaction. 
Step 3 Reverse Transcription Reaction: 
The following mastermix was prepared in a fresh sterile 1.5mL microcentrifuge tube; 
Component Per Reaction 
5X RT Buffer 6µL 
dNTP Mix (25mM each) 1.2µL 
20X Universal RT Primer 1.5µL 
10X RT Enzyme Mix 3µL 
RNase-Free Water 3.3µL 
Total Volume 15µL 
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The mastermix was vortexed and 15µL was combined with all 15µL from the Ligation 
Reaction (30µL total). Tubes were vortexed briefly and centrifuged to spin down contents. 
Tubes were then placed in a SimpliAmp Thermal Cycler (Thermo Fisher Scientific, 
Massachusetts, USA) under the following conditions.    
Step Temperature Duration 
Reverse Transcription 42°C 15 minutes 
Stop Reaction 85°C 5 minutes 
 
We then proceeded immediately to the miR-Amp Reaction. 
 Step 4: miR-Amp Reaction 
The following mastermix was prepared in a fresh sterile 1.5mL microcentrifuge tube; 
Component Per Reaction 
2X miR-Amp Master Mix 25µL 
20X miR-Amp Primer Mix 2.5µL 
RNase-Free Water 17.5µL 
Total Volume 45µL 
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The mastermix was vortexed and 45µL was combined with 5µL of the reverse transcription 
reaction in a fresh PCR tube. Tubes were vortexed briefly and centrifuged to spin down 
contents. Tubes were then placed in a SimpliAmp Thermal Cycler (Thermo Fisher Scientific, 
Massachusetts, USA) under the following conditions.    
Step Temperature Duration Cycles 
Enzyme Activation 95°C 5 minutes 1 
Denature 95°C 3 seconds 
14 
Anneal/Extend 60°C 30 seconds 
Stop Reaction 99°C 10 minutes 1 
 
Samples were then diluted 1:10 and stored at -20°C until use. 
2.7.3.2 Standard miRNA Reverse Transcription 
miRNA Reverse Transcription was carried out using a TaqMan MicroRNA Reverse 
Transcription Kit (Thermo Fisher Scientific, Massachusetts, USA) following the manufacturers 
protocol as detailed below. The protocol recommends using a maximum of 10ng of RNA per 
reaction, and as each reaction contains 5µL the RNA was diluted to a maximum of 2ng/µL.  
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All components were thawed and kept on ice throughout. The following mastermix was 
prepared:  
  Component Per Reaction 
100mM dNTPs (with dTTP) 0.15µL 
MultiScribeTM Reverse Transcriptase, 50U/µL 1µL 
10X Reverse Transcription Buffer 1.5µL 
RNase Inhibitor, 20U/µL 0.19µL 
Nuclease-Free Water 4.16µL 
Total Volume 7µL 
 
In a sterile PCR tube 7µL of mastermix was combined with 3µL of primer and 5µL of RNA 
sample. The solution was gently pipetted up and down to mix. Tubes were centrifuged to 
spin down contents and then placed in a SimpliAmp Thermal Cycler (Thermo Fisher Scientific, 
Massachusetts, USA) under the following conditions:  
Temperature Duration 
16°C 30 minutes 
42°C 30 minutes 
85°C 5 minutes 
cDNA samples were then stored at -20°C until use.  
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2.7.3.3 mRNA Reverse Transcription 
RNA was diluted to 500ng in 10µL of PCR water to be reverse transcribed into cDNA. 10µL of 
GoScriptTM Reverse Transcription Mix, Oligo(dT) (Promega) was added to the RNA in a sterile 
PCR tube (20µL total). The mixture was vortexed and briefly centrifuged before being placed 
in a SimpliAmp Thermal Cycler (Thermo Fisher Scientific, Massachusetts, USA) under the 
following conditions: 
Temperature Duration 
25°C 5 minutes 
42°C 60 minutes 
70°C 15 minutes 
 
At this point samples were diluted 1:5 with PCR water and stored at -20°C until use.  
2.7.4 Quantitative (q)PCR 
All qPCR reactions were prepared in MicroAmp Fast Optical, barcoded, 96 well plates 
(Thermo Fisher Scientific, Massachusetts, USA) using clear optical adhesive seals 
(PrimerDesign, Southampton, UK). 
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2.7.4.1 SYBR® Green qPCR 
SYBR® Green qPCR was performed on mRNA generated from the mRNA reverse transcription 
(section 2.7.3.3). For each reaction, 2µL of cDNA (diluted 1:5 as detailed in section 2.7.3.3) 
was combined with 8µL of mastermix containing the following components: 
Component Per Reaction 
Sybr® Green PCR Master Mix 5µL 
2.5pmol Primer Mix* 1µL 
Nuclease-Free Water 2µL 
Total Volume 8µL 
*Primer Mix was a pre-made mix of 1µL forward primer, 1µL reverse primer and 38µL 
nuclease free water 
Plates were placed in a StepOnePlusTM Real-Time PCR System Cycler (Thermo Fisher 
Scientific, Massachusetts, USA) under the following cycling conditions: 
Stage Temperature Duration 
Enzyme Activation 95°C 10 minutes 
Cycling (50 cycles) 
95°C 15 seconds 
60°C 60 seconds 
 
CT values were recorded and gene expression was then quantified using the ΔΔCT method 
normalised to GAPDH and RPL-19 housekeeping genes for human cells and HPRT and β-Actin 
for mouse cells.  
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2.7.4.2 Taqman® qPCR 
Conventional Taqman qPCR 
Taqman® qPCR was also performed on mRNA generated from the mRNA reverse 
transcription (section 2.7.3.3). For each reaction, 2µL of cDNA (diluted 1:5 as detailed in 
section 2.7.3.3) was combined with 8µL of mastermix containing the following components: 
Component Per Reaction 
Precision Fast 2x qPCR MasterMix 5µL 
20x Primer 0.5µL 
Nuclease-Free Water 2.5µL 
Total Volume 8µL 
 
Plates were placed in a StepOnePlusTM Real-Time PCR System Cycler (Thermo Fisher 
Scientific, Massachusetts, USA) under the following cycling conditions: 
Stage Temperature Duration 
Enzyme Activation 95°C 20 seconds 
Cycling (50 cycles) 
95°C 1 second 
60°C 20 seconds 
 
CT values were recorded and gene expression was then quantified using the ΔΔCT method 
normalised to GAPDH and RPL-19 housekeeping genes for human cells and HPRT and β-Actin 
for mouse cells.  
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Advanced miRNA Taqman® qPCR 
Taqman® qPCR was also performed on cDNA reverse transcribed using the Taqman® 
Advanced miRNA Assays kit (section 2.7.3.1). 
For each reaction, 5µL of cDNA (diluted 1:10 as described in section 2.7.3.1) was combined 
with 15µL of mastermix containing the following components: 
Component Per Reaction 
Precision Fast 2x qPCR MasterMix 10µL 
20x Primer 1µL 
Nuclease-Free Water 4µL 
Total Volume 15µL 
 
Plates were placed in a StepOnePlusTM Real-Time PCR System Cycler (Thermo Fisher 
Scientific, Massachusetts, USA) under the following cycling conditions: 
Stage Temperature Duration 
Enzyme Activation 95°C 20 seconds 
Cycling (50 cycles) 
95°C 1 second 
60°C 20 seconds 
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2.7.5 Gel Electrophoresis 
DNA fragments were separated based on their size using agarose gel electrophoresis. 
Samples were loaded onto a 0.5-2% w/v agarose gel, dependant on the size of the DNA 
fragment. Agarose gels were prepared by measuring 50 or 150mL of 1x Tris/Borate/EDTA 
(TBE) (depending on the size of the gel tank used) into a flask and adding an appropriate 
weight of agarose (Melford Chemicals, Suffolk, UK) depending on the % of the gel. The 
mixture was then heated in a microwave until the agarose was completely dissolved. The 
agarose solution was allowed to cool slightly before 10-20µL of SYBR safe (Abnova, Taiwan) 
was added, depending on the gel volume. Gels were then poured into the tanks which 
contained plastic combs (SCIE-PLAS, Cambridge, UK), allowing the formation of loading wells 
within the gel. Once the gels had cooled to room temperature and solidified, they were 
submerged in 1x TBE and the combs were removed. Five microlitres of ladder (either PCR 
ranger or high ranger depending on expected fragment size) was added to the first well and 
8-20µL of sample was added to the remaining wells. Gel tanks were then connected to EV243 
power consorts (Topac Inc., Cohasset, USA) and run using electrophoresis conditions of 100V, 
150mA and 50W for 30 minutes to 2 hours to separate DNA fragments sufficiently.  
Gels were visualised using a U: Genius 3 Gel Doc system (Syngene, Cambridge, UK), which 
was also used to capture images of the gels.  
2.7.5.1 Gel Purification 
DNA bands are located using the U: Genius 3 Gel Doc system (Syngene, Cambridge, UK) 
following the manufacturers protocol. Gel bands are then excised using a scalpel and added 
to 1.5mL microcentrifuge tubes before being weighed. For DNA extraction, a Wizard® SV Gel 
and PCR Clean-Up System kit (Promega, Wisconsin, USA) was used. Ten microlitres of 
Membrane Binding solution per 10mg of gel was added to each tube. Tubes were incubated 
at 50-65°C until the gels had completely dissolved.  One SV Minicolumn per gel was inserted 
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into a fresh tube and the dissolved gel solutions were added. Tubes were incubated at room 
temperature for 1 minute and centrifuged at 16,000xg for 1 minute, flowthrough was 
discarded. SV Minicolumns were reinserted and 700µL of Membrane Wash Solution was 
added to each column. Tubes were centrifuged again at 16,000xg and flowthrough was again 
discarded. The wash step was then repeated with 500µL and tubes were centrifuged at 
16,000xg for 5 minutes. Flowthrough was discarded and the empty SV Minicolumns were 
centrifuged at 16,000xg for 1 minute with lids open to remove residual ethanol. SV 
Minicolumns were transferred to fresh 1.5mL microcentrifuge tubes and 50µL of nuclease-
free water was added to the membrane of each column. Columns were incubated for 1 
minute at room temperature centrifuged at 16,000xg for 1 minute to elute the DNA. SV 
Minicolumns were discarded and microcentrifuge tubes containing eluted DNA were stored 
at -20°C.  
2.7.6 Bioanalysis 
Bioanalysis displays the size and quantity of RNAs within the population you are measuring 
using micro-capillary based electrophoresis. For RNA destined for sequencing or digestion by 
RNase, bioanalysis was used to visualise the isolated RNA population. An agilent RNA 6000 
Nano Kit was used for sequencing library visualisation or the Agilent RNA 6000 Pico Kit for 
sEV RNA digest visualisation. As per the manufacturer’s instructions, running gel was added 
to the analysis chip along with ladder and the RNA sample and samples were analysed using 
a 2100 Bioanalyser (Agilent, Santa Clara, CA, USA).   
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 Methods for Plasmid Cloning 
2.8.1 Preparation of Over Expression Plasmids 
Coding regions of genes were amplified from original plasmids or cDNA by PCR using primers 
detailed in table 2.4. For amplification, the following mix was combined in a fresh PCR tube: 
Component Amount 
GoTaq®G2 Green Master Mix 15µL 
PCR Water 12.5µL 
15ng/µl cDNA/Plasmid 2µL 
10pmol Forward Primer 0.25µL 
10pmol Reverse Primer 0.25µL 
Total Volume 30µL 
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The mixture was then placed in a StepOnePlusTM Real-Time PCR System Cycler (Thermo 
Fisher Scientific, Massachusetts, USA) under the following cycling conditions: 
Step Temperature Duration Cycles 
Initial Denaturation 95°C 5 minutes 1 
Denaturation 94°C 30 seconds 
25 Annealing 55°C 40 seconds 
Extension 72°C 1 minute per kb 
Final Elongation 72°C 10 minutes 1 
Hold 4°C ∞ 1 
 
 
DNA was inserted into the pEF6/V5-His TOPO vector for over expression. This vector ligates 
the PCR product directly into the plasmid backbone. For insertion, the following components 
were combined in a fresh PCR tube and incubated at room temperature for 5 minutes, before 
being placed on ice ready for use: 
Component Amount 
10ng/µl pEF6/V5-His TOPO 1µL 
DNA (neat from amplification step) 4µL 
Salt Solution* 1µL 
Total Volume 6µL 
*Salt solution: 1.2M NaCl, 0.06M MgCl2 
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Overexpression plasmids were now ready for transformation into E. coli.  
2.8.2 Preparation of miRNA Luciferase Reporter Plasmid 
2.8.2.1 Annealing miRNA Oligos 
Forward and reverse miRNA oligos (Eurofins Scientific, Luxembourg) were annealed by 
combining the following components in a fresh PCR tube: 
Component Amount 
1µg/µl Forward Oligo 1µL 
1µg/µl Reverse Oligo 1µL 
Annealing Buffer* 46µL 
Total Volume 50µL 
*Annealing Buffer: 10mM Tris-HCl pH7.5-8, 50mM NaCl, 1mM EDTA. 
The mix was then vortexed and centrifuged briefly to combine and placed in a StepOnePlusTM 
Real-Time PCR System Cycler (Thermo Fisher Scientific, Massachusetts, USA) under the 
following cycling conditions: 
Temperature Duration 
90°C 3 minutes 
37°C 15 minutes 
Oligos were then diluted 1:10.  
2.8.2.2 Cutting pmirGLO Vector for Insertion 
The pmirGLO vector was then cut twice using restriction enzymes ready for insertion as 
follows: 
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The following components were combined in a fresh PCR tube and heated at 37°C for 1 hour: 
Component Amount 
300ng/µl pmirGLO Plasmid 30µL 
5U/µl PME1 2µL 
10X Buffer* 5µL 
Nuclease-Free Water 13µL 
Total Volume 50µL 
*PME1 requires buffer B (Thermo Fisher) 
The vector was then purified using a Wizard® SV Gel and PCR Clean-Up System kit (Promega, 
Wisconsin, USA) as detailed in section 2.7.6.1 (treating 50µL as 50µg of gel) and eluted in 
30µL of RNase free water. 
The purified vector was then combined with the following components and heated to 37°C 
for 1 hour again: 
Component Amount 
Purified pmirGLO Plasmid (cut 1 time) 30µL 
10U/µl XBAI 1µL 
10X Buffer* 4µL 
Nuclease-Free Water 4µL 
Total Volume 40µL 
*XBAI requires SH buffer (Sigma) 
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The vector, now cut twice, was run on a 1% agarose gel. A band within the gel at 7.3Kb, 
representing the cut vector, was extracted and purified using a Wizard® SV Gel and PCR 
Clean-Up System kit (Promega, Wisconsin, USA) as detailed in section 2.7.6.1, and quantified 
(16.5ng/µL).  
2.8.2.3 Ligating miRNA Insert and Cut pmirGLO Vector 
For ligation, the following components were combined in a fresh PCR tube and left at 16°C 
overnight: 
Component Amount 
Purified pmirGLO Plasmid (cut 2 times) (50ng*) 3µL 
Annealed Oligos (neat from annealing reaction) 1µL 
400U/µl T4 DNA Ligase  1µL 
10X T4 DNA Ligase Buffer 1µL 
Nuclease-Free Water 4µL 
Total Volume 10µL 
*50ng total= ~3µl of 16.5ng/µl (from previous reaction) 
pmirGLO reporter was now ready for transformation into E. coli. 
2.8.3 Transformation of Chemically Competent E. coli 
Transformations were performed using One Shot® TOP10 Chemically Competent E. coli 
(Thermo Fisher Scientific, Massachusetts, USA) following the manufacturers protocol as 
detailed below.  
Per transformation, one vial (~60µL each) of One Shot® TOP10 chemically competent cells 
were thawed on ice. One to five microlitres of DNA (10pg-100ng) was added per vial and 
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mixed gently (not via pipetting). A control was included by adding 10pg of pUC19 to an extra 
vial of One Shot® TOP10 chemically competent cells, to show transformation efficiency. Vials, 
now containing E. coli and DNA, were incubated on ice for 30 minutes and heat-shocked at 
42°C for 30 seconds before returning them to ice for another 2 minutes. In a sterile class II 
laminar flow cabinet, 250µL of room temperature S.O.C Medium was aseptically added to 
each vial. Vials were tightly capped and shaken horizontally at 37°C for one hour at 225 rpm. 
After one hour 100µL and 50µL from each vial was spread onto two room temperature 
selective plates made from LB-agar (see section 2.4.4.2) with 1µL/mL Ampicillin (plating two 
volumes gives a greater chance for one plate to have well-spaced colonies for picking). For 
the pUC19 control, the transformation mix was diluted 1:10 in LB (2.4.4.1 which was then 
plated the same way as the sample vials. Plates were inverted and stored upside down at 
37°C overnight. The following day, individual colonies were carefully picked using an 
inoculation loop and shaken at 225 rpm at 37°C in 5mL of LB for a further 24 hours.  
2.8.4 Plasmid Extraction 
Plasmid extraction was done using a GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich) 
following the manufacturers protocol as described below. All centrifugations were 
performed at 12,000g unless stated otherwise. 
Five millilitres of overnight cultured plasmid containing cells was pelleted in a sterile 2mL 
microcentrifuge tube and supernatant was discarded. Samples were centrifuged at a 
maximum volume of 2mL due to the maximum volume of the microcentrifuge tubes, 
therefore for any volumes over 2mL cells were centrifuged multiple times with supernatant 
being discarded in between. Cell pellets were then resuspended in 200µL of Resuspension 
Solution by vortexing or pipetting. Two hundred microlitres of Lysis Solution was added to 
each tube and mixed gently by inversion before allowing to clear for 5 minutes. Three 
hundred and fifty microlitres of Neutralisation Solution was added and tubes were inverted 
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4-6 times to mix thoroughly. Neutralisation of the solution created a cloudy precipitate 
within the tube which was pelleted at 14,000g for 10 minutes. Whilst the neutralised mixture 
was pelleting one GenElute Miniprep Binding Column per sample was placed in a fresh 2mL 
collection tube. The table below details the remaining solutions added to each column for 
the plasmid washing and elution. Between the additions of each solution, the columns were 
centrifuged for 1 minute and the flow through collected in the 2mL collection tube was 
discarded. 
 
Component Amount 
Column Preparation Solution 500µL 
Clear Lysate from Neutralisation Step All Supernatant 
Optional Wash Solution 500µL 
Wash Solution 750µL 
 
Following the discarding of the flowed through Wash Solution, tubes were placed back in the 
centrifuge and centrifuged for a further minute to dry the columns. Columns were then 
transferred to a fresh 2mL collection tube and 50µL of Elution Solution was carefully added 
onto the membrane within the column. Tubes were then centrifuged for a final time for 1 
minute to collect the purified plasmid, which was stored at -20°C until use.  
2.8.5 Plasmid Quantification 
Plasmid quantity and purity was measured using an Implen Nanophotometer (Munchen, 
Germany) set to detect DNA. Absorbance was measured at 260nm and compared to unused 
Elution Solution from the GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich) as a blank.  
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2.8.6 Plasmid Verification 
Further restriction enzyme digestion of plasmids was used to verify insertion of DNA 
sequences was successful. Successfully inserted plasmids were then sent for sequencing to 
determine whether orientation of the inserts was correct and that mutations had not 
occurred. 
2.8.7 Large Scale Plasmid Extraction 
Once sequencing had confirmed the positive insertion of the DNA sequence, E. coli were re-
transformed and the plasmid was extracted on a larger scale using a PureYield™ Plasmid 
Maxiprep System (Promega). 200mL of E. coli was pelleted at 5,000xg for 10 minutes at room 
temperature, 50mL at a time, in a 50mL falcon tube. Pellets were resuspended in 12mL of 
Cell Resuspension Solution and another 12mL of Cell Lysis Solution was added and mixed. 
12mL of Neutralisation Solution was then added and mixed thoroughly. Neutralised solution 
was centrifuged at 7,000xg for 30 minutes at room temperature. Plasmid purification was 
performed using a vacuum pump and PureYieldTM Clearing/Maxi-Binding Columns. All 
supernatant from the centrifuged neutralised solution was filtered and washed with 5mL 
Endotoxin Removal Wash and 20mL of Column Wash. Once dry, the plasmid was eluted from 
the filter using 1mL f nuclease free water, quantified and stored at -20°C until use.
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2.8.8 Plasmid Transfections 
Cells were transfected using a LipofectamineTM 3000 kit (Thermo Fisher Scientific, 
Massachusetts, USA) following the manufacturers protocol. Cells to be transfected were 
seeded and allowed to reach ~80% confluency. Transfections were prepared in two separate 
tubes, the components of which are described as following (per transfection):  
Component Tube A Tube B 
Opti-MEM® Medium 
6 Well: 125µL 6 Well: 125µL 
24 Well: 25µL 24 Well: 25µL 
96 Well: 5µL 96 Well: 5µL 
Lipofectamine® 3000 
Reagent 
6 Well: 3.75µL 
n/a 24 Well: 0.75µL 
96 Well: 0.15µL 
Plasmid n/a 
6 Well: 5µg 
24 Well: 1µg 
96 Well: 0.2µg 
P3000TM Reagent n/a 
6 Well: 10µL 
24 Well: 2µL 
96 Well: 0.4µL 
 
The two tubes were then combined and incubated for 15 minutes at room temperature. The 
mixture was then added to medium of the plated cells and cells were incubated for 2 days. 
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Cells were then selected with antibiotic media depending on the resistance gene found 
within the plasmid, and single colonies collected and expanded.
 Methods for Oligo Transfection 
miRNA oligos were transfected using a LipofectamineTM 3000 kit (Thermo Fisher Scientific, 
Massachusetts, USA) following the manufacturers protocol for RNA. For RNA transfection, 
P3000 reagent is not used. Cells to be transfected were seeded and allowed to reach ~80% 
confluency. Transfections were prepared in two separate tubes, the components of which 
are described as following (per transfection): 
Component Tube A Tube B 
Opti-MEM® Medium 
6 Well: 125µL 6 Well: 125µL 
24 Well: 25µL 24 Well: 25µL 
96 Well: 5µL 96 Well: 5µL 
Lipofectamine® 3000 
Reagent 
6 Well: 3.75µL 
n/a 24 Well: 0.75µL 
96 Well: 0.15µL 
Oligo (10pmol/µL) n/a 
6 Well: 12.5µL 
24 Well: 2.5µL 
96 Well: 0.5µL 
 
The two tubes were then combined and incubated for 15 minutes at room temperature. The 
mixture was then added to medium of the plated cells and cells were incubated for 2-3 days. 
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 Methods for Sequencing 
Two forms of sequencing were performed during this research project; miRNA sequencing 
and mRNA sequencing. The preparation of these two libraries is different, as detailed below. 
However, prepared libraries are sequenced using a common protocol, detailed after the 
library preparation sections.  
2.10.1 Preparation of cDNA Libraries 
2.10.1.1 Preparation of small RNA cDNA Library 
RNA was extracted from cells and sEVs using TRI Reagent (Sigma) as detailed in section 
2.7.1.1. RNA was then filtered to remove any RNA >200nt using a mirVana miRNA Isolation 
Kit (LifeTechnologies) following the manufacturers protocol. miRNA cDNA libraries were then 
prepared using a NEXTFlexTM Small RNA-Seq Kit v3 (Bioo Scientific, Texas, USA) following the 
manufacturers protocol. Library sizes were analysed by bioanalysis. 
2.10.1.2 Preparation of mRNA cDNA Library 
PolyA mRNA was isolated from total RNA using a Dynabeads mRNA DIRECT Kit (Life 
Technologies). mRNA cDNA libraries were then prepared using the Total RNA-seq kit (Life 
Technologies) following the manufacturers protocol. Briefly, mRNAs were fragmented using 
RNase III to produce a library of <200bp.  
2.10.2 Common Library Generation and Templating Steps  
Once a library of <200nt RNA was generated, either by filtration in the case of miRNA or 
fragmentation in the case of mRNA, there are a number of common steps used to generate 
cDNA libraries ready for sequencing.  The first step is the ligation of adaptors onto the RNA 
to allow for reverse transcription, generating cDNA. cDNA is then amplified using unique 
barcoded primers and attached to the surface of Ion SphereTM Particles (ISPs) using an Ion 
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PITM Template OT2 200 Kit v3 (Life Technologies) performed on an Ion OneTouch-TM 
Instrument (Life Technologies). Attachment of cDNA to ISPs is performed in a 1:1 ratio with 
the aim of attaching a single cDNA strand to each bead. An emulsion PCR was used to amplify 
this single cDNA strand up to coat the surface of the bead. Template positive ISPs were 
loaded onto a P1 chip and sequenced using an Ion Proton Sequencer (Life Technologies). 
An overview of this final common process, from adapter ligation to sequencing is shown in 
figure 2.2.
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NNNN 
3’ Adenylated Adapter RNA 5’ Adapter 
NNNN 
1) Ligation of 3’ Adenylated 
Adapter and 5’ Adapter 
NNNN 
3’ Adenylated Adapter RNA 5’ Adapter 
RT Primer 1st strand synthesis product 
2) Reverse Transcription  
1st strand synthesis product 
Universal Primer 
Barcode Primer 1 3) PCR and Size Selection  
4) Attachment of cDNA to 
Ion SphereTM Particles  
5) Sequencing of cDNA G G T A A A G T T C 
Figure 2.2: Overview of Common Library Preparation and Templating Steps for 
Sequencing. Adapted from Bioo Scientific and Life Technologies kits. 
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2.10.3  Bioinformatics 
2.10.3.1 Partek Genomics Suite 
Sequencing produced BAM files which were processed using Partek Genomics Suite. Raw 
data was processed according to the following flow diagram (figure 2.3): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base Calling  
(Determining bases based on the 
pH signals from the sequencer) 
Adapter Trimming 
(Removal of adaptor sequences 
ligated as part of library 
preparation) 
Barcode Deconvolution 
(Sorting of reads into samples 
based on individual barcodes) 
Alignment of Reads to Human 
Genome 19 
Map to Reference Genes 
(map reads to genomic locations 
and determine which RNA the read 
corresponds to) 
Reads per Kilobase per Million 
Mapped Reads (RPKM) 
Normalisation 
Normalises reads based on the 
length of the RNA and the number 
of overall reads 
Figure 2.3: Brief overview of Partek Genomics Suite processing of sequencing data.   
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2.10.3.2 Ingenuity Pathway Analysis (IPA) 
IPA was used for pathway analysis, in the prediction of both upstream regulators and 
downstream affected pathways. P values for gene changes between treated and untreated 
cells were uploaded and a “bone cell” downstream pathways were predicted, along with 
upstream regulators, including miRNAs.  
 Methods for Protein Detection  
2.11.1 Protein Extraction 
Flasks were washed 3 times with PBS and scraped into lysis buffer (150mM NaCL, 50mM Tris, 
0.02% Sodium azide, 0.5% Sodium deoxycholate, 1.5% Triton X-100 and a protease inhibitor 
tablet) (250µL for T25 and 500µL for T75 flasks). Lysate was then transferred to a 1.5mL 
microcentrifuge tube and placed on a Labinoco rotating wheel (Wold Laboratories, York, UK) 
for at least 1 hour at 25rpm and 4°C. Lysates were then centrifuged at 16,000xg for 15 
minutes and the supernatant was transferred to a fresh 1.5mL microcentrifuge tube. 
2.11.2 Protein Quantification 
A Bio-Rad DCTM Protein Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK) was used to 
determine protein concentrations of samples. A standard curve was made using BSA serially 
diluted 12 times (1:2) in lysis buffer from 50mg/mL to 0.024mg/mL. 5µL of samples and 
standards were added to a 96-well plate. 25µL of reagent A’ (2% (v/v) reagent S in reagent 
A) was added to each sample, followed by 200µL of reagent B. After 15 minutes, absorbance 
was read at 750nm using an ELx800 plate reading spectrophotometer (Bio-Tek, Wolf 
Laboratories, York, UK). A standard curve was generated from the serially diluted BSA. All 
samples were performed in duplicate and protein concentration was extrapolated from the 
standard curve using a third-order polynomial equation. 
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Protein samples were the diluted to the same concentrations and combined 1:1 with 2x 
Laemmli Buffer (Sigma-Aldrich). Samples were then boiled at 100°C for 10 minutes and 
frozen at -20°C until use.  
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2.11.3 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Separation of protein by SDS-PAGE was done using a 2-part gel system, consisting of 5% 
stacking gel and 10% resolving gel (for components and volumes see tables 2.6 and 2.7 
respectively). Proteins were separated using a polyacrylamide gel; stacking gel – 5% (v/v), 
running gel 10% (v/v).  
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Table 2.6 Components and volumes for 5% stacking gel 
Component Volume (mL) 
H2O 2.7 
30% Acrylamide/Bis-Acrylamide Solution 0.67 
1.5M Tris (pH 8.8) 0.5 
10% SDS 0.04 
10% Ammonium Persulfate 0.04 
TEMED 0.004 
 
Table 2.7 Components and volumes for 10% resolving gel 
Component Volume (mL) 
H2O 5.9 
30% Acrylamide/Bis-Acrylamide Solution 5 
1.5M Tris (pH 6.8) 3.8 
10% SDS 0.15 
10% Ammonium Persulfate 0.15 
TEMED 0.006 
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Once prepared, the resolving gel was loaded between glass plated held in place by a loading 
cassette, and left to polymerase at room temperature. When set, the stacking gel was 
prepared and loaded on top of the resolving gel. A well forming Teflon comb was added to 
the stacking gel whilst still liquid. Once set, the loading cassette was transferred to an 
electrophoresis tank and filled with running buffer. Combs were removed and samples were 
loaded along with 8µL of BLUeye Prestained Protein Ladder (Geneflow Ltd., Staffordshire, 
UK). Electrophoresis was run at 120V, 60mA, 50W for 2 hours.  
2.11.4 Transfer of Protein onto Polyvinylidene Fluoride (PVDF) Membrane 
PVDF membranes were first activated in 100% methanol, before being washed in H2O and 
finally in transfer buffer. 2 pieces of filter paper were also soaked in transfer buffer. Filter 
paper was placed on the bottom part of the semi-dry transfer tank and the PVDF membrane 
was added on top. Gels were removed from the glass plates and placed on top of the 
membrane, followed by the second piece of filter paper. Air bubbles were removed with a 
roller and the top section of the semi-dry transfer tank was placed on top. Semi-dry transfer 
was run at 15V, 500mA, 50W for 50 minutes.  
2.11.5 Immuno-Blotting  
Membranes were blocked using 5% (w/v) powdered milk (Marvel) in TBS-Tween (TBS-T) for 
1 hour. Membranes were incubated with primary antibody overnight in TBS-T with 3% (w/v) 
powdered milk solution and 0.1% (v/v) Tween-20, under rotation at 4°C (for primary antibody 
dilutions see table 2.4). The following day, membranes were washed 3 times with 0.1% (v/v) 
TBS-T, under rotation at RT for 10 minutes. Membranes were then incubated with secondary 
antibodies, diluted 1:1000 in TBS-T with 3% (w/v) powdered milk solution, under rotation at 
RT for 1 hour. Membranes were then washed 2 times with 0.1% (v/v) TBS-Tween-20 and a 
final time with TBS, under rotation at RT for 10 minutes. Membranes were developed for 3 
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minutes in EZ-ECL solution (Biological Industries) prepared by mixing equal parts solution A 
and B. Images were captured using the G-BOX (Syngene). Semi-quantitative analysis was 
performed using Image J software (National Institute of Health, NY, USA). 
 Methods for Cellular Assays 
2.12.1 Calcium Staining 
Quantification of calcium staining was performed using a 2 part method, staining calcium 
with Alizarin Red S and subsequently normalising to cell number using a crystal violet assay. 
2.12.1.1 Alizarin Red S Stain 
Calcium staining was performed to visualise the level of mineralisation in cultured bone cells. 
Alazarin Red (2% w/v, pH 4.2) was used to stain for calcium. Cells were grown in 6, 24 or 96 
well plates. Once ready for staining, cells were removed from the incubator and media was 
carefully aspirated. Cells were then gently washed with PBS, and enough 10% formalin was 
added to cover the cells for at least 30 minutes (1mL for 6 wells, 500µL for 24 wells, 100µL 
for 96 wells). After at least 30 minutes, the formalin was aspirated and cells were washed 
with the same volume of distilled water. After allowing the plate to dry, the same volume of 
Alizarin Red S was added to each well to completely cover the cells and wells were incubated 
for 45 minutes at room temperature in the dark. The stain was them aspirated and cells were 
washed 4 times with the same volume of distilled water. Cells were then imaged using a light 
microscope. For stain quantification, Alizarin Red S stain was eluted in 10% acetic acid (1mL 
for 6 wells, 500µL for 24 wells and 200µL for 96 wells), using an oscillating plate for at least 
15 minutes to completely dissolve the Alizarin Red S. 200µL was then transferred to a clear 
96 well plate and absorbance was calculated at 450nm using a GloMax plate reader 
(Promega).  
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2.12.1.2 Crystal Violet Assay 
Crystal violet assays were performed on wells following Alizarin Red S staining to visualise 
and quantify cell density. Acetic acid remaining from Alizarin Red S staining was removed and 
wells were carefully washed with water 3 times. After washing, plates were placed upside 
down on tissue to dry completely. Enough crystal violet solution to cover the cells was then 
added and left for 15 minutes. Crystal violet was then aspirated and wells were washed 4 
times with water. 10% acetic acid was then added (5mL for 6 well, 1mL for 24 well, 200µL for 
96 well) and left on an oscillating plate for at least 15 minutes to completely dissolve the 
crystal violet. 200µL was then transferred to a clear 96 well plate and absorbance was 
calculated at 600nm using a GloMax plate reader (Promega). 
2.12.2  Additional Osteoblast Staining 
2.12.2.1 Alkaline phosphatase (AP) Stain 
One SigmaFastTM 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) 
tablet (Sigma Aldrich) was dissolved in 10mL dH2O. Media was removed and cells were 
washed with PBS. Cells were fixed in 10% formalin for 60 seconds and washed with dH2O. 
Enough BCIP/NBT solution to cover the cells was added and incubated in the dark for 10 
minutes. BCIP/NBT solution was then removed and cells were washed with PBS. Cells were 
then visualised under a light microscope to observe alkaline phosphatase staining.  
2.12.2.2 Von Kossa Stain 
Media was removed from cells and cells were washed with dH2O. 1% aqueous silver nitrate 
(w/v in dH2O) was added to cells and incubated for 1 hour in UV light. Silver nitrate was then 
removed and cells were washed with dH2O. Excess silver nitrate was removed by covering 
cells with 5% sodium thiosulfate (w/v in dH2O) for 5 minutes. Cells were then washed for a 
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final time in dH2O. Cells were then visualised under a light microscope to observe Von Kossa 
staining.  
2.12.3  Luciferase Assay 
Luciferase assays were performed using the Dual-Glo® Luciferase Assay System (Promega) 
Cells were grown on 96 well plates. After treatment, media was removed, 20µL 1x reporter 
lysis buffer was added and plates were frozen at -20°C for 1 hour to allow full lysis. Plates 
were then defrosted, 100µL of Dual-Glo® Reagent was added and after 15 minutes, 100µL 
was transferred to a white 96 well plate and firefly luminescence was analysed. 100µL of 
Dual-Glo® Stop & Glo® Reagent was then added, and after 15 minutes, Renilla luminescence 
was analysed. For calculating relative luminescence, firefly luciferase was divided by Renilla 
luciferase for each sample. (Luminescence was analysed using a GloMax Plate Reader 
(Promega)). 
2.12.4  MTT Assay 
Cells were plated on clear 96 well plates. 100mg of Thiazolyl Blue Tetrazolium Bromide (MTT) 
(Sigma Aldrich) was diluted in 20mL of PBS and filtered through a minisart 0.2 μm sterile filter 
(Sartorius Stedim Biotech) to sterilise. MTT was added 1:10 to the media (11µL added to 
100µL media) and incubated at 37°C or 4 hours. Media was subsequently aspirated and the 
purple precipitate was dissolved in 200µL DMSO. Absorbance was quantified at 600nm using 
a GloMax Plate Reader (Promega). 
2.12.5  Cell Death Assay 
Cell death assay was performed using a CellToxTM Green Cytotoxicity Assay (Promega). 
1000x CellToxTM Green Dye was diluted 500x in Assay Buffer to make a 2X Reagent. This was 
then combined 1:1 with media (100µL + 100µL) and incubated for 15 minutes at room 
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temperature in the dark. Fluorescence was then measured at 490nm excitation and 510-570 
emission using a GloMax Plate Reader (Promega). 
2.12.6  ROS Production Assay 
ROS production assay was performed using the ROS-GloTM H2O2 Assay (Promega). 
Reconstitution buffer and lyophilised Luciferin Detection Reagent were combined to make 
the Reconstituted Luciferin Detection Reagent. Before use, 10µL of D-Cysteine and Signal 
Enhancer Solution was added to 1mL Reconstituted Luciferin Detection Reagent to make the 
ROS-GloTM Detection Solution. After treatment, 20µL of H2O2 Substrate Solution was added 
to 80µL of media and cells were incubated at 37°C for 6 hours. 100µL of ROS-GloTM Detection 
Solution was then added and cells were incubated for 20 minutes at room temperature. 
Luminescence was then analysed using a GloMax Plate Reader (Promega). 
2.12.7  Osteoclast Pit Formation Assay 
RAW 264.7 cells were seeded in a 24 well Corning® Osteo Assay Surface plates (30,000 
cells/well) and left to seed overnight. Cells were then treated for 7 days, after which media 
was removed and cells were removed by incubation with 10% bleach for 5 minutes. Bleach 
was then removed and wells were washed 3 times each with dH2O. Wells were then covered 
with Alizarin Red S for 45 minutes, which was then removed and washed with dH2O. After 
drying, wells were imaged using a bright field microscope.  
To determine resorbed area, images were grouped and ImageJ software was used to 
highlight the resorption pits. A colourimetric threshold was chosen that highlighted 
resorption pits and differentiated them from unresorbed calcium. This same threshold was 
applied to all grouped images to maintain consistency. Once highlighted, combined pit area 
for each image was calculated using the same ImageJ software. 
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 Statistical Analysis 
SigmaPlot 11.0 (Systat, San Jose, USA) was used for all statistical analysis, with the exception 
of sequencing IPA. Experiments were repeated at least 3 times (unless otherwise stated), 
showing the mean of all repeats, with error bars showing either standard deviation (SD) or 
standard error of the mean (SEM) as stated in the figure legends. An unpaired T-test or one-
way ANOVA were performed to test statistical significance. For ANOVA analysis, post hoc 
tests are described in the figure legend. Mann-Whitney Rank Sum test was used on non-
normally distributed data. Significance symbolised by asterisk (*), *p<0.05, **p<0.01 and 
***p<0.001.  
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3 Characterisation of the Mineralising 7F2 Osteoblast 
Cell Line  
3.1 Introduction 
The metastases of PCa cancer are associated with considerably higher rates of morbidity and 
mortality than localised PCa (Sieh et al., 2013; Tangen et al., 2003). The most common 
metastatic site of PCa is the bone, which represents around 84% of secondary tumours 
(Gandaglia et al., 2014). Although several hypotheses exist, the exact nature of this 
preferential tendency of PCa to metastasise to the bone is not fully understood. 
Furthermore, once the cancer cells reach the bone there are several stages associated with 
the progression of a secondary tumour. These include invasion of the bone marrow via the 
vasculature, an initial osteoclastic stage of localised bone debulking to allow PCa cell entry 
and finally the development of a secondary tumour (metastatic deposit) and its associated 
bone lesion. These lesions can be either osteolytic or osteoblastic depending on whether the 
osteoclasts or osteoblasts (respectively) dominate. Roughly 84% of lesions caused by PCa 
secondary tumours are osteoblastic (Charhon et al., 1983; Roudier et al., 2004), thus the 
hypotheses of this chapter and thesis are primarily focused on osteoblast function.  
PCa metastases are associated with considerably higher mortality rates (Sieh et al., 2013; 
Tangen et al., 2003) and lead to a heavily reduced quality of life. For example, the local cells 
within an osteoblastic lesion produce a number of pro-hyperalgesic (pain sensitising) 
mediators (Muralidharan & Smith, 2013) and can also influence the sprouting of new pain 
sensing nerves known as nociceptors (Jimenez-Andrade et al., 2010), resulting in significant 
pain. The debilitating nature of PCa bone metastases, along with decreased survival, 
highlights why a greater understanding of the pathophysiology is crucial.  
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The signalling network that governs the balance between osteoclast and osteoblast function 
is complex and features a wide range of molecules. These factors promote an environment 
in which osteoblastogenesis and osteoblast function are increased.  
Osteoblasts produce bone in a two-step process, firstly through the production of an organic 
bone matrix, consisting of type I collagen and other proteins such as bone sialoprotein (BSP), 
osteonectin and proteoglycans (Del Fattore et al., 2012). Subsequently, osteoblasts produce 
vesicles containing HA crystals, forming the mineralised component that surrounds the 
previously produced matrix proteins. Crucially, osteoblast mineralisation, in the form of 
mineralised matrix deposition can be induced in vitro (Guo et al., 2014) and 
visualised/measured using an Alizarin Red S (ARS) calcium stain.  
An understanding of the process of osteoblast mineralisation, and the genes that control it, 
will be crucial as we aim to understand how PCa cells may influence it. Therefore, in order to 
conduct molecular studies of how PCa cells may influence osteoblasts, a robust but simple 
model of osteoblast mineralisation is required. Several cell lines exist, which would provide 
such models including 7F2, human foetal osteoblast (hFOB) and sarcoma osteogenic (SaOS2). 
However, we used the 7F2 mouse bone marrow cell line as a simplified in vitro model of 
osteoblast mineralisation, as inducing these cells to mineralise, as well as the ability to 
manipulate this mineralisation with treatments is well characterised (Hwang et al., 2016; Yeh 
et al., 2015). Human prostate cancer cell lines grown as xenografts readily form bone 
metastases in mice, therefore indicating that this process is common across species and that 
the factors controlling the complex bone remodelling process share sufficient homology. In 
this chapter we look to characterise the 7F2 mineralising osteoblasts at both the functional 
and gene expression level. Characterisation of mineralising cells in this way will provide 
insight into the mechanisms of mineralisation as well as providing a basis to allow analysis of 
the effects of external factors i.e. PCa cells or factors secreted from them.   
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3.2 Chapter Aims 
The aim of this chapter is to characterise the 7F2 osteoblast cell line used in this thesis. 
Characterisation of this cell line will provide a model of osteoblastogenesis, in which the 
effects of PCa cells and various treatments can be tested. Therefore, the specific aims of this 
chapter are: 
 To show that osteoblasts can be induced to mineralise in vitro and determine the 
kinetics of this mineralisation 
 To show that mineralisation of osteoblasts in vitro can be reliably quantified  
 To determine the key genes that change during osteoblast mineralisation  
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3.3 Results 
Morphology of 7F2 Cell Line 
The 7F2 cell line was purchased from the ATCC and cells were frozen in low passage stocks. 
Cells were cultured up to a passage number of 20, at this point cells were discarded and low 
passage cells were defrosted. 7F2 cells are an immortalised Mus musculus osteoblast cell line 
isolated from femoral bone marrow from p53-/- mouse. A 7F2 monolayer was visualised using 
a brightfield microscope (figure 3.1). The cells displayed a flattened, irregular, star shaped 
morphology (fibroblast-like) with multiple processes, consistent with images from the ATCC 
and the literature (Mayer-Kuckuk et al., 2005). 
 Stimulating Mineralisation in 7F2 Cells Using Osteogenic Media 
7F2 cells were stimulated to mineralise over a 14 day period by treating with osteogenic 
media (MEM + 5x10-3 Mmol/L β-glycerophosphate, 0.1g/L ascorbic acid, 10-8 mol/L 
menadione and 10-7 mol/L 1, 25(OH)2D3) (Guo et al., 2014), and were collected at daily 
intervals for mineralisation staining. Cells were compared with untreated 7F2 cells cultured 
for an equivalent time. Mineralisation was assessed by ARS staining from day 8 onwards in 
an attempt to catch the initiation of the mineralisation process, as the literature suggests 
mineralisation occurs shortly after this time point (Gharibi et al., 2016).  From day 8, plates 
were taken daily, fixed in 10% formalin and stained using ARS to measure calcium deposition. 
Whole well images were taken on each day immediately following staining (figure 3.2A) and 
the same wells are imaged at 10x magnification using a brightfield microscope (figure 3.2B). 
7F2 cells treated with osteogenic media began to show calcium deposition (in the form of 
HA) at day 10 as evidenced by the appearance of faint ARS staining at both the whole well 
and magnified level. This calcium deposition increased from days 10-12 at which point whole 
well staining appears to plateau. However, magnified images show subsequent increases in 
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calcium deposition up to day 14. ARS is a stain capable of reacting with free calcium. Other 
stains are available for monitoring changes associated with osteoblast mineralisation. 
BCIP/NBT is an alkaline phosphatase (AP) substrate, able to form a blue precipitate in the 
presence of the active enzyme. AP activity is greatly increased during osteoblastic 
mineralisation. Another calcium stain, Von Kossa’s stain, reacts with calcium phosphate 
produced by mineralising osteoblasts resulting in a dark brown/black precipitate. BCIP/NBT 
and Von Kossa’s stain was added to cells mineralised for 1 or 10 days (figure 3.2C). The 
presence of AP and calcium phosphate, both seen as dark coloured deposits was confirmed 
in mineralising 7F2 cells.  
Quantification of ARS staining is crucial for accurately measuring changes in mineralisation. 
A method of quantification was used whereby ARS staining for each well was quantified and 
normalised using a crystal violet stain on the same well. Staining in this way allowed for 
normalisation of ARS staining in the event of cell monolayer disturbance, which occasionally 
occurred during washing steps. To show how this method accounts for this, 6 7F2 cell 
containing wells were mineralised for 14 days. Cells were stained with ARS, and excess 
staining was removed by washing 3 times in distilled water. At this point, half of the cells in 
3 wells were removed by scraping (figure 3.3A). ARS staining was then dissolved in 10% acetic 
acid and quantified by measuring the absorbance of this solution at 450nm. This showed that 
ARS staining was stronger in whole wells compared to half wells (figure 3.3B). Wells were 
then washed 3 more times in distilled water and stained with crystal violet (figure 3.3C). 
Crystal violet staining was dissolved in 10% acetic acid and quantified by measuring the 
absorbance of this solution at 600nm, also showing that whole well staining was greater than 
that of half wells (figure 3.3D). Finally, the quantified ARS stain was divided by the quantified 
crystal violet stain for each well, which showed a similar level of normalised staining across 
the two groups (figure 3.3E). This showed that staining in this way is able to normalise ARS 
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intensity depending on cell monolayer integrity, allowing for comparison of ARS intensity 
across wells regardless of monolayer condition.  
7F2 cells cultured over 14 days in regular or osteogenic media were stained daily with ARS 
from days 8-14. ARS staining was quantified and normalised as described above (figure 3.4). 
Quantification confirmed that deposition of calcium initiated at day 10, evidenced by an 
increase in absorbance for the cells grown in osteogenic media compared to day 10 control 
cells grown in regular media. However, calcium quantification in the osteogenic media group 
appeared to plateau after 11 days and remained relatively constant up to day 14 (p<0.001 
from day 11-14). This plateau in calcium staining may be a result of either an inability of cells 
to further mineralise, or may reflect the upper limits of the dynamic range of our assay. 
Furthermore, at day 14, spontaneous mineralisation occurred in the control group. 
Chapter III: Characterisation of the Mineralising 7F2 Osteoblast Cell Line 
132 
 
 
 
 
 
 
 
Figure 3.1. Morphology of 7F2 cells. Brightfield microscopy images of 7F2 cell 
monolayers, grown on plastic in cell culture flasks. (A) Low density (~10% confluency), 
(B) High density (~90% confluency). Scale Bar: 100µm. 
A B 
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Figure 3.2. Staining of 7F2 cells grown in regular or osteogenic media. ARS staining of 7F2 cells over a 7 day period from days 8-14. (A) Whole 
well images. (B) 10x magnified images. (C) Magnified images of BCIP/Alk Phos Von Kossa stained 7F2 cells grown in osteogenic media for 1 or 
10 days.  
C 
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   Day 1                Day 10  
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Figure 3.3. Example of Alizarin Red S and Crystal Violet staining method. (A) ARS stained 
wells, (B) Quantification of the ARS staining for full and half wells, (C) Crystal violet stained 
wells, (D) Quantification of the ARS staining for full and half wells. (E) Quantified alizarin 
staining divided by quantified crystal violet staining. (Graphs show absorbance +SEM for 
triplicate wells). 
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Figure 3.4. Quantification of ARS staining over a 7 day period from days 8-12 for 
mineralising 7F2 cells grown in osteogenic media and control 7F2 cells grown in regular 
media. (Graph shows ARS stain normalised to crystal violet staining, +SEM, statistical 
significance assessed by unpaired ttest at each time point, **p<0.01, ***p<0.001, n=3). 
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Gene Changes in Mineralising 7F2 Cells 
The mineralisation and calcification of the 7F2 cells is a very complex process involving both 
rapid gene expression changes and slower physiological changes e.g. collagen deposition and 
consequent mineralisation. To get a more specific idea of the genetic changes that are 
associated with mineralisation, qPCR was done on mineralising 7F2 cells every 3 days from 
0-12 days. A number of documented osteoblast differentiation genes were tested relative to 
2 housekeeping genes (HPRT & β-actin), of these, 4 were selected based on the degree and 
direction of change compared to control cells; Activin A receptor, type I (ACVR1), Matrix 
metalloproteinase-3 (MMP3), distal-less homeobox 5 (DLX5) and Collagen type 1 alpha 1 
(COL1A1). As stated, other osteoblast differentiation genes were also tested, such as RUNX2, 
SP7 and BGLAP (see appendix 1). However, these genes showed expression patterns in 
treated vs control cells that were contrasting from their well-established patterns shown in 
the literature and were therefore not included.  
ACVR1 is a key receptor of bone morphogenetic protein (BMP) 7. In mineralising 7F2 cells, 
ACVR1 peaked at day 3 (figure 3.5A) compared to control cells, although this failed to reach 
significance. Expression then reduced greatly from day 3 to day 6 and continued to decrease 
up to day 12. However, although ACVR1 expression decreased after day 3, levels remained 
higher than control cells at both days 6 and 9, although not significant. By day 12, ACVR1 
levels had returned to the same level as control cells. MMP3 is an enzyme responsible for 
the breakdown and remodelling of extracellular matrix proteins such as collagens, 
proteoglycans and elastin. In mineralising osteoblasts, MMP3 showed a significant increase 
in expression at day 3 compared to control cells with a further increase in expression seen at 
day 6 (p<0.05 for both) (figure 3.5B). A gradual decrease in expression was seen in 
mineralising cells between days 6 and 12 although expression was still greatly increased at 
all time points compared to control cells, albeit not significant. COL1A1 is a collagen protein 
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produced in large amounts by osteoblasts during the early stages of bone matrix formation. 
COL1A1 expression showed a sharp increase at day 3 in mineralising 7F2s (figure 3.5C), 
however this increase was not significant. Expression had returned to normal by day 6 and 
both mineralising and control cells showed a gradual decrease in expression between days 6 
and 12. Of the genes selected, DLX5 was the only one to decrease in expression compared 
to control cells (figure 3.5D). Decreased DLX5 expression in mineralising cells compared to 
control cells was seen at all time points with a further gradual reduction in expression seen 
in mineralising cells up to day 12. However, DLX5 expression in mineralising cells failed to 
reach statistical significance compared to control cells. To confirm that these gene changes 
were occurring as a part of the mineralisation process, control and mineralising 7F2 cells 
were cultured alongside those destined for RNA extraction and were stained with ARS and 
quantified (figure 3.5E). ARS quantification confirmed that mineralisation was occurring in 
these cells, and therefore the gene changes witnessed were representative of different 
stages of the mineralisation process. A summary of the changes in expression of these 4 
genes, adapted from figures 3.5 A-D is shown in figure 3.6.  
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Figure 3.5. qPCR of Mineralising and Control 7F2 Cells Across a 12 Day Period. (A) ACVR1 expression, 
(B) MMP3 expression, (C) COL1A1 expression, (D) DLX5 expression. (Graphs A-D show ΔΔCT values 
normalised to housekeeping genes +SEM, significance between treated and control cells was assessed 
using Mann-Whitney U test, *=p<0.05, n=4). (E) Quantified ARS staining of cells cultured alongside those 
used for qPCR. (Graph shows ARS stain normalised to crystal violet staining, +SEM, n=2).     
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Figure 3.6. Summary of Gene Changes in Mineralising 7F2 Cells. Changes in gene expression in mineralising 7F2s 
relative to control cells adapted from data displayed in figure 3.5. Vertical dashed line represents the 3 day treatment 
period used in following experiments.  
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3.4 Discussion 
Osteoblast overactivation, resulting in excess deposition of mineralised bone, is a hallmark 
of osteoblastic PCa bone metastases. Therefore, the aim of this chapter was to characterise 
an in vitro mineralising osteoblast model during different stages of mineralisation. By doing 
this, we would obtain a platform against which the effects of interactions with PCa cells or 
secreted factors can be compared.  
For this study, 7F2 bone marrow osteoblast cells were used. This cell line was selected for its 
relative normality, non-disease related origin and ability to readily mineralise in osteogenic 
media. 7F2 cells showed a flattened, star shaped morphology (fibroblast-like) as expected, 
based on reference images from the ATCC.  
Osteoblastic bone deposition is a two-step process, as discussed in section 1.3.2.1.1. The first 
step in this process is the secretion of uncalcified matrix, consisting of primarily type I 
collagen. This collagenous structure is then mineralised by the osteoblasts via the deposition 
of CaPO4 in the form of HA (Clarke, 2008). ARS is a commonly used stain in osteogenic studies, 
favoured for its ease of quantification. ARS reacts with calcium within the hydroxyapetite via 
the following chemical equation to form a red precipitate (shown in bold) (Misra, 1992): 
 Ca10(OH)2(PO4)6 + AzHNa → 10CaAz↓ + 4HPO4
2- + 2H2PO4
- + 10Na+ + 2H2O 
After the ARS solution is removed and cells are washed, this red precipitate remains visible, 
as shown in figure 3.2A and B. The steady increase in red staining of 7F2 cells grown in 
osteogenic media shown in figure 3.2A and B indicates a gradual deposition of calcium. Thus, 
we show that culture in osteogenic media is sufficient to induce 7F2 mineralisation and that 
the calcium deposition is detectable roughly 10 days after treatment. BCIP/NBT and Von 
Kossa staining showed that AP was increased and calcium phosphate was deposited after 
treatment with osteogenic media for 10 days. AP activity and calcium phosphate deposition 
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are increased during mineralisation, therefore these positive staining results further 
emphasise that complex mineralisation is occurring in these cells.          
Reliable quantification of ARS staining is a crucial step that will allow for a more specific 
measurement of the effects of any subsequent treatments on 7F2 function. ARS staining 
features several washing steps, which, due to the extremely fragile nature of the 7F2 
monolayer, occasionally results in the accidental removal of patches of 7F2 cells. To account 
for this, ARS staining was normalised to crystal violet staining for each well. A visual display 
of this process is shown in figure 3.3. The reduction of ARS staining seen in half full wells 
compared to full wells matched the reduction of crystal violet staining of the same wells, 
resulting in similar normalised ARS staining levels. Thus, we show that ARS staining can be 
accurately calculated and compared for all wells. 
Figure 3.4 shows the quantified ARS staining for control and mineralising 7F2s, which 
correlates with the increase in ARS seen from visual inspection of cells in figure 3.2A and B. 
This graph confirms that increases in ARS staining are quantifiable and that any changes in 
mineralisation seen with subsequent treatments can be measured colourimetrically. 
Together, figures 3.2 A and B, and figure 3.4, indicate that subsequent treatments measured 
by ARS staining should have a treatment period of 10 days. This period of time is long enough 
to induce calcium deposition, whilst minimising the risk of reaching the limits of cell 
differentiation and/or the dynamic range of ARS staining seen at later days. BCIP/NBT and 
Von Kossa staining was effective in showing the presence of AP and calcium phosphates, two 
further markers of mineralisation. However, measuring the changes in BCIP/NBT and Von 
Kossa staining is qualitative and detecting subtle changes in staining levels between future 
treatments may not be possible. Therefore, ARS staining remained the principle measure of 
overall mineralisation.  
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Mineralisation, in the form of calcium deposition, represents the overall change (or end 
point) in the function of the osteoblasts compared to non-mineralising control cells. 
However, for a more specific idea of how the 7F2s change during this process, the gene 
expression changes in these cells were measured at 3 day increments from treatment 
through to complete mineralisation. Genes regulating osteoblast differentiation are well 
characterised, such as RUNX2, COL I, Alkaline phosphatase and Osteocalcin (Rutkovskiy et 
al., 2016). However, in 7F2 cells, the gene changes that occur during mineralisation, either 
driving it or occurring as a result, have not been well characterised. Therefore, we tested a 
number osteogenic markers in 7F2 cells throughout the mineralisation process. From this 
panel, 4 genes showed an expression pattern indicative of an osteogenic marker across the 
treated and control time courses; ACVR1, MMP3, COL1A1 and DLX5. The expression of other 
well characterised osteoblast differentiation genes, such as RUNX2, SP7 and BGLAP were also 
tested. However, these genes showed reduced expression in mineralising cells vs control 
cells. As these genes are so well characterised as markers of osteoblastic differentiation, it 
was decided not to include them based on their unexpected results. The decrease seen in 
RUNX2 may reflect the inhibitory effect of RUNX2 in late osteoblasts (Komori, 2006). 
However, given the relative uncertainty of RUNX2 expression in differentiating 7F2 cells, it 
was decided not to use RUNX2 as a marker in this project. 
ACVR1, is a BMP receptor belonging to the TGFβ family subgroup. ACVR1 has been linked to 
several aspects of musculoskeletal development. For example, Acvr1 ablation resulted in 
hypotrophic craniofacial abnormalities and decreased ossification in mice (Dudas et al., 
2004). However, Kamiya et al. (2011) showed that osteoblast specific Acvr1-null mice had 
increased bone mass due to an increase in osteoblastic Wnt signalling, thus suggesting an 
inhibitory role of Acvr1 in osteoblast function. These findings suggest that Acvr1 has multiple 
and complex roles within bone development. Our data showed a strong increase in Acvr1 
expression early in mineralising 7F2s compared to control cells, peaking at day 3 where 
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expression in mineralising cells was over 18x higher than controls. As discussed, mineralising 
genes have not been well characterised in 7F2 cells and therefore Acvr1 may play a different 
role in the differentiation of these cells. 
MMP3 is an enzyme involved in the breakdown of extracellular matrix (ECM) proteins such 
as type III, IV and V collagens and fibronectin during tissue remodelling (Birkedal-Hansen et 
al., 1993). Bauer et al. (2015) showed that mice lacking osteoblastic Runx3 had decreased 
bone matrix formation and ossification. These Runx3-deficient cells also showed a >5-fold 
reduction in Mmp3 expression compared to controls, suggesting either a functional role of 
Mmp3 in osteoblastic bone deposition or a concurrent loss in expression with decreased 
osteogenesis. Our data agrees with these findings, with a substantial increase in Mmp3 
expression seen in mineralising osteoblasts compared to control cells. One reason for this 
could be that Mmp3 may aid in remodelling collagen fibres for mineralisation. 
The COL1A1 gene produces the pro-alpha1(I) chain, a key component of type I collagen along 
with the pro-alpha2(I) chain. Type I collagen is secreted by early differentiating osteoblasts 
and forms the majority of the organic phase of bone matrix (Del Fattore et al., 2012), which 
is later mineralised by the osteoblasts. In our mineralising 7F2 cells, Col1a1 expression 
peaked at day 3 compared to control cells before returning to control levels by day 6. This 
early pulse in Col1a1 expression is expected based on the literature, which as discussed, 
states that type I collagen production occurs early and precedes matrix mineralisation.   
Dlx5 was the only selected gene to show decreased expression in mineralising cells compared 
to controls. Dlx5 is a homeobox transcription factor which forms a bigene cluster with Dlx6. 
DLX5 expression correlates with osteoblast differentiation and is suggested to induce 
differentiation through activation of other transcription factors such as Runx2 and Osx 
(Osterix) (Laxman et al., 2016; Ryoo et al., 1997).  Dlx5/6-/- mice show “severe limb, 
craniofacial and axial skeletal defects” including retarded axial skeletal growth (Robledo et 
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al., 2002). These findings seem to contradict our own, which actually suggests that Dlx5 is 
lost during 7F2 differentiation and subsequent mineralisation. However, as discussed, data 
on Dlx5 expression in 7F2 cells is limited. One study linking osteoblast differentiation and 
Dlx5 in 7F2 cells showed that Dlx5 is down regulated >3x in FGF2 treated cells compared to 
controls (Sugimoto et al., 2016). Given that FGF2 is known to stimulate osteoblast 
differentiation and bone formation (Fei et al., 2011), it’s possible that decreased Dlx5 
expression either drives 7F2 differentiation or is lost as a result.  
Although the selected genes showed a sizable difference in expression in mineralising vs 
control cells, this change failed to reach significance in 3 out of 4 genes. However, these gene 
expression patterns are used in combination with ARS staining to determine overall cell 
changes, and are therefore still viable markers able add a degree of certainty to any change 
in differentiation seen with future treatments. Furthermore, the lack of protein validation 
means that connections between the expression of these genes and a direct functional role 
in osteoblast mineralisation can not be made.  
Although some of the gene expression patterns discussed appear to differ from the expected 
based on the literature, the data on 7F2 gene changes is poorly explored. The difference in 
differentiation stage between commonly studied osteoblast cell lines is just one of several 
factors that could explain variations in gene expression between these cells. Another factor 
that could explain the difference in gene expression compared to the literature could be 
differences in the contents of osteogenic medias. Many different formulations of osteogenic 
media have been described, containing a combination of β-glycerol phosphate, ascorbic acid, 
vitamin D and other chemicals such as dexamethasone (Olivares-Navarrete et al., 2012). 
These various formulations may induce different changes in gene expression, making direct 
comparisons difficult.  
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The changes in expression of the selected genes compared to control cells is summarised in 
figure 3.6, using adapted data to show the general trends of expression for each gene. This 
summary also helps to outline why future treatments involving validation of osteoblast 
differentiation by gene expression involve 3 day treatment periods (represented by the 
vertical dashed line). This is because although some genes (ACVR1, COL1A1) are early 
responding and some (MMP3) are late responding, all genes were different to control cells 
at day 3, whereas the expression of some genes had returned to the level of control cells at 
later time points.  
In conclusion, we showed that 7F2 cells can be stimulated to mineralise in vitro via treatment 
with osteogenic media, and that this mineralisation can be visualised with ARS staining. By 
subsequently showing that ARS staining can be quantified, we were able to provide a more 
accurate way for 7F2 mineralisation to be measured. Finally, by measuring the gene changes 
associated with 7F2 mineralisation we were able to gain a more in depth, specific idea of 
how mineralising 7F2 cells differ from their equivalent controls. By showing that 
mineralisation can be measured at the functional and gene expression level, we have 
successfully characterised mineralising 7F2 cells, thus providing a good osteoblastic bone 
model for  future use in monitoring bone and prostate cancer cell interactions.  
3.5 Summary of Key Points 
Mineralisation of 7F2 cells in vitro was successful, and staining by ARS provides both a visual 
and measurable way to monitor this. Measuring gene changes in mineralising 7F2 cells 
provided a panel of 4 genes that are differentially expressed compared to control cells; 
ACVR1, MMP3, COL1A1 and DLX5. Analysis of time points shows that treatment periods 
should be 10 days for ARS staining and 3 days for gene expression quantification. 
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4 Effect of Prostate cancer cells on Osteoblasts 
4.1 Introduction  
Within the last 30 years, multiple new forms of non-coding RNAs have been discovered (Cech 
& Steitz, 2014). The functions of most of these nucleic acids lies within their ability to alter 
the activity of other forms of RNA (Clouet d'Orval et al., 2001; Darzacq et al., 2002; Elbashir 
et al., 2001; Hammond et al., 2000). This information has drastically increased the 
understanding of a number of both physiological and pathophysiological pathways. miRNAs 
in particular have gathered much attention due to their widespread ability to regulate gene 
expression and alter a number of cellular processes (Esau et al., 2006; Naguibneva et al., 
2006).  
The activity of miRNAs has been linked to multiple facets of cancer development such as 
proliferation, evasion of apoptosis and have even been linked to metastatic processes such 
as epithelial–mesenchymal transition (EMT) (Peng & Croce, 2016). The aberrant expression 
of miRNAs has been noted in virtually all major cancers and numerous other diseases, 
indicating that their role in these cellular pathways may be significant (Ha, 2011; Wu & Lu, 
2017).  
A crucial discovery in the field of miRNAs came from Chim et al. (2008) who discovered the 
presence of miRNAs in extracellular biological fluids. This discovery that miRNAs are 
ubiquitous in bodily fluids has paved the way for a number of novel hypotheses centred 
around miRNAs being potential mediators of intercellular communication (Weber et al., 
2010).  
Signalling between PCa cells and bone cells within the secondary tumour environment is 
extensive. This signalling involves a multitude of protein and growth factors, and many of 
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these factors are well characterised such as OPG, IGF and TGFβ.  Within the context of bone 
metastatic lesions, miRNAs have been implicated in several aspects of development 
including osteotropism (Zoni et al., 2015), regulation of angiogenic–osteogenic coupling (Li 
et al., 2013) and even modulation of bone cell function (Eguchi et al., 2013). 
Models of human prostate cancer cells which metastasise to the bone, in mouse xenograft 
models, are available for study. The PC3 and VCaP (vertebral metastasis harvested PCa cell 
line) cell lines frequently metastasise to the bone, whereas LNCaP (lymph node harvested 
Pca cell line) cells have a lower propensity, but can do so more readily as aggressive 
subclones (Sobel & Sadar, 2005). In this chapter we looked to determine whether PCa cells 
are able to signal to osteoblasts in vitro via exported factors, examining what effect this has 
on their ability to differentiate and mineralise. By analysing PC3 cell conditioned media for 
the presence of miRNAs, we then attempted to ascertain whether miRNAs could function as 
intercellular communication between cancer cells and bone cells - in parallel or in 
combination with protein and other signalling mediators.
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4.2 Chapter Aims 
The aim of this chapter is to characterise the effects of communication between PCa cells 
and osteoblasts, using the bone model described in the previous chapter, and to discuss 
factors that may mechanistically explain this. To achieve this the specific aims of the chapter 
are: 
 To analyse the effects of PC3 cell secreted signalling molecules on 7F2 mineralisation 
and differentiation using a co-culture system 
 To determine whether this effect is specific to PC3 cells 
 To analyse the miRNA content of PC3 cell conditioned media and use differential 
centrifugation to indicate which extracellular structures these miRNAs may be 
associated with 
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4.3 Results 
Co-Culture of Osteoblasts with PCa Cells 
To determine the effects of PCa cell signalling on osteoblast function, we set up a co-culture, 
where osteoblasts were seeded on the surface of a 24well plate, and 0.4µm pore size inserts 
containing increasing amounts of the highly aggressive PC3 PCa cells were added above 
(figure 4.1A). Osteoblasts and inserts were cultured in either regular or osteogenic media for 
6 days and stained with ARS. In regular media, 7F2 cells cultured with increasing amounts of 
PC3 cells showed no change in their level of mineralisation. In osteogenic media, co-culturing 
7F2s with PC3 cells increased mineralisation of the osteoblast cells in a PC3 cell number 
dependant manner. This dose dependent effect showed an increase in ARS staining reaching 
statistical significance at 40,000 PC3 cells (p<0.05 for all) (figure 4.1A). 
Additionally, it was observed that a more intense region of mineralisation staining was 
present in the immediate vicinity of the insert containing the PC3 cells (figure 4.1B). This 
pattern was noticeably absent in 7F2 cells cultured with empty inserts. Furthermore, crystal 
violet staining of these cells revealed a decrease in cell confluency below the PC3 containing 
insert, corresponding with the pattern seen with ARS staining. Again, this pattern was not 
seen in cells cultured with empty inserts.  
To confirm that PC3 cells were inducing 7F2 differentiation at the gene expression level, the 
expression of 4 genes, characterised as part of the osteoblast model, were measured in 7F2 
cells co-cultured with 20,000 and 40,000 PC3 cells, in regular and osteogenic media. In cells 
cultured in regular media, co-culture with PC3s had no effect on the expression of these 
genes. DlX5, which showed reduced expression during the model of osteoblast 
differentiation, was further decreased during co-culture with PC3 cells in osteogenic media 
in a cell number dependant manner. This reduction in DLX5 was significant for both 1x and 
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2x PC3 cells (p=0.011 and p=0.003 respectively). COL1A1, MMP3 and ACVR1 all showed 
increased expression during the 7F2 differentiation model. COL1A1 showed no change in 
expression during co-culture. However, MMP3 and ACVR1 both showed increased 
expression during co-culture in osteogenic media, in a cell number dependant manner, with 
ACVR1 showing a significant increase with 2x PC3 cells (p=0.009). 
To validate that the induction of mineralisation seen in our co-culture model was specific to 
PCa cells and not simply a result of (unspecific) cell number and the associated signalling 
molecules released, we mineralised 7F2 cells in the presence of a range of prostate cell line 
conditioned medias (figure 4.3). Non-cancerous, immortalised, prostate epithelial cell, 
namely PZ-HPV-7, conditioned media as well as conditioned media from three PCa cell lines 
was compared to osteogenic MEM. DU145 cells, another aggressive metastatic PCa cell line, 
as well as LNCaP, a less aggressive metastatic cell line, were included alongside PC3 cell 
conditioned media. Conditioned media was collected after 48 hours from equal numbers of 
cells and centrifuged twice, first at 2,000xg for 5 minutes and subsequently at 16,000xg for 
15. All media contained the same concentrations of osteogenic supplements (described 
previously  in section 3.3). Compared to osteogenic MEM, PZ-HPV-7 conditioned media had 
no effect on the level of 7F2 mineralisation.  DU145 cell conditioned media was able to 
induce a 34% increase in 7F2 mineralisation, however, this change failed to reach statistical 
significance. PC3 cell conditioned media induced a 70% increase in 7F2 mineralisation 
(p<0.001). LNCaP cell conditioned media stimulated a minimal increase in mineralisation of 
around 15%. 
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Figure 4.1: ARS staining of 7F2 cells co-cultured with increasing amounts of PC3 cells in 
either regular or osteogenic MEM. (A) Quantified ARS staining of co-cultured 7F2s, 1x = 
20,000 PC3 cells seeded in the insert. (Graph shows average fold change compared to “no 
min, no insert” +SEM, n=3) (Statistical significance assessed by one-way ANOVA using 
Holm-Sidak multiple comparisons test between treatment and control (0x cell insert in 
mineralising media), *p<0.05, **p<0.01). (B) Representative whole well images of wells 
beneath either empty or PC3 cell containing inserts cultured in mineralising media, stained 
with ARS or crystal violet. 
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 Figure 4.2: qPCR of osteoblast differentiation genes in 7F2 cells co-cultured with increasing amounts of PC3 cells in either regular 
or osteogenic MEM. (A) DLX5 expression, (B) COL1A1 expression, (C) MMP3 expression, (D) ACVR1 expression in 7F2 cells co 
cultured with PC3 cells 1x = 20,000 PC3 cells seeded in the insert. (Graphs show average fold change compared to empty controls 
+SEM, n=3) Statistical significance assessed by one-way ANOVA using Holm-Sidak multiple comparisons test, *p<0.05, **p<0.01. 
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Figure 4.3: Effect of conditioned media from various prostate cell lines on 7F2 
mineralisation. 7F2 cells were mineralised for 10 days in conditioned media from 
the prostate epithelial PZ-HPV-7 (PZ) and prostate cancer PC3 and DU145 cell lines 
with mineralisation supplements and compared to regular osteogenic MEM. 
(Graph shows average fold change compared to control +SEM, n=3). Statistical 
significance assessed between control and conditioned media groups by one-way 
ANOVA using Holm-Sidak multiple comparisons test, ***P<0.001.  
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Analysing the miRNA Content of PC3 Conditioned Media 
After showing that secreted signalling molecules from PCa cells can influence the activity of 
7F2 cells, we looked to analyse the contents of PC3 cell conditioned media, for evidence of 
miRNAs. We hypothesised that PCa cells use secreted miRNAs to affect the gene expression 
in the recipient 7F2 cells and, therefore, their activity. We therefore looked to analyse the 
miRNA content of PC3 cell conditioned media.  
PC3 cell conditioned media was centrifuged twice, first at 2,000xg for 5 minutes, and 
subsequently at 16,000xg for 15 minutes, to remove cells and cellular debris. RNA was 
extracted from the supernatant using Trizol-LS, analysed using a bioanalyser and compared 
to DMEM and DMEM + 10% FCS (figure 4.4). Bioanalysis revealed a population of small RNAs 
<150nt released by PC3 cells into the media.  
To confirm that this population of small RNAs contains miRNAs, qPCR was performed on the 
PC3 conditioned media RNA (figure 4.5). The presence of 5 miRNAs; miR-16-5p, miR-423-3p, 
miR-222-3p, miR-93-5p and miR-221-3p, was analysed and compared to DMEM and DMEM 
+ 10% FCS. All 5 miRNAs were found at significantly higher levels in PC3 conditioned media 
compared to DMEM + 10% FCS (P<0.05 for miR-93-5p, p<0.01 for all remaining miRs), 
indicating that these miRNAs are PC3 cell derived. 
After confirming the presence of miRNAs in PC3 cell conditioned media, we looked to analyse 
how these are distributed. PC3 cell conditioned media was therefore centrifuged at 
increasing forces (xg), to remove various debris and other components, and the remaining 
supernatant was analysed to assess the concurrent loss in miRNA by qPCR (figure 4.6A-E). 
Centrifugation in this way removes different cellular contents at each stage; 2,000xg – cells, 
dead cells and apoptotic bodies, 16,000xg – cell debris and lEVs such as microvesicles, 
100,000xg – sEVs such as exosomes and smaller microvesicles (Szatanek et al., 2015). miRNAs 
were expressed at different levels in PC3 cell conditioned media, for example miR-16-5p and 
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miR-221-3p showed much higher expression than miR-423-3p, miR-222-3p and miR-93-5p. 
This matches the expression pattern seen in figure 4.5. However, although miRNAs were 
expressed at different levels, all tested miRNAs showed the same trends of depletion with 
increasing centrifugation, detailed as follows. Centrifuging cells at 2,000xg for 5 minutes 
resulted in no change in miRNA level. However, centrifugation at 16,000xg for 15 minutes 
removed an average of 12.5% of the miRNA found in uncentrifuged PC3 cell conditioned 
media. Centrifuging media at 100,000xg for 90 minutes resulted in a reduction in the levels 
of all tested miRNAs compared to media centrifuged at 16,000xg, This reduction in miRNA 
level failed to reach significance for individual miRNAs. Howver, the average miRNA loss 
between 16,000xg and 100,000xg centrifugation steps for the 5 miRNAs was >17% (p=0.006) 
(Figure 4.6E). Overall this shows that miRNAs are associated with various structures within 
conditioned media, and that the vast majority of miRNAs are likely not vesicle associated.  
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Figure 4.4: Bioanalyser Traces of Media Samples. Bioanalyser histograms showing levels of 
RNA in (A) Serum Free DMEM (B) DMEM + 10% FCS (C) DMEM + 10% FCS, conditioned with 
PC3 cells for 48 hours.  
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Figure 4.5: qPCR of miRNAs in PC3 Cell Conditioned Media. Levels of (A) miR-16-5p, (B) 
miR-423-3p, (C) miR-222-3p, (D) miR-93-5p, (E) miR-221-3p in DMEM + 10% FCS and PC3 
conditioned DMEM. (Graph shows mean+SEM, n=3) (Statistical significance assessed by 
unpaired t-test, *p<0.05, **P<0.01)  
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Figure 4.6: qPCR of miRNAs in PC3 Cell Conditioned Media Subjected to Increasing Force 
Centrifugation. Levels of (A) miR-16-5p, (B) miR-423-3p, (C) miR-222-3p, (D) miR-93-5p, 
(E) miR-221-3p in PC3 conditioned media after centrifugation at increasing forces) (F) 
Average of miRNA loss between 16,000xg and 100,000xg centrifugation steps (Graphs 
show mean+SEM, n=3, statistical significance assessed by one-way ANOVA for figures 
4.6A-E and unpaired t-test for figure 4.6F, *p<0.05, **p<0.01) 
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4.4 Discussion 
Cancer cell induced changes to the function of cells within the bone microenvironment drives 
the osteolytic/osteoblastic presentation seen in bone metastases. Metastases from PCa form 
predominantly osteoblastic lesions, characterised by increases in both osteoblastogenesis 
and osteoblast function (Ottewell, 2016; Ye et al., 2007). Therefore, the aim of this chapter 
was to analyse the effect of local PCa cells on the osteoblastic bone model described in the 
previous chapter.  
To test the effect of PCa cells on the osteoblastic model described earlier, we set up a co-
culture experiment using 7F2 osteoblast cells and PC3 PCa cells. PC3 cells are PCa cells 
isolated from a bone metastasis. PC3 cells are androgen receptor negative and are often used 
for their aggressive nature compared to other PCa cell lines such as LNCaPs (Tai et al., 2011). 
The 7F2 cells used in this co-culture were a gift from Dr Bronwen Evans, and mineralisation 
in these cells initiated at around day 6. These cells were later replaced with 7F2 cells from 
the ATCC, in which mineralisation initiated at around day 10, as shown in the previous 
chapter. These 7F2 cells were therefore mineralised in the presence of PC3 cells for 6 days. 
Using inserts with a 0.4µm pore size is a commonly utilised method of preventing cell 
migration whilst allowing the passage of small signalling molecules (Alexander et al., 2015; 
Guo et al., 2016). Crucially, a pore size of 0.4µm allows the passage of particular sEVs, such 
as exosomes, whilst limiting the passage of lEVs including MVs and apoptotic bodies. 
Mineralising osteoblasts in this way would allow us to determine whether communication 
between the two cell lines can affect mineralisation, and to what extent. Staining of co-
cultured 7F2 cells revealed that PC3 cells had no effect on mineralisation in regular MEM, 
therefore indicating the PC3 cells do not produce factors that alone initiate mineralisation 
on this time scale. However, in osteogenic MEM, PC3 cells were able to enhance 
mineralisation in the 7F2 cells in a PC3 cell number dependant manner. Furthermore, visual 
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inspection of ARS stained co-cultured 7F2s revealed that areas of increased mineralisation 
were localised to the area directly beneath the insert. Crystal violet staining showed that 
these patches also displayed decreased cell confluence, likely a result of the cell cycle exit 
that occurs upon cell differentiation and as a precursor to matrix mineralisation (Rutkovskiy 
et al., 2016). These staining patterns further indicate that differentiation is stimulated by 
secreted factors from the PC3 cells above. The osteoblastic model described in the previous 
chapter also detailed 4 genes that showed differential expression in mineralising vs control 
7F2s. In this model, DLX5 showed decreased expression whereas COL1A1, MMP3 and ACVR1 
all showed increased expression. 7F2 cells co-cultured with PC3 cells in regular media 
showed no change in the pattern of expression, an unsurprising result given that no increase 
in ARS staining was seen in this group. In mineralising media, co-culture with PC3 cells 
induced cell number dependant changes in these genes consistent with those seen in the 
mineralising 7F2 model in all genes bar COL1A1, which showed no change. The overall 
pattern seen in these gene changes supports ARS staining data suggesting that 
communication between the two cell lines has a pro-osteoblastic outcome in an 
environment that allows mineralisation. 
As discussed, increased osteoblast function is characteristic of an osteoblastic lesion. 
However, PC3 cells are known to form osteolytic lesions (Akech et al., 2010; Fradet et al., 
2013), and have been shown to have an inhibitory effect on the mineralisation of the 
osteosarcoma cell line SaOS-2 (Yuen et al., 2010). Therefore, it was interesting to note that 
in this osteoblastic model, using 7F2 cells, that PC3 cells promoted mineralisation. PC3 cells 
do express a number of factors such as, TGF-β1 (Lee et al., 2003b), BMP-4 and BMP-6 (Keller 
& Brown, 2004) that are known to induce osteoblast differentiation (Chen et al., 2012; 
Yamaguchi et al., 1996; Zhu et al., 2012).  
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It could be argued that these pro-mineralising effects are not specific to PCa cells and are 
simply due to the presence of secreted signalling molecules from cells, regardless of origin. 
To test this, 7F2 cells were mineralised in osteogenic conditioned media from PCa cells as 
well as non-cancerous prostate cells. Compared to unconditioned osteogenic media, 
prostate epithelial PZ-HPV-7 conditioned media had no effect on the level of 7F2 
mineralisation, whereas PC3 conditioned media induced a significant increase. Another PCa 
cell line, DU145, was also able to induce mineralisation, albeit to a lesser extent than PC3 
cells. DU145 cells are also an aggressive metastatic PCa cell line, harvested from a brain 
metastasis. DU145 cells also form osteolytic lesions, again making their effect on osteoblasts 
surprising. LNCaP cells showed a minimal induction of mineralisation in the 7F2 cells, far less 
than seen with PC3 or DU145 cells. LNCaP cells are a PCa cell line harvested from a left 
supraclavicular lymph node metastasis. LNCaP cells are less aggressive than PC3 and DU145 
cells with respect to their abilities to form metastases in mice, but do form mixed lesions, as 
opposed to the typically osteolytic lesions seen in PC3/DU145 metastases (Dai et al., 2016). 
Together, the conditioned media results suggest that these pro-mineralising effects seen are 
specific to aggressive PCa cell lines, and do not correlate with the typical 
osteolytic/osteoblastic presentation seen in mouse bone lesions from the same cells.  
As discussed, PCa cells produce a number of well characterised signalling molecules capable 
of inducing increased osteoblast function, such as BMPs, TGF-β, endothelin 1 (ET1), vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and many more 
(Guise et al., 2006; Logothetis & Lin, 2005). More recently, the role of miRNAs in the 
differentiation of osteoblasts has been investigated, with a number of miRNAs showing a 
propensity to either promote or inhibit this process (Peng et al., 2016). For example, miR-27 
promoted differentiation in hFOB1.19 cells via modulation of the Wnt signalling pathway 
(Wang & Xu, 2010) whereas miR-31 inhibited the differentiation of human mesenchymal 
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stem cells (hMSCs) by repressing special AT-rich sequence-binding protein 2 (SATB2) (Xie et 
al., 2014). 
To test whether the effects seen in our co-culture model may be mediated by miRNAs, we 
tested PC3 cell conditioned media for the presence of 5 miRNAs known to be expressed in 
PCa (Galardi et al., 2007; Hellwinkel et al., 2013; Luu et al., 2017; Song et al., 2017). All 5 
miRNAs showed significantly higher expression in PC3 cell conditioned media compared to 
DMEM +10% FCS, indicating miRNA release from PC3 cells during culture. Interestingly, miR-
16-5p and miR-221-3p showed roughly 20x higher expression in PC3 cell conditioned media 
than miR-423-3p, miR-222-3p and miR-93-5p.  
Differential centrifugation of PC3 cell conditioned media from 2,000xg up to 100,000xg gave 
insight into which structures these miRNAs are associated with, within the conditioned 
media. Differential centrifugation showed no decrease in miRNAs at 2,000xg, which, given 
that miRNAs are known to be associated with apoptotic bodies (Zernecke et al., 2009), and 
that apoptotic bodies are removed at 2,000xg (Szatanek et al., 2015), indicates a potential 
lack of dead cells and apoptotic bodies within the conditioned media. This is unsurprising 
given cells were only cultured for 48 hours and exhibited the morphology of healthy cells. A 
decrease in miRNA was seen at 16,000xg indicating that a fraction of miRNAs within the 
conditioned media are likely associated with cell debris, or with microvesicles, which is well 
documented (Jansen et al., 2014). Centrifugation at 100,000xg resulted in a further decrease 
in miRNA expression. Centrifuging at forces of ≥100,000xg is well known to pellet sEVs 
including exosomes (Li et al., 2017; Webber & Clayton, 2013), as well as other sEVs and 
contaminants, therefore the loss in miRNAs seen at this stage likely reflects sEV associated 
miRNAs. As discussed, centrifugation at 16,000xg removes larger particles such as cell debris 
and microvesicles (Szatanek et al., 2015). Therefore conditioned media centrifuged at 
100,000xg was compared to conditioned media centrifuged at 16,000xg, as the difference 
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between these two reflects the loss of miRNAs from media containing only sEVs and other 
small contaminating molecules/proteins. Overall, the loss of miRNAs between these two 
groups was around 17%, indicating that this fraction of miRNAs are associated with small EVs 
or other co-pelleted contaminants. miRNAs are known to be exported from cells associated 
with argonaute proteins (Arroyo et al., 2011), which likely reflects some of the miRNAs 
remaining after 100,000xg centrifugation, which as a whole, represents the majority of 
secreted miRNAs.  
Combined, the results of the differential centrifugation give an idea of the mechanisms by 
which miRNAs are exported from PC3 cells, as well as indicating the relative amount of 
miRNAs that are exported in each way. Namely, miRNAs appear to be exported in three main 
groups, two smaller populations of miRNAs associated with microvesicles and smaller EVs, 
and a larger population of miRNAs associated with smaller molecules such as argonaute, that 
do not pellet at 100,000xg.  
Overall, the results from this chapter show that PC3s are able to stimulate a pro-osteoblastic 
effect in mineralising 7F2 cells. Analysis of PC3 cell conditioned media confirmed the 
presence of miRNAs, of which a fraction were lost at 100,000xg. Together this suggests that 
miRNAs from PC3 cells may be mediating this pro-osteoblastic effect and that miRNAs 
associated with EVs are a possible mechanism by which this occurs.  
4.5 Summary of Key Points 
7F2 cells co-cultured with PC3 cells showed increased mineralisation in osteogenic media in 
a PC3 cell number dependant manner. This effect was seen at the gene expression level using 
genes characterised in the 7F2 differentiation model. The mineralising effects of various 
prostate cell conditioned media indicates that this process is specific to the more aggressive 
PCa cell lines. PC3 cells export miRNAs during culture which are detectable in conditioned 
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media. Differential centrifugation of this media indicates that a fraction of these miRNAs are 
lost at 100,000xg, a force commonly used to pellet sEVs including exosomes. 
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5 Isolation of SEVs and Analysis of their miRNA 
Content 
5.1 Introduction 
Cell signalling is one of the most studied aspects of cell biology. The majority of this time has 
been focussed on signalling through molecules such as secreted proteins or hormones. 
However, recently, the field of intercellular communication has shifted focus, with signalling 
through extracellular vesicles (EVs) becoming an exponentially growing research field (Lotvall 
et al., 2014). EVs have gained much attention due to the variety of cargo they are able to 
transport, including proteins, DNA, mRNA and a wide variety of non-coding RNAs as well as 
the profound changes they drive in recipient cells.   
As discussed, Chim et al. (2008) discovered the presence of miRNAs in extracellular biological 
fluids, indicating their potential as mediators of cellular communication. It is now known that 
miRNAs are exported from cells in two main ways; either attached to structures such as HDLs 
(Vickers et al., 2011) and argonaute proteins (Arroyo et al., 2011) or released associated with 
(or within) extracellular vesicles (Yu et al., 2016; Zhang et al., 2015). Previous data from Dr 
Alwyn Dart, using Sepharose CL-2B size exclusion chromatography of prostate cancer cell 
conditioned media, showed that miR-27 was released from PC3 cells in two distinct groups 
co-purifying with either smaller species in fractions 19-29 (i) or with larger species in fractions 
7-13 (ii) (figure 5.1A). Previous chromatography work from Welton et al. (2015) on plasma 
samples showed a peak signal of CD9, an exosomal surface marker, in fractions 7-16 and a 
peak signal of albumin from fractions 20-30. The similar trends in peaks between the miRNA 
and the vesicles/free protein levels between these two figures further validates the idea that 
PC3 miRNAs are released associated with (or within) vesicles and other smaller non-vesicular 
molecules. This data is also consistent with findings from the previous chapter, which suggest 
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that PC3 exported miRNAs associate with both larger and smaller EVs, pelleted at 16,000xg 
and 100,000xg respectively, as well as with lighter non-pelleted structures. 
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Figure 5.1: Size Exclusion Chromatography. (A) Data from Dr Alwyn Dart showing 
miRNA detection in fractionated PC3 cell conditioned Media using qPCR. ii: miRNAs 
associated with larger species. i: miRNAs associated with smaller species. (B) 
Fractionated plasma, tested for the presence of the exosomal surface marker CD9 and 
albumin (HSA) by ELISA (Welton et al., 2015). 
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miRNAs can be exported from cells in both lEVs such as microvesicles and sEVS such as 
exosomes. Exosomes are roughly 40-150nm in size. Exosome biogenesis originates within 
endosomes, where inward budding of the endosomal membrane creates a multivesicular 
endosome (MVE) containing many exosomes (Huotari & Helenius, 2011). Subsequent fusion 
of the MVE with the cell membrane releases the exosome cargo into the extracellular space. 
This process involves a complex network of cargo sorting and release proteins such as ALIX 
(Baietti et al., 2012), TSG101 (Nabhan et al., 2012) and ESCRTs (Kowal et al., 2014). This 
biogenesis pathway is significantly more complex than microvesicle biogenesis, which 
although also involving several protein families, is centred around budding from the cell 
surface. The complex biogenesis of exosomes could explain why the internal RNA population 
of sEVs appears more specialised than that of lEVs. For example, sEVs have a higher 
proportion of small RNAs than lEVs and are absent of ribosomal (r)RNA (Crescitelli et al., 
2013; Ji et al., 2014). 
Delivery of functional miRNAs by exosomes was first shown by Pegtel et al. (2010) between 
Epstein-Barr virus (EBV) infected B cells and Monocyte-Derived dendritic cells. Since then a 
number of studies have shown delivery of exosomal miRNAs in various bone related models, 
with varying results. Cui et al. (2016) showed that exosomes from mineralising osteoblasts 
induced osteoblastic differentiation in bone marrow-derived stromal cells, implicating 
exosomal miRNAs in this process. Li et al. (2016a) showed that osteoclast exosomal miR-214-
3p was delivered to osteoblasts, resulting in decreased bone formation. Crucially, this 
process was rescued by treating osteoclasts with antagomiR-214-3p. Finally, Ye et al. (2017) 
showed that MDA PCa 2b cell derived exosomal miR-141-3p induced proliferation and 
mineralisation in osteoblasts. Furthermore, they showed that exosomal miR-141-3p 
promoted osteoblastic metastasis of PCa in vivo, with miR-141-3p inhibition resulting in 
decreased metastases and increased survival.  
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Based on the current literature, including the aforementioned studies, we believe sEV 
miRNAs from PCa cells to play multiple, crucial roles in the development and progression of 
bone metastases. Size exclusion chromatography and differential centrifugation of PCa cell 
conditioned media suggests that miRNAs exported by these cells may be associated with 
sEVs. Therefore, in this chapter we look to analyse the miRNA content of isolated sEVs from 
highly aggressive PCa cell lines using next generation sequencing. As a high quality sEV 
sample will be crucial for our experiments, the isolation and characterisation of sEVs is first 
discussed. Analysing cellular and sEV miRNAs from the same cells allows for direct 
comparison of miRNA concentrations. It has been shown that some miRNAs are selectively 
packaged into sEVs under certain conditions (Goldie et al., 2014; Guduric-Fuchs et al., 2012; 
Ohshima et al., 2010). Thus, analysing cellular and sEV samples in this way and highlighting 
any selective packaging that may take place, will further validate the idea of miRNAs as 
mediators of intercellular communication. 
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5.2 Chapter Aims 
The aims of this chapter are to characterise the sEVs used in this research project and analyse 
their miRNA content, thus providing an insight into how the PCa cells communicate with 
other cells, including cells of the bone microenvironment. Therefore, the specific aims of this 
chapter are: 
 To  assess whether that sEVs secreted and isolated from PCa cells are consistent with 
exosomes  
 To analyse the miRNA content of these sEVs and their associated cells of origin, using 
next generation sequencing 
 To identify whether miRNAs are being selectively or randomly packaged into PCa cell 
sEVs 
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5.3 Results 
Isolation of SEVs from PC3 Conditioned Media 
SEVs were isolated from conditioned media based on their density using ultracentrifugation 
and a 1.210g/mL sucrose cushion, a reliable, commonly utilised method (Lamparski et al., 
2002). Sucrose cushions were then washed in PBS and subsequently pelleted, before being 
resuspended in PBS.  
The presence of exosome surface characterisation proteins, namely the tetraspanins CD9, 
CD63 and CD81, were analysed using an Immuno-phenotyping assay. SEVs were coated onto 
protein binding 96 well strips overnight and analysed for the presence of these common 
exosomal surface markers, measured by time-resolved fluorescence (TRF) (figure 5.2A). The 
expression of CD9, CD63 and CD81 was 1.82x105, 8.6x104 and 3.4x104 TRF respectively, after 
removal of isotype control background which was 2.7x103 TRF for IgG2B (CD9) and 986 TRF 
for IgG1 (CD63 & CD81).  
A western blot was then performed on our isolated samples to probe for an exosome 
enriched protein as well as a protein known to be absent in exosomes. The ESCRT associated 
protein ALG-2-interacting protein X (ALIX), known to be present in exosomes was detected 
in both cell lysate and sEVs from PC3 cells (figure 5.2B). Calnexin, a chaperone protein 
exclusive to the endoplasmic reticulum (ER) was absent in the sEV sample but present in PC3 
cell lysate protein. These results are consistent with those of a high purity exosome 
containing sEV sample (Aqil et al., 2014), in that vesicles appear devoid of cell-derived 
contaminants. 
Nanoparticle tracking analysis (NTA) was used to assess the size of the isolated particles. The 
mean sizes for the PC3 isolations were 116nm, 107nm and 118nm (figure 5.3A, B & C 
respectively), an expected size based on the literature (Webber & Clayton, 2013). 
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Furthermore, no particles >400nm were detected, indicating a lack of any larger 
contaminants such as larger MVs or apoptotic blebs.   
NTA was also used to calculate a particle count for each sample, given in particles/mL. A BCA 
assay, a quantitative colourimetric protein assay, was then used to calculate total protein 
concentrations of the same samples. Combining these two values gives a particles:protein 
(P:P) ratio for the isolated sEV samples. Contaminating protein has been shown to reduce 
P:P values (Webber & Clayton, 2013), as a result, sEV samples with a P:P < 1x1010 are 
considered impure. P:P values were calculated for 3 isolated sEV samples, as a representative 
example of vesicle isolates used in this thesis. For the presented isolated PC3 sEVs, P:P values 
of 2.24x1010, 2.22x1010 and 2.06x1010 were calculated (Table 3.1), indicating a high level of 
purity.  
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Figure 5.2: Characterisation of PC3 sEV protein. (A) Immuno-phenotyping assay of PC3 sEVs 
(1μg/well) for exosome associated tetraspanins; CD9, CD63 and CD81 compared to isotype 
controls. Graph shows average, minus isotype control, for triplicate wells, +SD. (B) Western 
blot of exosome characterisation proteins; ALIX and Calnexin from PC3 whole cell lysate (CL) 
(20µg) and PC3 sEV lysate (EXO) (20µg). 
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Figure 5.3: Size distribution of isolated vesicles. sEVs isolated from PC3 cell conditioned 
media using a sucrose cushion analysed by NanosightTM NTA. Analysis was performed on sEVs 
isolated on 22/11/16 (A), 12/05/17 (B) and 29/01/18 (C).  Histograms show average of 3 
repeats, each taken from a 60 second video, for each isolation, displaying mean and mode 
of particle size.  
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Table 5.1: The purity of sEV isolations from PC3 cells was assessed using the particles:protein 
ratio. Particles:protein ratios were calculated by dividing particle concentration (determined 
by NTA) by the protein concentration (calculated using a BCA assay).  
 
 
 
 
 
 
 
 
 
 
 
 
Isolation Date Particles/ml 
Protein 
Conc 
(µg/ml) 
Particles:Protein 
1 
22/11/16 6.7x1013 2994.42 2.24x1010 
2 
12/05/17 1.20x1014 5412.98 2.22x1010 
3 
29/01/18 3.76x1013 1827.28 2.06x1010 
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To determine the miRNA content of PCa sEVs, next generation small RNA sequencing was 
used. To get a better idea of the general trends of miRNA expression seen in PCa cells and 
sEVs, DU145 samples were also run. Running two aggressive PCa cell lines would allow for a 
comparison in the expression of miRNAs, adding validity to any trends found, and isolating 
any common miRs associated with aggressive PCa. For efficient sequencing of small RNAs, a 
filtration process was utilised to remove as much contaminating larger RNA as possible. RNA 
from PC3 cells and sEVs was used alongside RNA from DU145 cells and sEVs (DU145 sEVs 
were a gift from Prof Aled Clayton). Both sets of sEVs were isolated based on density using 
an ultracentrifugation sucrose cushion method (Webber & Clayton, 2013). RNA was 
extracted from all samples and filtered using a LifeTechnologies mirVana miRNA Isolation Kit. 
This separates the RNA into fractions greater than and less than 200nt using glass fibre filters. 
The larger RNAs captured within the filter, as well as the smaller RNAs found in the eluate 
were run along with unseparated RNA from the same samples on an Agilent Bioanalyser chip.  
For PC3 samples (figure 5.4), the cellular unfractionated RNA sample included a peak for the 
small RNA population as well as large amounts of 18s and 28s rRNA. For the captured cellular 
RNAs, the rRNA still remains but the small peak at 25-30s has been removed. In the eluted 
cellular RNA, the rRNA has been completely removed and only a population of small RNAs 
remains. sEV unfractionated RNA also contained a population of small RNA but only a small 
amount of 18s rRNA. In the captured sEV RNA, the 18s rRNA is still present. The peak 
representing the smaller RNAs is still present, but the amount of RNA has reduced by over 
50%. For the eluted sEV RNA, the small amounts of 18s rRNA has been removed, but the 
small RNA population remains.    
For DU145 samples (figure 5.4), the cellular unfractionated RNA showed a peak for the small 
RNAs and substantial peaks for the 18s and 28s rRNAs. For the captured cellular RNAs, the 
peak at 25-30s has been filtered out but the rRNA still remains. For the eluted cellular RNA, 
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the rRNA has been completely removed and only the population of small RNAs remains. In 
the sEV total RNA, only a small amount of 18s rRNA is present. Small RNAs are present 
represented by a small peak at 25-30s. In the captured sEV RNA, the 18s rRNA is no longer 
present but almost all of the small RNA has also been removed. Finally, in the eluted sEV 
RNA, the small amounts of 18s rRNA have been removed, and the population of small RNAs 
still remains.    
Overall, the results of the bioanalyser traces showed that RNA separation was successful as 
the larger rRNA appeared only in the unseparated and >200nt fractions and was absent in 
the <200nt sample. Small amounts of 18s rRNA were found in the sEV samples which is 
consistent with traces performed by Jenjaroenpun et al. (2013) on breast cancer exosomes. 
However, these were also successfully removed during the filtration process.     
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Figure 5.4: Bioanalyser Traces for PC3 Cell and sEV RNA samples. Traces on the left 
side are from PC3 cells whereas traces on the right side are from purified PC3 sEVs. 
The top row represents unfractionated RNA, the middle row represents RNAs 
captured within the RNA filter and the bottom row represents RNAs that were 
collected from the eluate from the filter.  
 
 
 
 
PC3 Cell RNA PC3 sEV RNA 
Unfractionated 
RNA 
Captured 
Fraction 
Eluted 
Fraction 
 [FU] 
200 
100 
0 
 [FU] 
40 
30 
0 
20 
10 
 [FU] 
80 
40 
0 
120 
 [FU] 
15 
10 
0 
5 
 [FU] 
15 
10 
0 
5 
 [FU] 
12 
8 
0 
4 
   20              30               40              50               60     [s]    20               30                40               50               60     [s] 
   20                30               40               50                60     [s]    20               30               40               50               60     [s] 
   20                30                40               50               60     [s]    20                30               40               50               60     [s] 
                           Chapter V: Isolation of sEVs and Analysis of their miRNA Content 
 
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Bioanalyser Traces for DU145 Cell and sEV RNA samples. Traces on the left side 
are from DU145 cells whereas traces on the right side are from purified DU145 sEVs. The top 
row represents unfractionated RNA, the middle row represents RNAs captured within the 
RNA filter and the bottom row represents RNAs that were collected from the eluate from the 
filter (n=1).  
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Filtered RNA samples of <200nt from PC3 cells and sEVs were sequenced using a 
Thermofisher Ion ProtonTM Sequencer. Small RNAs were reverse transcribed into cDNA and 
amplified by PCR, during which time, individual barcode regions were added to the samples 
to allow post-sequencing sorting. cDNA is then loaded onto Ion SphereTM Particles (ISPs) and 
amplified again using an emulsion PCR. These are then loaded onto the sequencing chip for 
analysis, with a single DNA coated bead filling each microscopic well within the sequencing 
chip, of which there are 150 million approx. Results from the summary of this sequencing 
run are shown in figure 5.6. Loading of the sequencing samples onto the sequencing chip 
was successful, with 83% loading achieved (figure 5.6A), producing a final sequencing library 
of over 67 million reads (figure 5.6B). The sequencing library showed no detectable reads 
above 200bp (figure 5.6C) and although the mean sequence length was 72bp, there was peak 
in reads at around 25-30bp indicative of a large miRNA population.  
Sequencing data was assigned to each sample, and subsequently deconvoluted based on 
their barcodes, before being aligned to human genome 19. Here, sequences were aligned to 
chromosomal locations, and mapped onto a genomic reference for each gene / miR locus 
(RefSeq 2017 and miRBase version 20). An example of this can be seen in figure 5.7, showing 
the alignment of a sequence from the PC3 samples to the human genome using Partek 
Genomics Suite. In this case, based on alignment with chromosome Xp11.3, the reads aligned 
to miR-221.   
A total of 218 miRNAs were detected in at least one sample. miRNA reads were normalised 
using a ‘reads per kilobase of transcript per million mapped reads’ (RPKM) method. 
Normalisation of reads in this way accounts for both gene size (per kilobase), usually more 
used in mRNA sequencing due to variable gene length, as well as read depth (per million 
mapped reads) for each sample. The RPKM values for the 5 highest expressed miRNAs were 
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recorded for each sample (figure 5.8). For reference, alongside these, the miRNA average is 
displayed, showing the average expression across all detected miRNAs for that sample.  
Looking at all 4 samples, 3 miRNAs appear most highly expressed; let-7a-5p, miR-16-5p and 
miR-221-3p (figure 5.8). miR-221-3p was the 4th highest expressed miRNA in PC3 cells and 
the highest expressed miRNA in PC3 sEVs. However, miR-221-3p was not in the 5 highest 
expressed miRNAs for either the DU145 cellular or sEV samples and was actually expressed 
at levels below the miRNA average. miR-16-5p was the highest expressed miRNA in DU145 
sEVs and was the second highest expressed miRNA in the remaining 3  samples. Let-7a-5p 
was the highest expressed miRNA in both cell samples and also featured in the top 3 highest 
expressed miRNA in both sEV samples.     
Sequencing results were then validated by qPCR for PC3 and DU145 cellular samples. The 
levels of two highly expressed miRNAs from cellular sequencing samples; miR-221-3p and 
miR-16-5p were compared to three miRNAs that showed much lower expression; miR-423-
3p, miR-423-5p and miR-93-5p. The results of these qPCRs are shown in figure 5.9B and 5.9D 
for PC3 and DU145 cells respectively and compared to sequencing results outlined in figures 
5.9A and 5.9C. qPCR confirmed that in PC3 cells, miR-221-3p and miR-16-5p are expressed 
at much higher levels than other miRNAs (p<0.001 for all). However, although sequencing 
showed miR-16-5p to be expressed at a higher level than miR-221-3p, qPCR showed the 
opposite pattern, with miR-221-3p showing higher expression than miR-16-5p (p<0.001). In 
DU145 cells, qPCR confirmed that miR-16-5p was highly expressed compared to other 
miRNAs (p<0.001 for all). However, miR-221-3p, which showed low expression in DU145 
sequencing, showed higher expression than other miRNAs in qPCR (p<0.001 compared to 
miR-423-3p and miR-423-5p) although miR-16-5p expression remained highest (p<0.001 
compared to miR-221-3p).  
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Together, although there are minor differences between qPCR and sequencing, expression 
patterns largely show the same trends. miR-16-5p and miR-221 were confirmed as highly 
expressed in PC3 cells and miR-16-5p was confirmed as highly expressed in DU145 cells.  
sEV RNA was limited, therefore qPCR validation on these samples could not be performed. 
However, miRNA qPCR of PC3 cell conditioned media showed that miR-221-3p and miR-16-
5p were highly expressed compared to miR-222-3p (figure 5.10B). This pattern matches the 
expression of these miRNAs in sEVs from sequencing (figure 5.10A). Although direct 
comparison of miRNAs in conditioned media and sEVs should not be made, the similarities 
in expression patterns between the two goes some way to validate the sEV sequencing 
results.  
To test whether the high expression of miRNAs such a miR-16-5p and miR-221-3p seen in 
sequencing and qPCR was specific to PCa cells, we analysed the expression of a range of 
miRNAs in both cell lines and the non-cancerous PZ cell line. qPCR of PZ cells revealed that 
miR-16-5p and miR-221-3p also show higher expression in these cells compared to other 
miRNAs. However, miR-16-5p showed significantly higher expression in PC3 and DU145 cells 
compared to PZ cells (p=0.004 & p=0.001 respectively). miR-221-3p showed significantly 
higher expression in PC3 cells compared to PZ cells (p<0.001), but showed no difference in 
expression between DU145 and PZ cells. For miR-93-5p, expression levels between PC3 and 
PZ cells showed no difference. For miR-423-3p and miR-423-5p, expression in DU145 and 
PC3 cells was higher than PZ cells for all three (p<0.01 for all).  
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A B 
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Figure 5.6: Overview of Sequencing Run. (A) Heat map showing chip loading efficiency, of 
the Ion P1 chip. (B) Bar graph showing % usable reads from the sample once polyclonal or 
untemplated beads were removed. (C) Read length of sequences including mean, median 
and mode for all samples combined.  
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Figure 5.7 Mapping of miR-221-3p and miR-221-5p sequences from PC3 samples to human genome 19, generated using Partek Genomics Suite.
Sequences from 
PC3 cell and sEV 
samples 
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Figure 5.8 miRNA Expression in PC3 and DU145 Cell and sEV Samples from miR-Seq. The top 5 highest 
expressed miRNAs compared to the average miRNA level in (A) PC3 Cells, (B) PC3 sEVs, (C) DU145 
Cells, (D) DU145 sEVs (n=1). 
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Figure 5.9. qPCR Validation of miRNA Sequencing Results in PC3 and DU145 Cells. High and low expression miRNAs from sequencing 
data in PC3 and DU145 cells (A & C respectively) were compared with qPCR of the same miRNAs in the same cell lines (B & D). Graphs B 
& D show average +SEM, n=3. Statistical significance assessed using one-way ANOVA with a Holm-Sidak multiple comparisons test, 
**p<0.01, ***p<0.001.  
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A 
B 
Figure 5.10. qPCR Validation of miRNA Sequencing Results in PC3 sEVs. 
High and low expression miRNAs from sequencing data in PC3 sEVs (A) were 
compared with qPCR of the same miRNAs in PC3 cell conditioned media (B). 
Graph B shows average +SEM, n=3.  
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 Figure 5.11: Comparison of miRNA Expression in PC3, DU145 and PZ-HPV-7 Cells. miRNAs with high and low 
expression in PCa cells selected from miRNA sequencing, analysed by qPCR in PC3, DU145 and PZ-HPV-7 cells. Graphs 
show average + SEM, n=3 (n=2 for PZ). Statistical significance assessed by one-way ANOVA for each miRNA using Holm 
Sidak multiple comparisons test, *p<0.05, **p<0.01, ***p<0.001.   
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The ratio of sEV:cellular miRNAs was calculated to determine whether miRNAs were being selectively 
packaged, excluded or randomly incorporated into sEVs. This was calculated by dividing the sEV RPKM 
value for each miRNA by its cellular RPKM value. For PC3 cells (figure 5.12) a total of 39 miRNAs were 
detected in both the cellular and sEV samples. A total of 14 miRNAs were found at higher 
concentrations in sEVs than in the cell and 19 were found at higher concentrations in the cell 
compared to the sEVs. Six miRNAs showed similar concentrations in both PC3 samples. miR-182-5p 
had the highest sEV to cellular ratio of all miRNAs at 1.96, indicating its selective inclusion into sEVs 
during biogenesis. miR-221-3p had a similar expression in PC3 cells and sEVs (ratio= 0.91). miR-16-5p 
and Let-7a-5p both had less than half the expression in PC3 sEVs as in cells (ratios= 0.28 & 0.22 
respectively).  
For DU145 cells (figure 5.13) 47 miRNAs in total were found in both cellular and sEV samples. Of these, 
46 miRNAs were found at higher concentrations in cells compared to sEVs, with 1 miRNA, miR-181b-
5p, showing marginally higher expression in sEVs than cells (ratio= 1.17). Although 98% of miRNAs 
were found at lower levels in sEVs than cells, there was a large degree of variability within these 
negative ratios. For example, miR-3184-5p had an sEV:cellular ratio of 0.58 whereas let-7b-5p had a 
ratio of 0.03, showing that exclusion from sEVs occurred at different extents for each miRNA, 
indicating a selective mechanism.  
To partner the ratio analysis, an XY plot was constructed showing the cellular and sEV RPKM values 
for each miRNA found in both cells and sEVs (figure 6.14). A spearman rank order correlation test was 
performed to assess the link between cellular and sEV miRNA concentrations. Both PC3 and Du145 
cells produced a correlation p value of <0.05 indicating a positive correlation. Combined with ratio 
analysis, these results suggest that miRNAs are packaged into sEVs largely based on cellular 
concentrations, but that some miRNAs may be selectively incorporated or excluded. 
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Figure 5.12: The ratio of sEV:Cellular miRNAs in PC3 samples. Ratio was calculated by dividing the RPKM for the sEV samples by the RPKM for the cellular 
samples for each miRNA (n=1).  
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Figure 5.13: The ratio of sEV:Cellular miRNAs in DU145 samples. Ratio was calculated by dividing the RPKM for the sEV samples by the RPKM for the cellular 
samples for each miRNA (n=1).  
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Figure 5.14: XY plot of cellular and sEV RPKM values. Cellular RPKM values 
for each miRNA were plotted against their sEV RPKM values in PC3 cells 
(A) and DU145 cells (B). Correlation assessed using Spearman Rank Order 
Correlation. Results are displayed as correlation coefficient and P value. 
(n=1).  
Correlation Coefficient: 0.395 
p=0.013 
Correlation Coefficient: 0.504 
p=0.0003 
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Intravesicular miRNAs are naturally more protected from circulating RNases, as they are 
surrounded by a membrane envelope. These miRNAs would logically have the highest chance 
of survival, outside the cell e.g. in circulation, and therefore the highest chance of uptake in 
recipient cells. Thus, these miRNAs would have the greatest signalling potential. Vesicular 
protection of RNA from RNase activity has been shown previously (Cheng et al., 2014). 
However, before the RNAs tested in this study can be considered as mediators of intercellular 
communication, their protection from RNase activity must also be demonstrated.  An RNase 
digest of the PC3 sEVs was therefore performed (figure 5.15A). sEVs were incubated with 
proteinase K, to remove surface proteins, and subsequently with RNase. The RNA content of 
RNase digested and control (untreated) sEVs was analysed using a bioanalyser. RNase digest 
resulted in a 14% (approx.) reduction in RNA concentration indicating that around 86% of 
the RNAs are protected from RNAse activity. Furthermore, by pre-treating with proteinase 
K, we show that the remaining miRNAs are not attached to surface proteins, another 
mechanism that could offer protection from RNases. It should be noted that the lateral shift 
in peaks is likely a result of sub-optimal ladder recognition by the bioanalyser, rather than a 
reduction in the size of the individual RNAs. To show that the RNase used was able to 
efficiently degrade RNA, sEV RNA was treated with RNase following RNA extraction and 
visualised using agarose gel electrophoresis (figure 5.15B). Treatment of extracted RNA with 
RNase resulted in complete RNA degradation, exemplified by a complete removal of visible 
RNA seen in the untreated sample. 
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Figure 5.15: Bioanalyser trace of RNase treated PC3 sEVs. (A) sEVs isolated from PC3 cell conditioned media were treated with proteinase k and RNase to 
digest extravesicular RNA. Remaining RNA was assessed using a bioanalyser (representative image, n=2). (B) sEV RNA was extracted and treated with RNase 
to validate RNase activity.  
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5.4 Discussion 
In the previous chapter, we showed that a miRNAs are released by PC3 cells into media. 
Furthermore, using differential centrifugation we showed that a population of these miRNAs 
are lost at 100,000xg indicative of miRNAs associated with small EVs such as exosomes. 
Interestingly, both differential centrifugation from the previous chapter and size exclusion 
chromatography from Dr Alwyn Dart suggest that the majority of miRNAs are non-vesicle 
associated. However, as discussed, the multiple sorting and uptake mechanisms of sEVs and 
their cargo make them interesting candidates for the delivery of miRNAs to near and distant 
target sites. Therefore, we focussed on the sEV population of miRNAs throughout this study.  
In order to analyse the miRNA content of sEVs, a method of reliably isolating pure sEV 
samples must be utilised. Therefore, sEVs were isolated from PC3 cell conditioned media 
using a two-step ultracentrifugation method, involving an initial sucrose cushion flotation 
step followed by a pelleting step. The sucrose cushion, comprised of 30% sucrose/D2O is 
known to have a density of 1.210 g/mL and is able to diffuse with H2O at the interphase 
between the cushion and conditioned media. This diffusion creates a mini density gradient 
within the bottom of the centrifuge tubes of around 1.100-1.180g/mL, ideal for capturing 
sEVs which are known to have a density of around 1.120-1.160g/mL (Escola et al., 1998). 
Recent data suggests that isolating sEVs from samples based on density alone may also result 
in the isolation of certain HDL species (Karimi et al., 2018). However, separation based on 
size is also insufficient to remove these HDL species. This highlights the difficulty of sEV 
isolation, especially when high yield is required. Cells used for the production of conditioned 
media were cultured in bioreactor flasks, to facilitate the required scale of material required. 
Collecting sEVs this way is proven to give both high yield and purity, especially in combination 
with the sucrose cushion isolation method (Webber & Clayton, 2013).  
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Several techniques are used to measure sEV purity, including analysing protein content, size 
and particle count. Surface proteins can be utilised for sEV characterisation. For example, the 
tetraspanins CD9, CD63 and CD81 are enriched on the surface of exosomes (Andreu & Yanez-
Mo, 2014). An Immuno-phenotyping assay of our purified samples showed high levels of 
these three tetraspanins compared to isotype controls, indicating the presence of exosomes 
within our sEV sample.  
Western blot can also be used to characterise sEVs as well as assess sample purity, based on 
the expression of two proteins; ALIX, a protein responsible for exosomal cargo sorting 
(Willms et al., 2016) and therefore abundant in exosomes, and Calnexin, a chaperone protein 
and marker of the ER, commonly used as a negative control and marker of exosome purity 
due to its absence in exosomes (Lasser et al., 2012). Western blot confirmed the presence of 
ALIX in our sEV sample whilst also showing a lack of any contaminating ER specific calnexin, 
which was present in the PC3 cell lysate.  
NTA revealed the particles within our sample to be a population of vesicles of around 60-
150nm in size, consistent with the 40-100nm size of sEVs commonly documented in the 
literature. NTA measures vesicles in a fluid phase, representing a more natural state, and 
therefore giving more reliable measurement of vesicle size compared to conventional fixed 
or dehydration measurements. However, due to the poor refractive index of biological 
particles, the lower limit of detection for NTA is around 40nm (Shang & Gao, 2014). Thus, the 
smaller EVs within our population are likely underrepresented, which may explain the slightly 
larger population size compared to the literature. Measuring sEVs by cryo-electron 
microscopy (cryo-EM) can result in a smaller average particle size compared to NTA (Skliar et 
al., 2018), reflecting the ability to detect smaller particles. However, using NTA is often 
favoured due to its high throughput and lower cost per sample. The lack of any detectable 
particles >400nm indicated an absence of larger contaminating extracellular particles such 
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as large microvesicles or apoptotic bodies (Crescitelli et al., 2013). As discussed, NTA also 
calculates particle counts for each sample, which can be combined with the results of a BCA 
quantitative protein assay to give a P:P ratio for each sample. are another way of measuring 
sEV sample purity. Webber and Clayton (2013) showed that P:P ratios directly correlate to 
sample purity, stating that impure sEVs had a P:P <1x1010. P:P values of >2x1010 were 
calculated for all sEVs samples further indicating their high level of purity.  
To determine the RNA content of sEVs, bioanalyser traces were performed on PC3 and 
DU145 cellular and sEV samples. Prior to analysis, RNAs were filtered into fractions of less 
than or greater than 200nt. The <200nt fraction would be used for sequencing as this would 
contain miRs but would minimise the presence of other larger RNAs such as mRNA and rRNA. 
By removing the larger RNA species that were not of interest, we could increase the 
efficiency of our sequencing run and ensure that wells within the sequencing chip contained 
RNA populations more likely to include miRs. Figure 5.4 shows that for the PC3 cellular and 
sEV samples, most large RNA species were removed during the filtration process. The same 
pattern is also shown for the DU145 samples in figure 5.5, meaning all 4 samples were largely 
free of contaminating RNAs and would have a higher efficiency when sequenced.  
PC3 and DU145, cells and sEVs were sequenced using an Ion ProtonTM sequencer. A summary 
of the sequencing run confirmed efficient loading of samples onto the sequencing chip with 
a final library of over 67 million reads. Within this, a large population of RNAs <50bp was 
sequenced. The filtering out of rRNA and other larger species resulted in an efficient miR 
sequencing run with read depths of over 200. 
Overall 218 different miRs were detected across the four samples. For each sample, the 5 
highest expressed miRs were recorded. miR-16-5p was in the 2 highest expressed miRs in all 
4 samples. As both cell lines are aggressive, metastatic PCa cell lines, miR-16-5p 
overexpression may correlate with PCa severity and contribute towards the aggressive cell 
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phenotype. Furthermore, sEVs are known to pre-condition metastatic sites (Alderton, 2012; 
Peinado et al., 2012), and as both cell lines have good metastatic potential it is possible that 
miR-16-5p enriched sEVs may also play a part in PCa metastasis. However, although some 
papers have shown an up-regulation of miR-16 in PCa (Lodes et al., 2009), in most cases, miR-
16-5p is actually down regulated in PCa samples compared to controls (Schaefer et al., 2010). 
Furthermore, although miR-16-5p was found at high levels in sEVs, ratio analysis suggests 
that it may be selectively excluded to some extent, evidenced by its higher expression in cells 
than in sEVs. However, it remains that miR-16-5p is very highly expressed in PCa sEVs so will 
likely play a part in any communication between these cells and their environment.    
miR-221-3p was found at high levels in both PC3 samples, consistent with data from Galardi 
et al. (2007) who also showed that miR-221-3p was overexpressed in PC3 cells. miR-221-3p 
targets p27KIP1, a cyclin-dependent kinase inhibitor (le Sage et al., 2007) which promotes 
cancer cell proliferation and is correlated with tumour grading (Guo et al., 1997). The high 
expression of miR-221-3p may explain, in part, the aggressiveness of the PC3 cell line. miR-
221-3p was not in the top 5 highest expressed miRNAs in DU145 cells, although another 
miRNAs, miR-26a-5p, was. miR-26a-5p targets Phosphatase and Tensin Homolog (PTEN) and 
downregulation of PTEN can lead to increased tumorigenesis through increased CXCR4 
signalling (Chetram et al., 2011). 
Hessvik et al. (2012) have previously sequenced PC3 exosomal miRNAs, detailing the 20 
highest expressed miRNAs. Surprisingly, the 5 miRNAs most highly expressed in our PC3 sEVs 
were not present in the 20 highest expressed sEV miRNAs presented by Hessvik et al. (2012). 
This indicates that packaging of sEV contents may vary depending on the specific handling of 
the cell lines, for example the cells used in this study were cultured for 24 hours in serum 
free medium, whereas our own cells were cultured for 1 week in sEV depleted FCS. miR-16 
was however in the 20 highest expressed miRNAs in PC3 cells in this study. However, as miR-
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16 was the 17th highest expressed miRNA in this study, this still reflects a sizable degree of 
variation between the two sequencing results.     
miRNA sequencing results were validated in PC3 and DU145 cells using qPCR. qPCR 
confirmed that miR-16-5p and mir-221-3p were highly expressed in PC3 cells and that miR-
16-5p was highly expressed in DU145 cells compared to other miRNAs. Although there were 
minor differences in the exact expression patterns of miRNAs between sequencing and qPCR, 
namely the apparent underrepresentation of miR-221-3p by sequencing, these results 
indicate that sequencing was effective in its ability to differentiate between high and low 
expression miRNAs in cellular samples.  
As discussed, sEV RNA was limited, therefore direct validation of sEV miRNA expression by 
qPCR was not possible. However, qPCR of PC3 cell conditioned media showed the same 
pattern of miRNA expression as PC3 sEVs. Analysing conditioned media for miRNAs is not 
ideal for accurately estimating sEV miRNA levels, due to the fact that, as shown, sEV miRNAs 
make up only a small portion of extracellular miRNAs. However, miRNAs tested in both 
sequencing and conditioned media qPCR showed the same pattern of expression, with miR-
16-5p and miR-221-3p showing high expression in both. This indicates that these miRNAs are 
exported to a greater extent than other miRNAs, which partially validates the fact that these 
miRNAs were seen at high levels in PC3 sEVs.     
The levels of highly expressed miRNAs such as miR-16-5p and miR-221-3p were compared in 
aggressive PCa PC3 and DU145 cells and the non-cancerous PZ cell line. Comparing miRNAs 
in this way would allow us to determine whether the high expression of these miRNAs are 
exclusive to the aggressive PCa cells. Analysis of PZ miRNA qPCR revealed that miR-16-5p and 
miR-221-3p showed higher expression than other miRNAs such as miR-93-5p and miR-423-
3p/5p, similar to the expression patterns seen in PC3 and DU145 cells. This suggests that 
higher expression of these two miRNAs may not be specific to PCa cells. However, although 
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these miRNAs show higher expression in all cell types compared to other miRNAs, the 
expression of miR-16-5p and miR-221-3p is significantly higher in PCa cells than in PZ cells 
whilst other miRNAs show generally more similar expression patterns to PZ cells. This 
suggests that although high expression of miR-16-5p and miR-221-3p is common at least 
among all the tested prostate cell samples, the expression of these miRNAs is over 
exaggerated in PCa cells and may reflect or contribute to their aggressive phenotype. As 
discussed, the high expression of miR-221-3p in PC3 cells has previously been shown (Galardi 
et al., 2007) and may contribute to their cancerous properties. Thus, high expression of miR-
221-3p in PC3 cells compared to PZ cells is expected. However, as also discussed, miR-16-5p 
shows mixed expression in PCa samples, but is widely regarded as a tumour suppressor, 
down regulated in PCa (Lodes et al., 2009; Schaefer et al., 2010). Thus by confirming high PCa 
cell miR-16-5p expression by qPCR and showing high expression compared to non-cancerous 
prostate cells, we validate miR-16-5p as playing a potential role in the aggressive cancerous 
phenotype seen in PC3 cells.  
Figure 5.12 shows the sEV:cellular ratios of each miRNA found in both PC3 samples. The mix 
of both positive and negative ratios within this data indicates that a selective packaging 
mechanism may be at play for sorting PC3 cell sEV miRNAs. For DU145 samples (figure 5.13), 
all miRNAs, with the exception of one, miR-181b-5p, showed negative sEV to cellular ratios. 
However, within this, certain miRNAs such as let-7b-5p had drastically lower ratios than 
others, such as miR-3184-5p. Correlation analysis between cellular and sEV miRNA 
concentrations suggests that the incorporation of miRNAs into sEVs may be a largely passive 
process based on cellular concentrations. Together this indicates that the incorporation of 
miRNAs into sEVs is likely a largely passive process, with some miRNAs being potentially 
included/excluded within this. However, the lack of repeats means that conclusions cannot 
confidently be drawn at this stage.  
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From figure 5.7, it can be seen that the cellular expression of miR-221 3p and 5p was 
disproportionate, in favour of miR-221-3p expression. However, this ratio appears much 
more exaggerated in the sEV sample, with the 5p strand showing considerably lower 
expression than the 3p strand. This, therefore, suggests a mechanism of vesicular miRNA 
strand sorting. As opposing strands have different sequences and therefore different mRNA 
targets, this potentially acts as a mechanism of packaging miRNAs more advantageous in PCa 
signalling. This strand selectivity can also be seen in figure 5.12, where let-7d-3p appeared 
to be selectively packaged into sEVs whereas let-7d-5p was selectively excluded. Strand 
selectivity has been shown previously, for example in human colon carcinoma LIM1863 (Ji et 
al., 2014) and cardiac fibroblast cells (Bang et al., 2014). However, the reason for this 
selectivity, and the mechanism by which it occurs, is still poorly understood. 
It should also be noted that although expression levels in sEVs vs cells for some miRNAs was 
drastically different, suggesting a selective packaging mechanism, there are clear links 
between the levels of miRNAs in both samples. For example, miR-16-5p, miR-221, has-let-
7a-5p and several others all showed high expression in both the PCa cells and sEVs. This 
suggests that although a selective packaging mechanism may be at play, the process of 
miRNA loading into sEVs may also be a partially passive process, influenced by the 
concentrations of miRNAs in the cytoplasm.  
Two cell lines were sequenced in this chapter to assess the commonality of miRNA 
expression in different PCa cell types. PC3 and DU145 cells are both aggressive PCa cell lines 
harvested from bone and brain metastatic sites respectively. Ratio analysis from both cell 
lines indicated that PC3 cells appear to have the more active selective packaging mechanism 
for sEV miRNAs, demonstrating that these may be more active signalling molecules. This was 
also demonstrated by a stronger correlation p value in DU145 cells than PC3 cells. 
Furthermore, in the wider context of the bone models used in this study, using a PCa cell line 
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harvested from a bone metastatic site will offer a more accurate representation of the 
communication between PCa cells and bone cells within the skeletal microenvironment. 
Therefore, subsequent sEV work will focus on PC3 sEVs, looking at the effects of transported 
miRNAs within this population.      
Finally, if sEV miRNAs are to act as mediators of intercellular communication, they must be 
protected from RNase activity, which is prolific within the circulation (Koberle et al., 2013; 
Tsui et al., 2002). Therefore, after showing that miRNAs are present within our sEVs, we 
looked at the ability of sEVs to protect RNA from RNase degradation. RNase treated sEVs 
contained over 85% of the small RNA of untreated sEVs. This indicates that the vast majority 
of small RNA is intravesicular and therefore protected from external factors. This ability of 
sEVs to protect RNA is well documented (Cheng et al., 2014; Koga et al., 2011), indicating 
that sEVs are suitable carriers for both local and distant miRNA based signalling. 
To conclude, in this chapter we looked to analyse the miRNA content of PCa sEVs. 
Characterisation of vesicles indicated a size and protein content consistent with those 
documented for sEVs. Sequencing of the miRNAs within these sEVs revealed a number of 
highly expressed miRNAs, which was later confirmed by qPCR. qPCR also revealed that these 
highly expressed miRNAs show differential expression in cancerous and non-cancerous 
prostate cell lines. Ratio analysis of sEV and cellular miRNAs revealed that miRNAs are 
differentially expressed in cells and sEVs, whereas correlation analysis suggests a link 
between cellular and sEV concentrations, suggesting both mechanisms may be at play. 
Furthermore, sEVs were able to protect this miRNA cargo from the effects of RNase 
treatment, thus suggesting that PCa cells may be using sEVs as mechanism of protecting 
miRNAs for extracellular transport. Regardless, the high expression of particular miRNAs in 
both cells and sEVs, indicates a possible functional role for these sEV miRNAs, which may 
include their use in extracellular communication.  
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5.5 Summary of Key Points 
miRs secreted from PCa cells were present as both non-vesicle associated (bound to proteins, 
lipoproteins or as free molecules) and associated with EVs. Vesicles isolated from PCa cell 
conditioned media had an average size of just over 100nm and were abundant in the 
tetraspanins CD9, CD63 and CD81, key exosomal surface markers. Expression of the ESCRT 
protein Alix and absence of the cellular protein Calnexin confirmed effective isolation of 
vesicles from cellular contaminants. Together, this characterisation indicates the isolated 
vesicles are sEVs consistent with exosomes. Sequencing of PCa cellular and sEV miRNAs 
revealed a number of highly expressed miRNAs including miR-221-3p, miR-16-5p and Let-7a-
5p. qPCR confirmed the high expression of miR-16-5p in DU145 cells and miR-16-5p and miR-
221-3p in PC3 cells. qPCR also showed that these miRNAs show much higher expression in 
PCa cells compared to non-cancerous prostate cell lines. Ratio and correlation analysis 
revealed miRNAs are likely sorted into sEVs using a combination of selective packaging 
mechanisms and unselective incorporation based on cytoplasmic concentrations. Finally, 
RNase treatment showed that miRNAs are protected from external factors by sEVs.
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6 The Effects of PCa sEVs on Osteoblast Differentiation 
 Introduction 
Previously, we have shown an ability for PCa cells to communicate with osteoblasts via 
secreted factors, with a pro-osteoblastic outcome. Crucial advances in the field of sEV 
research, including the availability of easy to use isolation kits such as ExoQuick® (Tang et al., 
2017), as well as advances in characterisation of EVs (Lotvall et al., 2014; Szatanek et al., 
2017), have allowed this research field to expand exponentially. Treatment of cells with sEVs 
in isolation has displayed their ability to induce functional changes in recipient cells, in the 
absence of any additional cellular signalling (Zhao et al., 2018). As discussed, EVs are known 
to play a role in a multitude of biological processes and are implicated heavily in the 
progression of many cancers (Xu et al., 2018b). Furthermore, sEVs have shown the ability to 
alter the function of cells within the bone microenvironment, including osteoblasts, a key 
factor in the development of debilitating osteoblastic lesions (Cui et al., 2015; Li et al., 2016c; 
Ye et al., 2017).  
In this chapter, we look to analyse the effect of PC3 cell sEVs in isolation, on the 
differentiation of 7F2 cells, and determine whether sEVs contribute to the pro-osteoblastic 
communication we have shown previously. Although the effects of sEV communication on 
osteoblast function have previously been analysed, expanding the range of both sEV 
producing cells and recipient bone cells used in this field will help build a more representative 
picture as to the effects of local sEV communication in the development and progression of 
metastatic bone lesions. By sequencing sEV treated 7F2s, we hope to uncover gene targets 
which are potentially modulated by miRNAs carried by PCa sEVs, thus uncovering novel 
pathways governed by this communication.    
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 Chapter Aims 
The aims of this chapter are to analyse if PC3 cell sEVs can alter 7F2 cell differentiation and 
function and explore if sEV miRNAs may be involved in these processes. To achieve this, the 
specific aims of this chapter are: 
 To examine if isolated PC3 cell sEVs can alter 7F2 differentiation using the osteoblast 
differentiation model described previously. 
 To use Next Generation Sequencing to identify changes in gene targets in recipient 7F2 
cells. 
 To select a miRNA (or miRNAs) of interest from this data and investigate its involvement 
in pro-osteoblastic sEV communication between PC3 and 7F2 cells, selecting specific 
mRNA targets.  
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 Results 
Mineralisation of 7F2 Cells Treated with PC3 Cell sEVs 
To determine whether sEVs can induce osteoblast mineralisation, 7F2 cells were incubated 
with 50 µg/mL, 100 µg/mL and 200 µg/mL (µg of sEV protein based on protein concentration 
assay) of isolated PC3 sEVs in either regular or osteogenic media for 10 days, and stained 
with ARS. In regular media, sEVs (up to 200 µg/mL) had no effect on 7F2 mineralisation 
(figure 6.1A). In osteogenic media, 50 µg/mL and 100 µg/mL of sEVs also had no effect on 
7F2 mineralisation, whereas 200 µg/mL of sEVs was able to induce a 90% increase in 
mineralisation (p=0.002) (figure 6.1B).  
To assess the ability of sEVs to induce expression of genes involved in 7F2 differentiation, the 
expression of the 4 osteogenic genes, discussed previously, were measured in 7F2 cells 
treated with 200µg/mL of sEVs (or equivalent volume of PBS vehicle) in either regular or 
osteogenic media (figure 6.2). As expected, sEVs were able to induce changes in all 4 genes 
in osteogenic media compared to vehicle controls, mirroring the effects of the sEVs on the 
mineralisation of these cells. DLX5, MMP3 and ACVR1 all differed significantly in these cells 
compared to vehicle controls (p<0.05 for all) although the increase in COL1A1 expression 
failed to reach significance (p=0.343). However, sEVs also demonstrated an ability to 
significantly alter the expression of these genes in regular media (p<0.05 for all), especially 
MMP3, which showed a ~200x increase in expression. This result is surprising given that sEVs 
in regular media failed to induce mineralisation, and that co-culture with PCa cells in regular 
media in chapter IV failed to induce any changes in these genes.  
The ability of sEVs to induce these gene changes, in the absence of any additional osteogenic 
supplements, lead us to re-think whether sEVs would be able to stimulate mineralisation in 
7F2 cells in non-osteogenic media under certain conditions. In osteogenic media, vitamin D, 
and vitamin K induce osteoblast differentiation, and ascorbic acid induces collagen synthesis, 
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whereas β-glycerophosphate provides the crucial phosphate source required for HA 
formation. Therefore, 7F2 cells were treated with β-glycerophosphate  (β-GP) alone with or 
without sEVs (figure 6.3). This would reveal whether sEVs are able to induce mineralisation 
in the absence of differentiation supplements. In these cells, sEVs were able to stimulate a 
22% increase in mineralisation (p<0.001).  
 
.
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Figure 6.1: Mineralisation of sEV Treated 7F2 Cells. Mineralisation of 7F2 cells 
cultured with 0-200µg/mL of sEVs for 10 days in either regular media (A) or 
osteogenic media (B) assessed by ARS/Crystal Violet staining. (Graphs show 
average +SEM, n=3.) Statistical significance assessed using one-way ANOVA and 
Holm-Sidak multiple comparisons test, **p<0.01.  
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Figure 6.2: qPCR of osteoblast differentiation genes in 7F2 cells treated with sEVs in either regular or osteogenic MEM. (A) DLX5 expression, (B) 
COL1A1 expression, (C) ACVR1 expression, (D) MMP3 expression in 7F2 cells treated with sEVs or vehicle (PBS) in regular or osteogenic media. (Graphs 
show average fold change compared to vehicle controls +SEM, n=4) Statistical significance assessed by unpaired ttest between sEV and vehicle fold 
change control, *p<0.05. 
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Figure 6.3: Mineralisation of sEV Treated 7F2 Cells with β-glycerophosphate. 
Mineralisation of 7F2 cells cultured with 200µg/mL of sEVs or vehicle (PBS) for 10 
days in media supplemented with β-glycerophosphate only. (Graph shows average 
+SEM, n=3) Statistical significance assessed using unpaired ttest, ***p<0.001.  
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Sequencing of sEV Treated 7F2 Cells 
Because the 7F2 cells seemed very responsive to sEV treatment in terms of their transcript 
changes, we decided to examine broadly the impact of sEV treatment on the recipient cell 
transcriptome. To test this, 7F2 cells treated with either osteogenic media + sEVs (OMEV) or 
osteogenic media only (OM) and were analysed by Next Generation Sequencing. RNA was 
extracted from 2 biological replicates of OM and OMEV treated 7F2s (4 samples total) and 
polyT beads were used to isolate the polyA mRNA fraction from this. The polyA mRNA library 
was then fragmented using RNase II, in order to achieve a library of smaller RNA fragments 
(<200 bases). The remaining stages of sequencing reflect those used in the previous chapter 
on the small RNA library; fragmented RNA strands were reverse transcribed to cDNA and 
unique oligo barcodes were added, cDNA was loaded onto ISPs and clonally amplified by PCR 
and finally cDNA coated beads were loaded onto a P1 chip for sequencing on an Ion Proton 
DNA Sequencer.  Results from the summary of this sequencing run are shown in figure 6.4. 
88% loading of ISPs onto the P1 chip was achieved (figure 6.4A). This resulted in a final usable 
library of over 90 million reads (figure 6.4B) with a mean and median read lengths of 125bp 
and 129bp respectively (figure 6.4C). 
Reads were assigned to samples based on barcodes as previously stated and aligned to 
chromosomal locations within mouse (Mus musculus) genome 10 (mm10) (RefSeq 2017). 
Reads were subsequently normalised using the RPKM method (Mortazavi et al., 2008) and a 
one way ANOVA was used to determine statistically differentially expressed genes between 
OM and OMEV treated 7F2 samples. Partek (Genomics Suite 6) software was used to 
generate a heatmap of our samples, with hierarchical clustering together of genes in order 
of change (figure 6.5A). The clustering together of replicates of OMEV and OM samples 
indicated good reproducibility of the gene changes seen between treatment groups. The 
total number of genes that were up or down regulated is shown in figure 6.5B and the 
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number of significantly up or down regulated genes (p<0.05) is shown in figure 6.5C. All 
available data indicates that a much higher proportion of genes were downregulated in the 
OMEV treated 7F2s compared to OM treated 7F2s than upregulated.   
Ingenuity® Pathway Analysis (IPA) was used to determine the biological pathways most likely 
to be affected by sEV treatment in 7F2 cells. IPA utilises millions of manually assessed peer-
reviewed findings, combined into a multitude of biological signalling networks, against which 
our own gene expression changes were mapped. Thus, a list of pathways most likely affected 
by the gene changes seen between our untreated and treated sequencing samples was 
generated. A bone cell specific analysis of the top 5 pathways most probably affected by sEV 
treatment are listed in table 6.1. Pathways including “skeletal development” or “skeletal 
disorders” featured in 4 of the top 5 most probably affected pathways, indicating that sEV 
treatment likely affects key osteogenic pathways and may reflect the dysregulation seen in 
osteoblasts neighbouring PCa bone metastases.  
In a similar way, IPA was also used to predict upstream regulators, likely responsible for 
regulating the gene changes seen between untreated and treated cells. A Fisher’s Exact Test 
is then used to generate an overlap p-value, a measure of the significance in the overlap 
between dataset genes and the genes regulated by particular transcriptional regulators. A 
total of 141 upstream regulators, including 7 miRNAs were indicated as statistically likely to 
be responsible for these gene changes. The miRNAs within this are listed in table 6.2. One of 
these miRNAs, miR-143 has been shown to reduce metastatic tendencies of PC3 cells (Huang 
et al., 2012), and is therefore surprising as a mediator of communication between PC3 cells 
and cells of the most common PCa metastatic site. Another miRNA, miR-21 is the most 
commonly up-regulated miRNA in solid cancers (Volinia et al., 2006). Interestingly, one of 
the miRNAs indicated by IPA was miR-16-5p (p=0.0469). miRNA sequencing and qPCR in the 
previous chapter showed miR-16-5p to be one of the most highly expressed miRNAs in PC3 
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cells and sEVs. Furthermore, miR-16-5p was significantly higher in 2 aggressive PCa cell lines 
compared to a non-cancerous prostate epithelial cell line. Combining this with the IPA data 
suggests that miR-16-5p may be a key mediator of the PC3 sEV induced changes in 7F2 cell 
differentiation and mineralisation.   
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Figure 6.4: Overview of Sequencing Run. (A) Heat map showing chip loading 
efficiency, of the Ion P1 chip. (B) Bar graph showing % usable reads from the sample 
once polyclonal or untemplated beads were removed. (C) Read length of sequences 
including mean, median and mode for all samples combined. 
B A 
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Figure 6.5: Gene Changes in 7F2s Treated with Osteogenic Media + sEVs (OMEV) vs 
Osteogenic Media Only (OM). (A) Hierarchical clustering of genes significantly (p<0.05) 
altered by treatment with OMEV vs treatment with OM. Red= upregulated genes, blue= 
down regulated genes. (B) Total up/down regulated genes in OMEV vs OM treated 7F2s. (C) 
Significantly up/down regulated genes in OMEV vs OM treated 7F2s. n=2.  
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Rank 
Disease and Function Pathways Most Correlated with 
Gene Changes 
p-Value 
1 Skeletal and Muscular Disorders 1.59x10-5 
2 
Connective Tissue Development and Function, Organ 
Morphology, Skeletal and Muscular System 
Development and Function, Tissue Development, Tissue 
Morphology 
 
2.04x10-5 
3 
Organismal Development, Skeletal and Muscular 
System Development and Function 
 
2.34x10-5 
4 
Embryonic Development, Organismal Development 
 
3.04x10-5 
5 
Organismal Development, Skeletal and Muscular 
Disorders, Skeletal and Muscular System Development 
and Function 
 
3.50x10-5 
 
Table 6.1. The top 5 pathways statistically likely to be affected by the gene 
changes seen between OMEV and OM treated 7F2 cells, according to IPA. n=2. 
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Upstream Regulator p-value of overlap 
mir-143 3.18x10-3 
miR-1-3p 3.18x10-3 
mir-21 2.28x10-2 
miR-199a-5p 2.34x10-2 
mir-199 2.34x10-2 
mir-140 4.63x10-2 
miR-16-5p 4.69x10-2 
 
Table 6.2. miRNAs statistically likely to have influenced the gene changes seen 
between OMEV and OM treated 7F2 cells, according to IPA. n=2. 
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miR-16-5p Delivery by PC3 sEVs 
As discussed, miR-16-5p showed high expression in PC3 cells and sEVs, and was also 
predicted to be involved in sEV communication between PC3 and 7F2 cells. Therefore, 
potential sEV delivery of miR-16-5p in communication between these cells was assessed. 
To analyse whether miR-16-5p levels are increased in recipient cells following sEV treatment, 
7F2 cells were treated with 200µg/mL of sEVs for 8 hours (figure 6.6). After 8 hours, excess 
sEVs were removed and cells were washed 3 times with PBS before RNA was collected. As a 
control, miR-30e-3p expression levels were also measured in vehicle and sEV treated 7F2 
cells, as miR-30e-3p was undetectable in our PC3 sEVs by sequencing. Furthermore, Hessvik 
et al. (2012) also showed that miR-30e-3p was undetectable in PC3 sEVs analysed by 
sequencing. The data indicated that the expression of miR-16-5p was almost 30% higher in 
cells incubated with PC3 sEVs compared to PBS vehicle (p=0.007), whereas miR-30e-3p 
showed no increase in expression (figure 6.6). 
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Figure 6.6: miR-16-5p and miR-30e-3p Expression in sEV Treated 7F2 Cells. qPCR of miR-
16-5p and miR-30e-3p in vehicle (PBS) and sEV treated 7F2 cells. Graphs show average 
+SEM, n=3. Statistical significance assessed by unpaired ttest between sEV and vehicle 
fold change controls, **p<0.01. 
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Detection of miR-16-5p Functional Activity in Recipient Cells 
To show that the miR-16-5p, increased as a result of sEV treatment, is functional, a 7F2 cell 
line with a stably integrated miR-16-5p pmirGlo reporter plasmid was created. Firstly, the 
pmirGLO plasmid (figure 6.7A) was cut with PmeI and XbaI restriction enzymes, producing a 
linear piece of DNA roughly 7.3Kb in size (figure 6.7B). Next, miR-16-5p forward and reverse 
oligonucleotides (oligos) were designed (figure 6.7C). Oligos contained the miR-16-5p 
binding site, as well as a NotI site, used for insertion check, and end sites complementary to 
XbaI/PmeI restriction sites on the cut plasmid. Oligos were then annealed and subsequently 
ligated into the cut plasmid using a T4 DNA Ligase enzyme, utilising the complementarity 
between the PmeI/XbaI end regions of the oligos and the cut plasmid. Insertion of the oligos 
was confirmed by performing a subsequent restriction enzyme step, using NotI. The pmirGLO 
plasmid contained a single NotI site, and the oligo insert contained an additional NotI site. 
Unsuccessful insertion would result in a single cut, producing a linear piece of DNA roughly 
7.3Kb in size, whereas successful insertion would result in two cuts, producing an additional 
piece of DNA roughly 140bp in size (along with the 7.1Kb vector backbone). To check for 
insertion, E. coli were transformed with the ligated plasmid and spread on LB-ampicillin (LB-
AMP) agar plates. 10 colonies were then picked and cultured in LB-AMP overnight. Plasmids 
were extracted from E. coli populations, digested with NotI and separated by agarose gel 
electrophoresis (figure 6.7D). Positive insertions can be seen in 3 of these 10 colonies, which 
were subsequently sent for sequencing for orientation confirmation.  
Stably transfected 7F2 cell lines were created containing either the miR-16-5p pmirGlo 
reporter, or a negative control empty pmirGlo reporter. Stable transfection was confirmed 
by detection of both firefly and renilla luciferase. To confirm the functionality of the miR-16-
5p reporter plasmid, 7F2 cells were first transfected with a miR-16-5p mimic oligonucleotide 
(oligo) using Lipofectamine 3000. qPCR of miR-16-5p transfected cells revealed significantly 
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higher levels of miR-16-5p compared to cells transfected with a negative control (scrambled) 
oligo (figure 6.8A) (p=0.003). 7F2 cells containing either the miR-16-5p reporter, or an empty 
pmirGLO reporter, were then transfected with scrambled and miR-16-5p oligos in the same 
manner. miR-16-5p transfection had no effect on luciferase activity in empty reporter 7F2 
cells (figure 6.8B) compared to the scrambled oligo. However, in miR-16-5p reporter 7F2 
cells, transfection of miR-16-5p oligo resulted in a significant decrease in luciferase activity 
compared to transfection with the scrambled oligo (figure 6.8C) (p=0.015).  
After confirming the functionality of the miR-16-5p reporter, 7F2 empty and miR-16-5p 
reporter cell lines were treated with 200µg/mL of PC3 sEVs or equivalent volume of vehicle 
(PBS). In empty reporter 7F2 cells, sEV treatment had no effect on luciferase activity 
compared to vehicle treatment (figure 6.9A). In miR-16-5p reporter 7F2 cells, treatment with 
sEVs significantly reduced luciferase activity by 23% (figure 6.9B) (p=0.01). This is consistent 
with data showing a rise in miR-16-5p levels with sEV treatment, and demonstrates an ability 
of the sEV miR-16-5p to modulate complementary cytosolic targets.  
To test the effect of isolated miR-16-5p on 7F2 cell mineralisation, cells were transfected 
with scrambled or miR-16-5p oligos and treated with osteogenic media. miR-16-5p 
transfection resulted in a 13% increase in mineralisation compared to scrambled oligo (figure 
6.10A) (p=0.03).  The effect of miR-16-5p transfection was also tested on the expression of 
osteoblast differentiation genes. Although miR-16-5p transfection had no effect on DLX5 or 
COL1A1 expression, ACVR1 and MMP3 were significantly increased compared to scrambled 
oligo transfected cells (p<0.01 for both).  We therefore demonstrate that some transcripts, 
modulated by PC3 sEVs can also be modulated by exogenous delivery of miR-16-5p. Thus 
providing some evidence that vesicular miR-16-5p may be responsible for part of the 
biological response seen with sEV treatment. 
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Figure 6.7: Synthesis of miR-16-5p pmirGLO Reporter. (A) pmirGLO Vector map showing 
multiple cloning site (MCS) (image from Promega). (B) Plasmid digested with PmeI and 
XbaI. (C) Design of miR-16-5p forward and reverse oligos to be annealed and inserted into 
the cut plasmid. Oligos contain internal NotI site, miR-16-5p binding site and 
complementary sites to PmeI and XbaI restriction sites on the cut plasmid. (D) Orientation 
check of ligated plasmid and oligos illustrating successful insertion of oligos (seen as 
~140bp product). 
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Luciferase Luciferase miR-16-5p 
pmirGLO Empty pmirGLO miR-16-5p 
Figure 6.8: Testing of miR-16-5p Reporter with miR-16-5p Transfection. (A) qPCR of miR-
16-5p in 7F2 cells transfected with scrambled or miR-16-5p oligo (5pmol). (B) Luciferase 
activity of empty reporter 7F2 cell line transfected with scrambled of miR-16-5p oligo 
(25pmol/mL). (C) Luciferase activity of miR-16-5p reporter cell line transfected with 
scrambled or miR-16-5p oligo (25pmol/mL). (D) Schematic representation of empty and 
miR-16-5p reporters used. Graphs show average +SEM, n=3. Statistical significance 
assessed by unpaired ttest, *p<0.05, **p<0.01. 
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Figure 6.9: miR-16-5p Reporter Activity in sEV Treated 7F2 Cells. (A) Luciferase activity of 
empty reporter 7F2 cell line treated with vehicle (PBS) or sEVs (200µg/mL). (B) Luciferase 
activity of miR-16-5p reporter cell line treated with vehicle (PBS) or sEVs (200µg/mL). (C) 
Schematic representation of empty and miR-16-5p reporters used. Graphs show average 
+SEM, n=3. Statistical significance assessed by unpaired ttest, *p<0.05. 
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Figure 6.10: Mineralisation of 7F2 Cells Transfected with Scrambled or miR-16-5p 
Oligos. (A) ARS staining, (B) Osteoblast differentiation gene expression changes of 
miR-16-5p or scrambled oligo transfected 7F2 cells cultured in osteogenic media.  
Graphs show average +SEM, n≥3. Statistical significance assessed by unpaired ttest 
or Mann-Whitney U test, *p<0.05, **p<0.01. 
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Selection of miR-16-5p targets 
After discovering that miR-16-5p was likely to be involved in the pro-osteoblastic sEV 
communication between PC3 and 7F2 cells, and confirming that miR-16-5p is likely 
transferred by PC3 sEVs to 7F2 cells, we looked for changes in miR-16-5p mRNA targets in 
sEV treated 7F2 cells that may explain this effect. Targets were selected in a step wise 
manner from sequencing data of PC3 sEV treated 7F2 cells, outlined in figure 6.11. 
Sequencing generated a list of over 12,000 detected genes, which was cross-referenced with 
predicted miR-16-5p targets from 3 independent databases (Targetscan, miRDB and 
microrna.org) using Microsoft Access, to generate a list of 616 miR-16-5p targets. From this 
list, genes that were increased or that had reduced by less than the arbitrary cut off of 1.5x 
were removed, leaving 95 genes. A manual literature search was performed on the 
remaining genes, of which 19 were found to have links to bone related studies. From this list 
of genes, 4 were found to be linked to osteoblast function, and were therefore selected as 
potential mediators of the increased osteoblast function seen with sEV treatment (table 6.3). 
The selected genes were delta like canonical notch ligand 1 (DLL1), AXIN2, phospholipid 
scramblase 4 (PLSCR4) and beta-2 adrenergic receptor (ADRB2) It is acknowledged that the 
final selection of the target genes based on their known function introduced a degree of bias.   
To confirm the complementarity between miR-16-5p and the 4 selected targets, the genes 
were searched using TargetScan. TargetScan confirmed that miR-16-5p had 
complementarity based binding sites on all 4 selected genes, with two miR-16-5p binding 
sites on the DLL gene (figure 6.12). This search revealed that miR-16-5p binds via the 7mer-
m8 sites on the target genes. This means that binding involves pairing of 7 bases, namely all 
6 bases within the seed region of the miRNA (see introduction section 1.4.2.1 for details) 
including a 7th base at miRNA position 8, hence 7mer-m8.  
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Entire gene list from sequencing 
Selected targets based on role in 
osteoblast function 
Manually searched genes for 
links to bone  
Selected genes that decreased 
>1.5 times  
Used Microsoft Access to merge 
gene expression data (from 
sequencing) and miR-16-5p 
target databases (Targetscan, 
microRNA.org and miRDB) and 
combined common genes 
12,758 
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Figure 6.11: Schematic Representation of How Candidate miR-16-5p Targets Were 
Selected. Flow chart of how miR-16-5p targets in sEV treated 7F2 cells were selected. 
Figure shows method of selection at each stage as well as the number of genes remaining 
after each selection. 
Method of miR-16-5p 
Target Selection 
Remaining 
Genes at 
Each Stage 
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Table 6.3: Final 4 Selected miR-16-5p Targets  
 
Gene Fold Change Log Change Description Reference 
DLL1 0.029 -5.116 
DLL1 increases the 
expansion of bone 
forming cells but reduces 
the maturation of 
osteoblasts. DLL1 is a 
ligand for Notch 
receptors. Notch 
signalling inhibits 
osteoblast differentiation. 
(Muguruma et al., 
2017; Zanotti et al., 
2008) 
AXIN2 0.203 -2.301 
Osteoblast proliferation 
and differentiation was 
increased in AXIN2 ko 
mice 
(Yan et al., 2009) 
RUNX2 repressed AXIN2 
in maturing osteoblasts 
(McGee-Lawrence 
et al., 2013) 
AXIN2 is linked to 
multiple aspects of Wnt 
signalling in 
osteoblastogenesis 
(Huraskin et al., 
2016; Liu et al., 
2007) 
PLSCR4 0.206 -2.277 
PLSCR4 is downregulated 
in osteoblastic vs non 
osteoblastic 
osteosarcomas. 
Conversely, PLSCR4 is 
upregulated in high bone-
forming vs low bone-
forming hBMSC clones. 
(Andersen et al., 
2015; Kubista et al., 
2011) 
ADRB2 0.295 -1.760 
ADRB2 signalling inhibits 
osteoblast proliferation 
and promotes osteoclast 
maturation 
(Ma et al., 2011) 
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Figure 6.12: Confirmation of miR16-5p Complementarity to Selected Targets. 
Complementarity between miR-16-5p and DLL1 (A), AXIN2 (B), PLSCR4 (C) and 
ADRB2 (D) is shown, including the binding position on the target gene. Note; 
DLL1 has two miR-16-5p binding sites. Images from http://www.targetscan.org  
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Validation of miR-16-5p targets 
To confirm that these targets are modulated by miR-16-5p, 7F2 cells were transfected with 
25pmol/mL of either a scrambled or miR-16-5p oligos, and the expression of the 4 genes was 
analysed by qPCR (figure 6.13A). Transfection of miR-16-5p resulted in a significant decrease 
in the expression of all 4 genes compared to scrambled oligo transfected cells of 21-33% 
(p<0.05 for all).  
To test whether the increase in cellular miR-16-5p seen with sEV treatment is sufficient to 
modulate these genes, 7F2 cells were treated with 200µg/mL of sEVs or vehicle (PBS) and 
the expression of these genes was analysed by qPCR (figure 6.13B). The expression of all 4 
genes was reduced in sEV treated cells compared to controls by 23-27%. However, whilst the 
reductions in the expression of DLL1, PLSCR4 and ADRB2 were all significant (p<0.05 for all), 
the reduction AXIN2 narrowly failed to reach significance (p=0.08).  
The qPCR of sEV treated 7F2 cells highlights the modulation of gene expression seen in these 
cells. However, qPCR alone is unable to address the cellular mechanisms by which these 
regulatory effects may occur. To aid this, luciferase reporters were utilised. Mouse 
miTargetTM 3’UTR reporters were purchased from GeneCopoedia (no Mus musculus PLSCR4 
plasmid was available at the time of the study) and were transiently co-transfected with 
either scrambled or miR-16-5p oligos or with PC3 sEVs. Transiently transfected empty 
pmirGLO was again used as a control. When co-transfected with miR-16-5p, there was a 
significant reduction in the relative luminescence from the DLL1, ADRB2 and AXIN2 reporters 
compared to the scrambled oligo (p<0.05 for all) (figure 6.14A). When co-treated with sEVs, 
there was again a significant reduction in the relative luminescence of the DLL1 and AXIN2 
reporters (p<0.05 for both) (figure 6.14B), whilst the reduction seen with the ADRB2 plasmid 
narrowly failed to reach significance (p=0.09).
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Figure 6.13: Changes in Expression of miR-16-5p Targets in Oligo or sEV Treated 
7F2 Cells. (A) qPCR of miR-16-5p target genes in 7F2 cells transfected with 
scrambled or miR-16-5p oligos (25pmol/mL) (B) qPCR of 7F2 cells treated with 
vehicle or sEVs (200µg/mL). Graphs show average +SEM, n=3. Statistical 
significance assessed by unpaired ttest between treated and vehicle fold change 
controls, *p<0.05, **p<0.01. 
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Figure 6.14: Validation of Gene Targeting Using Luciferase Reporters. (A) 
Luciferase activity in 7F2 cells co-transfected with target reporter (1µg/mL) and 
scrambled/miR-16-5p oligos (25pmol/mL). (B) Luciferase activity in 7F2 cells 
transfected with target reporter (1µg/mL) and treated with vehicle or sEVs 
(200µg/mL). (C) Schematic representation of empty and miR-16-5p target 
reporters used. Graphs show average +SEM, n=3. Statistical significance assessed 
by unpaired ttest between treated and vehicle fold change controls, *p<0.05, 
**p<0.01.  
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Overexpression of miR-16-5p targets 
To test the effect of the overexpression of these miR-16-5p targets, pEF6 plasmids (figure 
6.15) containing the coding regions of these genes were synthesised. Genes were amplified 
from 7F2 cDNA by PCR, with the exception of AXIN2, which due to its severely low expression, 
was amplified from the Myc-Axin2 plasmid (Addgene – 21279) (all primers for coding region 
amplification detailed in table 2.4). PCR products were then separated on an agarose gel, 
extracted and ligated with the pEF6 plasmid. E. coli were then transformed with the ligated 
plasmids, which were subsequently extracted and sequenced to confirm insertion and 
orientation. Finally, plasmids were transfected into 7F2cells using Lipofectamine 3000 
(Thermo Fisher) and clones were selected using Blasticidin. Overexpression appeared to have 
little effect on 7F2 cell growth in culture.  
Overexpression of the genes of interest was first validated at the gene expression level, by 
qPCR (figure 6.16). All genes showed a marked increase in expression, reaching significance 
for DLL1 (p<0.05) as well as PLSCR4 and ADRB2 (p<0.001 for both). The increase in gene 
expression seen in AXIN2 overexpression failed to reach significance (p=0.1), but did show 
>500x higher expression compared to empty pEF6 7F2 cells.  
The next step was to assess, via western blot, whether overexpression was occurring at the 
protein level. Protein was extracted from all overexpression cell lines and compared to 
empty pEF6 7F2 cells. Unfortunately, even with multiple attempts at optimisation, clear 
protein bands in the expected region could not be seen for DLL1, and ADRB2, with multiple 
unspecific bands seen (data not shown). This likely reflects the poor quality of the antibodies, 
as GAPDH was easily detectable for these samples. Antibodies towards AXIN2 and PLSCR4 
were able to generate specific bands (figure 6.17A and 6.17B) and were able to confirm 
protein overexpression. This overexpression was quantified using ImageJ software (figure 
Chapter VI: The Effects of PCa sEVs on Osteoblast Differentiation 
237 
 
6.17C and 6.17D), which revealed a >3x in band density for AXIN2, although this narrowly 
failed to reach significance (p=0.089), and a >1.8x increase for PLSCR4 (p=0.03). 
To test the functionality of the overexpression cell lines, cells were mineralised alongside 
empty pEF6 7F2 cells for 10 days. The level of ARS staining relative to crystal violet was then 
analysed. ADRB2 (figure 6.18A), PLSCR4 (figure 6.18B) and DLL1 (figure 6.18C) 
overexpression resulted in a decrease in mineralisation relative to control cells (p<0.05 for 
PLSCR4, p<0.01 for ADRB2 and DLL1). Conversely, overexpression of AXIN2 (figure 6.18D) 
resulted in an increase in mineralisation, although this increase failed to reach significance 
(p=0.22). We therefore conclude, that PLSCR4, ADRB2 and DLL1 may repress osteoblast 
differentiation, and that AXIN2 may augment differentiation.  
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Figure 6.15: Plasmid Map of pEF6/V5-His-TOPO. miR-16-5p targets to be 
overexpressed were subcloned into the pEF6/V5-His-TOPO vector. Insertion and 
orientation were then confirmed by sequencing. 
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Figure 6.16: qPCR of Overexpression 7F2 Cell Lines. Expression of target genes 
in AXIN2 (A), DLL1 (B), PLSCR4 (C) and ADRB2 (D) overexpression 7F2 cell lines 
compared to empty pEF6 control cells. Graphs show average +SEM, n=3. 
Statistical significance assessed by unpaired ttest, *p<0.05, ***p<0.001.   
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Figure 6.17: Western Blot of Overexpression 7F2 Cell Lines. Representative image showing expression of AXIN2 protein in AXIN2 
overexpression 7F2 cells (A) and PLSCR4 protein in PLSCR4 overexpression cells (B) compared to empty pEF6 control cells analysed 
by western blot (20µg). Semi-quantification of band density using ImageJ software for AXIN2 (B) and PLSCR4 overexpression vs 
empty pEF6 cells. Graphs show average +SEM, n=3. Statistical significance assessed by unpaired ttest. 
A 
C 
B 
D 
P L S C R 4
P
L
S
C
R
4
/G
A
P
D
H
 (
D
e
n
s
it
o
m
e
tr
y
)
p E F 6 -E m p ty p E F 6 -P L S C R 4
0 .0
0 .2
0 .4
0 .6
0 .8
*
A X IN 2
A
X
IN
2
/G
A
P
D
H
  
(D
e
n
s
it
o
m
e
tr
y
)
p E F 6 -E m p ty p E F 6 -AX IN 2
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
Chapter VI: The Effects of PCa sEVs on Osteoblast Differentiation 
241 
 
A D R B 2
R
e
la
ti
v
e
 A
li
z
a
r
in
/C
r
y
s
ta
l 
V
io
le
t 
(A
b
s
)
p E F 6 -E m p ty p E F 6 -AD R B 2
0 .0
0 .5
1 .0
1 .5
**
P L S C R 4
R
e
la
ti
v
e
 A
li
z
a
r
in
/C
r
y
s
ta
l 
V
io
le
t 
(A
b
s
)
p E F 6 -E m p ty p E F 6 -P L S C R 4
0 .0
0 .5
1 .0
1 .5
*
D L L 1
R
e
la
ti
v
e
 A
li
z
a
r
in
/C
r
y
s
ta
l 
V
io
le
t 
(A
b
s
)
p E F 6 -E m p ty p E F 6 -D L L 1
0 .0
0 .5
1 .0
1 .5
**
A X IN 2
R
e
la
ti
v
e
 A
li
z
a
r
in
/C
r
y
s
ta
l 
V
io
le
t 
(A
b
s
)
p E F 6 -E m p ty p E F 6 -AX IN 2
0 .0
0 .5
1 .0
1 .5
2 .0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.18: ARS Staining of Overexpression 7F2 Cell Lines. Quantified 
Alizarin Red S staining of (A) ADRB2, (B) PLSCR4, (C) DLL1 and (D) AXIN2 
overexpression 7F2 cell lines relative to empty pEF6 control cells. Graphs 
show average +SEM, n=3. Statistical significance assessed by unpaired ttest, 
*p<0.05, **p<0.01. 
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 Discussion 
Cell to cell communication within bone metastatic sites drives a viscous cycle that ultimately 
leads to increased tumour growth and development of the metastatic lesion. We previously 
showed that PCa cells are able to stimulate increased osteoblast function in vitro and 
hypothesised that sEV miRNAs may be involved. After subsequently characterising the 
miRNA content of PCa sEVs, we looked to examine their effect on osteoblasts in isolation. 
We found that although PC3 cell sEVs were unable to stimulate mineralisation of 7F2 cells in 
regular media, 200µg/mL of sEVs was sufficient to enhance mineralisation of 7F2 cells grown 
in osteogenic media. Conversely, doses of 50µg/mL or 100µg/mL were unable to stimulate 
any enhancement of 7F2 mineralisation. However, it is acknowledged that leaving cells to 
mineralise for longer than 10 days may have yielded a more significant change in calcium 
deposition, although this was balanced by the risk of reaching the upper limit of the ARS 
assays dynamic range. Dosing of sEVs to match physiological levels found in and around 
tumours is inherently difficult due to an inability to accurately measure local sEV 
concentrations in vivo, with the exception of easily accessed fluids such as blood and urine 
(Li et al., 2014). Dosages of sEVs vary drastically in the literature, from <10µg/mL (Ferguson 
et al., 2018b) to >300µg/mL (Atay et al., 2014; Li et al., 2018a). Thus, a dose of 200µg/mL 
may be considered high. However, due to the close proximity of PCa cells and osteoblasts 
within a metastatic lesion (Shiirevnyamba et al., 2011), and the fact that cancer cells may 
produce more sEVs than their non-cancerous equivalents (Riches et al., 2014) and in a 
continuous manner, means that a high concentration of PCa cell sEVs in the localised tumour 
space surrounding the osteoblasts is feasible.        
To confirm the increase in mineralisation seen with sEV was reflected at the gene expression 
level, 7F2 cells were treated with 200µg/mL of sEVs for 3 days in regular or osteogenic media, 
and the expression of the 4 osteoblast mineralisation genes outlined previously were 
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analysed. As expected, the expression of these genes was altered by sEV treatment in 
osteogenic media, reflecting the increase in mineralisation seen in these cells. However, 
surprisingly the expression of these genes was also significantly altered by sEV treatment in 
regular media. This change in gene expression but absence of mineralisation suggested these 
cells likely lack the ability to deposit HA as opposed to failing to respond to sEV treatment. 
Therefore, 7F2 cells were treated with β-glycerophosphate alone with or without sEVs. The 
increased mineralisation seen in sEV treated cells within this context, displays an ability of 
sEVs to induce differentiation of 7F2 cells, as opposed to only synergistically boosting 
differentiation when combined with osteogenic supplements. Although the ability of sEVs to 
modulate osteoblast differentiation has been demonstrated previously (Sun et al., 2016), it 
was interesting to note that the dose of sEVs, able to stimulate an increase in mineralisation, 
was able to induce differentiation in regular media. Whereas PC3 cells used in a co-culture 
setup, able to stimulate similar levels of mineralisation, had little effect on differentiation in 
regular media. This suggests that sEVs have a greater potential to induce osteoblast 
differentiation compared to all combined secreted factors from their original cells. 
Gene expression changes in sEV treated 7F2 cells were analysed by RNA sequencing, to gain 
a deeper understanding of the effects on gene expression and the associated cellular 
pathways. sEVs were given in addition to osteogenic media in order to assess the effects of 
sEV communication on top of regular mineralisation, as this closer reflects a biological 
environment, where vitamins and phosphate sources are readily available.  
Sequencing revealed that >82% of genes detectable in both samples were down regulated 
following sEV treatment, with >98% of significantly changed genes showing down regulation. 
This unbalanced effect on gene expression may be the result of sEVs containing vast amounts 
of non-coding RNA, whose function generally lies in the down-regulation of other RNA 
species. When sequencing exosome vs PBS treated mesenchymal stem cells, Zhang et al. 
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(2016) showed that almost 80% of genes were down regulated following treatment, 
validating this unbalanced effect on gene expression. Together, this suggests that the effect 
of sEV treatment is primarily the downregulation of target cell genes. However, whether this 
is due to non-coding RNA delivery or via other signalling pathways remains to be seen. 
IPA revealed that 4 skeletal development/disorder pathways were among the top 5 
pathways most affected by sEV treatment, indicating that sEVs may target specific 
osteogenic pathways. IPA also revealed miR-16-5p as statistically likely to be involved as an 
upstream regulator of the gene changes seen in sEV treated cells. As previously discussed, 
although miR-16-5p is widely considered a tumour suppressor, it showed high expression in 
PC3 cells and sEVs. Green et al. (2017) showed that miR-16-5p is down regulated in Paget’s 
disease of bone (PDB), which is characterised by over activity of osteoclasts. Conversely, miR-
16-5p was shown to be overexpressed in Paget’s associated osteosarcoma (PDB-OS) which 
presents as an osteoblastic lesion. Thus, miR-16-5p may regulate key genes within 
osteoblasts to promote differentiation and increase function. miR-16-5p was therefore 
selected as the primary miRNA candidate for future work looking at sEV communication 
between PC3 and 7F2 cells.  
qPCR of sEV treated 7F2 cells confirmed a significant increase in miR-16-5p expression. By 
using foreign RNAs or RNA-dye based imaging, delivery of sEV RNA can be confirmed (Buck 
et al., 2014; Li et al., 2014). However, as mmu-miR-16-5p and hsa-miR-16-5p have the same 
sequence, it is not possible to determine, in this context, whether miR-16-5p is delivered by 
sEVs or upregulated by the target cell as a result of a separate signalling pathway. To give 
weight to the argument that miR-16-5p is delivered by sEVs, miR-30e-3p was also measured. 
miR-30e-3p was found to be absent in PC3 sEVs analysed by ourselves as well as by Hessvik 
et al. (2012). miR-30e-3p showed no increase in sEV treated cells, as expected. Thus, we show 
that sEV treatment does not result in global miRNA increases, and instead show that 
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increases are specific to certain miRNAs. However, again this does not disprove the fact that 
changes in miR-16-5p may be a result of alterations in target cell gene regulation, via another 
method of sEV stimulation, rather than sEV delivery. 
A miR-16-5p pmirGLO reporter was synthesised, to show that the resultant increase in miR-
16-5p following sEV treatment was associated with an increase in miR-16-5p function, as the 
plasmid accounts for the downregulation caused by endogenous miR-16-5p. Transfection of 
a miR-16-5p oligo was used to confirm the functionality of the reporter itself, which showed 
a significant reduction in luciferase activity. By also showing that miR-16-5p had no effect on 
the empty reporter, as well as showing that a scrambled oligo had no effect on the miR-16-
5p reporter, we concluded that the miR-16-5p reporter was both functional and specific. The 
reduction in the miR-16-5p reporter seen with sEV treatment matches the increase in miR-
16-5p levels shown by qPCR. However, again this also gives little insight as to the source of 
the miR-16-5p.  
At this point, the combined findings suggest that sEV miR-16-5p is involved in communication 
between PC3 and 7F2 cells. Therefore, we looked to analyse the effects of miR-16-5p in 
isolation, on mineralisation. 7F2 cells transfected with miR-16-5p showed a small but 
consistent increase in mineralisation. Transfection of miR-16-5p had no effect on DLX5 or 
COL1A1 expression but was able to significantly increase the expression of ACVR1 and 
MMP3. The increase in only 2 of the 4 mineralisation genes may reflect the fact that 
mineralisation was only increased by 13%, as opposed to the 90% increase in mineralisation 
seen with 200µg/mL of sEVs. Furthermore, this also suggests, as expected, that whilst 
induction of mineralisation by sEVs likely involves miR-16-5p, the complete mechanism is 
multifactorial, and miR-16-5p only plays a part in the process.  Nevertheless, the ability of 
miR-16-5p to increase mineralisation in the absence of any additional signalling molecules is 
novel, and thus, potential mechanisms for this interaction are hereby explored.  
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The gene expression changes, as analysed by RNAseq, in sEV treated 7F2 cells, was re-
analysed in order to find miR-16-5p targets, modulated by sEV treatment. Targetscan, 
microRNA.org and miRDB databases were used to compile a conclusive list of miR-16-5p 
targets within the sequencing data. Of these, genes that reduced by >1.5x were selected, as 
these were considered to have shown a significant reduction. Although miRNAs have 
displayed an ability to induce target gene expression (Vasudevan et al., 2007), their primary 
documented function lies in the repression of target genes. Therefore, for this study only 
genes showing reduced expression were considered. From the remaining genes, manual 
searches were performed to uncover links between them and any aspect of bone physiology 
or disease. Of these, 4 genes were documented to alter osteoblast proliferation, 
differentiation or function and were thus selected as candidate genes for further functional 
study. The 4 selected genes were; DLL1, AXIN2, PLSCR4 and ADRB2. Although selection of 
genes based on their documented function introduced a degree of bias, the time constraints 
of the project meant that functional analysis of all 19 bone related target genes was 
unachievable. But it should be considered that the remaining genes, also modulated by miR-
16-5p, may have different functional roles in mineralisation.    
After selecting gene targets, their modulation by miR-16-5p was assessed. All 4 genes 
showed a significant reduction in expression following transfection with miR-16-5p as 
expected. Furthermore, a reduction in all 4 genes was also seen following sEV treatment. 
However, as with the changes in miR-16-5p levels following sEV treatment, measuring gene 
expression reveals little of the mechanism by which the expression of these genes is reduced. 
To implicate miRNA-based modulation as a mechanism by which these genes are reduced, 
miTargetTM miRNA 3’ UTR reporters were utilised. It should be noted that a reporter for 
mouse PLSCR4 was unavailable at the time of study. A reduction of luciferase activity was 
seen for all reporters with miR-16-5p transfection, confirming that direct modulation of 
these gene by miR-16-5p was occurring. A reduction in luciferase activity was also seen for 
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all reporters with sEV treatment. However, although this confirms that sEV miRNAs are able 
to modulate these genes, implicating the specific miRNA(s) responsible for this is not 
possible. For example, the 3’ UTR region of DLL1 has 27 miRNA target sequences, of which 
only 2 are for miR-16-5p (Targetscan.org). A similar level of reduction in luciferase activity 
was seen between miR-16-5p transfected cells and sEV treated cells. miR-16-5p transfection 
was able to raise miR-16-5p levels by around 40% more than sEV treatment. This indicates 
that the reduction of luciferase activity seen in sEV treated cells is likely the result of the total 
miRNA population within the sEVs and not only miR-16-5p. An empty pmirGLO reporter was 
used as the control for these experiments, which consistently showed no change, but given 
the subtle differences in the luciferases between pmirGLO and miTargetTM plasmids, an 
empty miTargetTM plasmid should be used as a more accurate control for future work.  
It should be noted, that although human and mouse miR-16-5p share the same sequence, 
their mRNA targets may not. Thus miR-16-5p may have slightly different signalling 
mechanisms depending on the species. However, both human and mouse DLL1, ADRB2, 
AXIN2 and PLSCR4 contain miR-16-5p binding sites, and therefore miR-16-5p can be assumed 
to have a similar effect on these genes in both species. 
After linking a reduction in the expression of these genes to sEV miR-16-5p, we looked to 
analyse the effect of their overexpression. As a reduction in the expression of these genes 
was linked to increased osteoblast function, we hypothesised that overexpression would 
result in a mirrored decrease in osteoblast function. Reduced osteoblast differentiation and 
function would be beneficial in the management of osteoblastic lesions, the most common 
form of bone metastasis from PCa. Therefore, given the available time frame, overexpression 
of these genes was explored, as a potential reduction in osteoblast differentiation/function 
is a more clinically relevant outcome than that of a reduced expression model, which we 
hypothesised would further drive osteoblast differentiation/function.  
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All genes showed a substantial increase in expression at the transcript level, measured by 
qPCR, indicating that transfection and plasmid incorporation was successful. Furthermore, 
this demonstrates the ability of the plasmid to induce a high number of copies of the inserted 
gene. We then looked to analyse the overexpression cell lines at the protein level. For DLL1 
and ADRB2, antibody issues meant that, within the given time frame, protein overexpression 
could not be confirmed. Multiple unspecific bands and a lack of bands at the expected size 
meant that further optimisation, or new antibodies would be required. However, the AXIN2 
and PLSCR4 antibodies proved effective, giving a single band at the expected size. 
Furthermore, AXIN2 and PLSCR4 overexpression cells displayed a marked increase in target 
protein levels. Although protein overexpression could not be confirmed in all cell lines, 
confirmation of AXIN2 and PLSCR4 overexpression confirms that that the methodology, i.e. 
pEF6 plasmid containing a genes coding region, is able to induce protein overexpression.  
Overexpression of ADRB2, DLL1 and PLSCR4 all resulted in a significant decrease in the 
mineralisation of 7F2 cells. This indicates a role for these genes in the repression of 
osteoblast differentiation. ADRB2 signalling has displayed an ability to both promote and 
inhibit osteoblast proliferation (Fu et al., 2005). Given that osteoblast differentiation requires 
a cessation in proliferation (Raucci et al., 2008), altering this pathway was expected to affect 
mineralisation levels. As ADRB2 overexpression resulted in a decrease in mineralisation, it is 
likely that ADRB2 activation in culturing osteoblasts may be promoting proliferation and 
therefore subsequently reducing differentiation.  
PLSCR4 is poorly explored within osteoblast differentiation. However, studies have shown 
PLSCR4 expression changes in bone cell populations displaying different characteristics. 
Confusingly, the expression of PLSCR4 in two studies seems to be slightly conflicting, and 
means that hypothesising the function of PLSCR4 in osteoblasts is difficult. For example, 
Kubista et al. (2011) showed that PLSCR4 was downregulated in osteoblastic vs non-
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osteoblastic osteosarcomas, whereas Andersen et al. (2015) showed that PLSCR4 was 
upregulated in high bone forming vs low bone forming human bone marrow stromal cells 
(hBMSC) populations. Our data shows that overexpression of PLSCR4 leads to decreased 7F2 
mineralisation, therefore suggesting an anti-differentiation role of PLSCR4 in these cells. 
DLL1 appears to have multiple roles in the physiology of osteoblasts. Muguruma et al. (2017) 
showed that DLL1 likely plays a dual role in the regulation of osteoblastogenesis, depending 
on the stage of differentiation. DLL1 was shown to positively regulate the expansion of bone-
forming cells, whilst acting as a negative regulator of functional maturation in cells already 
committed to the osteoblast lineage. 7F2 cells appear to correspond to more mature 
osteoblasts, due to their AP expression and ability to secrete type I collagen (Thompson et 
al., 1998). Therefore, the action of DLL1 in reducing their differentiation, seen here by a 
reduction in their mineralisation levels, is in keeping with the findings of Muguruma et al. 
(2017).  
AXIN2 was the only gene whose overexpression resulted in an increase in the levels of 
mineralisation. Yan et al. (2009) showed that Axin2 KO mice had increased osteoblast 
differentiation and function, leading to an increase in bone volume, bone mineral density 
and bone mechanical strength. McGee-Lawrence et al. (2013) showed that AXIN2 prevents 
Wnt signalling required for osteoblast differentiation, and that AXIN2 was negatively 
regulated by RUNX2, which is itself upregulated during osteoblast differentiation. Together, 
these studies show that RUNX2 reduces AXIN2 expression during its upregulation in 
osteoblast differentiation, and that this resultant loss in AXIN2 contributes to increased 
osteoblast differentiation and function through a reduced repression of Wnt signalling. 
However, during the characterisation of our mineralisation model (Chapter III), we found 
that RUNX2 was actually decreased in 7F2 cells grown in osteogenic media, which as 
discussed is likely due to the inhibitory role of RUNX2 on more mature osteoblasts. This link 
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between AXIN2, Wnt signalling and RUNX2 suggests that the inhibitory role of AXIN2 seen in 
these studies occurs at the early stages of osteoblastogenesis. It is therefore possible that 
this signalling interaction may have a different outcome in 7F2 cells. However, the increase 
in mineralisation seen in AXIN2 overexpressing 7F2 cells was still surprising given its direct 
functional link with osteoblast differentiation (Yan et al., 2009).    
In conclusion, the results of this chapter show that PC3 sEVs are able to induce differentiation 
of 7F2 osteoblast cells. By sequencing sEV treated cells, we showed that a number of 
molecules may be affecting these changes, including miR-16-5p, which was highly expressed 
in PC3 cells and sEVs. By overexpressing targets of miR-16-5p, we showed that these genes 
may have a functional role in the differentiation of osteoblasts.  
 Summary of Key Points 
sEVs were able to induce an increase in the differentiation of 7F2 cells at both the functional 
and gene expression level when cultured in osteogenic media, or regular media with an 
appropriate phosphate source. Sequencing of sEV treated 7F2 cells revealed a number of 
upstream regulators, including miR-16-5p, which was shown by sequencing to be highly 
expressed in PC3 cells and sEVs. sEV treatment lead to a significant increase in the levels of 
miR-16-5p but not miR-30e-3p, a miRNA believed to be absent in PC3 sEVs. miR-16-5p 
reporters showed that sEV treatment lead to an increase in the functionality of miR-16-5p. 
Sequencing of sEV treated 7F2 cells was analysed again, and a number of significantly 
reduced miR-16-5p targets were found, from which ADRB2, AXIN2, PLSCR4 and DLL1 were 
selected, based on their links to osteoblast function. After confirming the reduction of these 
genes following sEV treatment, overexpression was performed. This revealed that 
overexpression of ADRB2, PLSCR4 and DLL1 results in a decrease in 7F2 mineralisation, 
whereas overexpression of AXIN2 results in increased 7F2 mineralisation.  
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7 The Effects of PCa sEVs on Osteoclast Differentiation 
7.1 Introduction 
Although PCa forms primarily osteoblastic lesions, the roles of osteoclasts in the 
pathophysiology of metastatic bone disease are vast. Osteolytic and mixed lesions, whilst 
rarer than osteoblastic lesions, still represent a significant proportion of metastatic PCa 
patients (Charhon et al., 1983; Roudier et al., 2004). Osteoclastic activity is also a precursor 
to bone metastatic site colonisation regardless of osteolytic or osteoblastic outcome 
(Msaouel et al., 2008), where debulking of the bone surface aids PCa cell seeding. 
Furthermore, even within osteoblastic lesions, osteoclasts display increased activity (Keller 
& Brown, 2004), which results in an increased release of bone matrix derived growth factors, 
further driving the development of the secondary tumour.  
Given the multiple roles of osteoclasts in various forms of bone metastases, and that bone 
remodelling is a balance of osteoclast and osteoblast activity, it was felt important to also 
consider the effects of PCa cell sEV signalling on osteoclast activity. PCa sEVs have displayed 
an ability to both induce and decrease osteoclast differentiation (Bijnsdorp et al., 2015; 
Karlsson et al., 2016), indicating the signalling relationship and associated outcome is likely 
dependant on both the PCa and osteoclast cell type as well as environmental factors. Thus 
we looked to test the effect of the PC3 sEVs, which have displayed an ability to induce 
osteoblastogenesis, on the osteoclastic differentiation of RAW 264.7 murine macrophage 
cells. Osteoclasts develop from both immature cells of the monocyte-macrophage lineage, 
as well as mature macrophages In the presence of RANKL (Huang et al., 2017; Udagawa et 
al., 1990). By using sEVs from the same PCa cell line, we hope to more accurately model the 
effects of sEV communication from the same tumour on different cell types within the bone 
microenvironment, and how these effects may contribute to metastatic lesion development.     
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7.2 Chapter Aims 
The aims of this chapter are to examine the effects of PC3 cell sEVs on the differentiation 
and function of RAW 264.7 cells.  To achieve this, the specific aims of this chapter are: 
 To characterise the differentiation of RAW cells by looking at the expression of 
osteoclastic markers and visual assessment of mature osteoclast formation.  
 To analyse the effects of sEV treatment on both the expression of these osteoclast 
markers, and the formation of mature osteoclasts.  
 To assess the effect of sEV treatment on the function of osteoclasts. 
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7.3 Results 
Characterisaiton of RAW Cell Differentiation 
RAW 264.7 (RAW) cells are Abelson murine leukaemia virus-transformed macrophage cells, 
able to differentiate into multinucleated, bone resorbing osteoclasts when treated with 
RANKL (for overview of osteoclast differentiation see figure 1.7, section 1.3.2.3.1) (Collin-
Osdoby & Osdoby, 2012). Before analysing the effects of PC3 sEVs on RAW cells, their 
capacity to differentiate into mature osteoclasts in our hands was assessed. RAW cells were 
treated with 25ng/mL RANKL for 8 days. Cells were then stained for tartrate-resistant acid 
phosphatase (TRAP), a metalloenzyme involved in ROS production (Hirschfeld et al., 2017) 
and also responsible for increasing osteoclast migration by dephosphorylating OPN (Ek-
Rylander et al., 1994), a key protein for binding osteoclasts to the bone matrix. TRAP stained 
cells were then imaged using a brightfield microscope (figure 7.1). Positive TRAP staining is 
indicated by a maroon coloured precipitate. Although positive staining appeared to also be 
seen in undifferentiated cells, cells treated with RANKL were much darker, indicating 
increased TRAP levels. Most noticeably, within the RANKL treated cells, multiple 
multinucleated cells were visible, with a substantial cytoplasmic area, typical of successful 
osteoclastic differentiation.  
To further characterise RAW cell differentiation, cells were treated with 1-25ng/mL of RANKL 
then analysed by qPCR for changes in expression of TRAP and osteoclast-associated 
immunoglobulin-like receptor (OSCAR) (figure 7.2). OSCAR is an IgG-like receptor and an 
important costimulatory molecule for osteoclast differentiation via the activation of NFATc1 
(Nemeth et al., 2011). OSCAR is also commonly used as a marker of osteoclast differentiation 
(Kim et al., 2017). RANKL treatment increased the expression of OSCAR (figure 7.2A) and 
TRAP (figure 7.2B) in a dose dependent manner, reaching significance at 3ng/mL for OSCAR 
and 1ng/mL for TRAP (p<0.05 for all). 
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A B 
Figure 7.1: Morphology of RAW Cells. 10x magnified brightfield microscopy images of 
TRAP stained RAW cells grown on 6 well plates for 8 days in either regular DMEM (A) 
or DMEM + 25ng/mL RANKL (B) Scale Bar: 250µm. 
 B 
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Figure 7.2: Expression of Osteoclast Differentiation Genes in RAW Cells Treated with 
RANKL. Expression of OSCAR (A) and TRAP (B) in RAW cells treated with 0-25ng/mL of 
RANKL, analysed by qPCR. Graphs show average fold change compared to control 
+SEM, n=3. Statistical significance assessed by one-way ANOVA using Holm-Sidak 
multiple comparisons test, *p<0.05, **p<0.01, ***p<0.001. 
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Differentiation of RAW Cells Treated with PC3 sEVs 
To test the effect of PC3 sEVs on RAW cell differentiation, cells were treated with 200µg/mL 
of sEVs or vehicle in regular or 20ng/mL RANKL supplemented media (figure 7.3). Treatment 
with sEVs in regular media had no effect on OSCAR expression (figure 7.3A). Addition of 
RANKL alone caused aa increase in OSCAR expression, mirroring the result seen in figure 
7.2A. Treatment with sEVs in RANKL supplemented media caused an increase in OSCAR 
expression compared to RANKL alone. However, changes in OSCAR expression failed to reach 
significance although this narrowly failed to reach significance.  
sEV treatment in regular media had no effect TRAP expression (figure 7.3B). RANKL 
treatment alone caused a significant increase in TRAP (p<0.05) and sEV treatment with 
RANKL induced a small but insignificant increase in TRAP expression compared to RANKL 
alone.  
These results suggest that sEV treatment increases RAW cell differentiation in combination 
with RANKL but have no effect on differentiation in isolation. However, upon visual 
inspection, cells treated with RANKL and sEVs appeared to have a much higher rate of cell 
death/severe abnormality, seen by reduced cell number and multiple floating cells. Cells 
were imaged using a brightfield microscope (figure 7.4). Untreated cells showed an 
unchanged, round morphology, and were highly confluent, likely due to no cessation in their 
proliferation. Cells treated with RANKL alone showed multiple mature osteoclasts. RAW cells 
treated with sEVs alone showed a similar morphology to untreated cells, but with reduced 
cell number. Furthermore, a small number of cells showed an elongated and potentially 
partially differentiated morphology. Cells treated with RANKL and sEVs showed no clear 
evidence of fused cells, although some cells had appeared to cluster together. There was also 
substantially less cells compared to all other treatments, indicating either a marked 
reduction in proliferation, increased cell death or indeed, both.  
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After witnessing the effect of sEVs in combination with RANKL, which appeared to induce 
reduced proliferation and differentiation, we assessed the health of the cells using a number 
of cellular viability assays. A CellToxTM Green Cytotoxicity Assay was used to assess the levels 
of dead or damaged cells, with binding of the luminescent dye to cellular DNA only occurring 
in cells with damaged membranes. Compared to an untreated control, treatment with sEVs 
had no effect on the levels of luminescence, indicating no increase in cell damage/death 
(figure 7.5A). Addition of RANKL caused a resulted in >4x increase in luminescence (p<0.001) 
and treatment with sEVs in combination with RANKL, caused a further, significant, 22% 
increase in luminescence compared to treatment with RANKL (p=0.001) or sEVs (p<0.001) 
alone.  
Reactive oxygen species (ROS) production is another marker of cytotoxicity and excessive 
ROS production can lead to apoptosis (Lee et al., 2014). Compared to untreated cells, 
treatment of RAW cells with sEVs alone caused a significant increase in ROS production 
(p<0.001), and a similar increase in ROS production compared to control cells was seen in 
RANKL treated cells (p<0.001) (figure 7.5B). Treatment of cells with RANKL and sEVs resulted 
in an increase in ROS production compared to treatment with sEVs or RANKL alone (p=0.005 
for both). 
An MTT assay was used in parallel with the cytotoxicity assay, to measure the metabolic 
activity in these cells, as a marker of cellular function and health. MTT assays measure the 
production of insoluble purple formazan crystals, which are produced as a result of cellular 
reductase activity. The level of formazan production is then measured colourimetrically by 
absorbance, after the purple product is dissolved in DMSO. Thus, MTT assays are utilised as 
a high throughput measure of cell viability (Riss et al., 2004). As expected, the results of the 
MTT assay appear to generally oppose those shown in the cytotoxicity assay. Compared to 
untreated cells, absorbance was significantly reduced by both sEV treatment alone (<0.001) 
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and treatment with RANKL alone (p<0.001) (figure 7.5C). Absorbance was also significantly 
reduced in cells treated with RANKL and sEVs compared to sEVs or RANKL alone (p<0.001 for 
both).  
Given the synergistic effects of sEVs + RANKL on their ability to induce both changes in 
osteoclastic marker expression and changes in cell viability, we hypothesised that sEVs may 
contain additional RANKL. To test this, we analysed sEV lysate for the presence of RANKL. 
Western blot of PC3 sEV lysate confirmed the weak presence of PC3 sEV RANKL (figure 7.6), 
which combined, suggests that sEV RANKL may be involved in PCa sEV signalling to 
osteoclasts. However, based on the quality of this evidence, significant further work is 
needed to confirm this. 
Finally, to assess the overall effect of RANKL and sEV treatment on RAW cell function, a pit 
formation assay was performed. RAW cells (30,000/24 well) were seeded on calcium (HA) 
coated Corning® osteo assay surface plates. After 7 days, cells were removed, and ARS 
staining was used to visualise the remaining calcium, highlighting the newly formed 
osteoclast resorbed pits. Control or sEV treated RAW cells in the absence of RANKL resulted 
in no mature osteoclasts, and therefore no osteoclast pits (figure 7.7A). Treatment with 
RANKL resulted in a marked induction of differentiation, resulting in the formation of 
numerous osteoclast pits (figure 7.7B). Cells treated with RANKL and sEVs showed a 
decreased number of osteoclast pits, indicating a reduction of osteoclastogenesis (figure 
7.7B). To quantify the level of osteoclast activity, the total resorbed area for each well was 
calculated from 3 representative images using ImageJ software. Analysis in this way revealed 
a significant decrease in total resorbed area for RANKL + sEV treated cells compared to 
RANKL treated cells (p=0.046) (figure 7.7C). 
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Figure 7.3: Expression of Osteoclast Differentiation Genes in 
RAW Cells Treated with RANKL/sEVs. Expression of OSCAR (A) and 
TRAP (B) in RAW cells treated with 20ng/mL of RANKL (R) and 
200µg/mL of sEVs (E). Graphs show average fold change compared 
to control +SEM, n=3. Statistical significance assessed by Kruskal-
Wallis with Tukey test, *p<0.05, **p<0.01. 
A 
B 
O S C A R
R
e
la
ti
v
e
 E
x
p
r
e
s
s
io
n
 (


C
T
)
-R -E -R + E + R -E + R + E
0
1
2
3
5 0 0
1 0 0 0
1 5 0 0
**
T R A P
R
e
la
ti
v
e
 E
x
p
r
e
s
s
io
n
 (


C
T
)
-R -E -R + E + R -E + R + E
0
1
2
2 0
4 0
6 0
8 0
**
**
*
T R A P
R
e
la
ti
v
e
 E
x
p
r
e
s
s
io
n
 (


C
T
)
-R -E -R + E + R -E + R + E
0
1
2
2 0
4 0
6 0
8 0
**
**
Chapter VII: The Effects of PCa sEVs on Osteoclast Differentiation  
261 
 
 
 
 
 
 
 
 
 
 
 
 Figure 7.4: Morphology of RAW Cells Treated with RANKL/sEVs. 4x magnified brightfield images of RAW cells treated 
with 20ng/mL of RANKL and 200µg/mL of sEVs. Black arrows show fused, multinucleated, mature osteoclasts. Red arrow 
shows elongated cells, similar to those seen in RANKL treated cells. Scale bar: 500µm.  
-sEVs 
+sEVs 
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Figure 7.5: Cell Viability Assays on RANKL(R)/sEVs(E) Treated 
RAW Cells. CellToxGreen assay (A), H2O2 assay (B) and MTT assay 
(C) on RAW cells treated with 20ng/mL of RANKL (R) and 200µg/mL 
of sEVs (E). Graphs show average fold change compared to control 
+SEM, n=3. Statistical significance assessed by one-way ANOVA 
using a Holm-Sidak multiple comparisons test, **p<0.01, 
***p<0.001. 
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Figure 7.6: RANKL Expression in sEV Protein. Western blot of 
RANKL in PC3 sEV lysate (20µg).  
35kDa RANKL 
Ladder sEV Lysate 
Chapter VII: The Effects of PCa sEVs on Osteoclast Differentiation  
264 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Pit Formation Assay on RANKL and sEV Treated RAW Cells. Pit 
formation assay on RAW cells treated with 20ng/mL of RANKL and 200µg/mL of 
sEVs. (A) Control and sEV treated cells in the absence of RANKL. (B) Control and 
sEV treated cells with RANKL. (C) Average resorbed area of control and sEV 
treated cells with RANKL. Graphs show average +SEM, n=3. Statistical 
significance assessed by unpaired ttest, *p<0.05. 
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7.4 Discussion 
The balance of osteoclastic and osteoblastic activity in physiology is tightly regulated and is 
crucial for skeletal repair and mineral homeostasis. The dysregulation of this cycle leads to 
the osteoblastic and osteoclastic lesions seen in bone metastases. Therefore, after showing 
that PCa sEV communication drove osteoblastic differentiation, we looked to analyse the 
effects of this communication on osteoclasts in an osteoclast model system.  
RAW 264.7 cells were used to study osteoclast differentiation. Human and mouse osteoclast 
precursor cells such as macrophages or haematopoietic stem cells can be isolated from bone 
marrow or peripheral blood to study osteoclastogenesis (Cody et al., 2011; Iwaki et al., 2016; 
Susa et al., 2004). However, RAW cells are often favoured in osteoclast differentiation studies 
due to their ease of culture as well as their rapid and reproducible ability to differentiate. 
Furthermore, RAW cells can effectively differentiate in the absence of macrophage colony 
stimulating factor (M-CSF) (Vincent et al., 2009), allowing for treatments to be given with 
only RANKL, thus reducing the collateral cellular effects of additional differentiation 
supplements. RAW cells have previously been treated with exosomes from human cells 
including PC3 cells, and actually show markedly increased levels of PC3 exosome uptake 
compared to numerous human cell lines (Ferguson et al., 2018a).  
Osteoclast differentiation is easily characterised visually due to the obvious difference in 
morphology between osteoclast precursors, and the considerably larger, multinucleated 
mature osteoclasts. We saw that when RAW cells were treated with 25ng/mL RANKL, 
multiple multinucleated cells were visible with a vast cytoplasm, typical of mature 
osteoclasts (Quan et al., 2017). Whereas untreated cells remained small and circular, similar 
to cells in culture. However, untreated cells did show increased numbers, indicating their 
proliferation over the 8 day period.  
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As well as visual assessment of differentiation, genetic markers of osteoclast differentiation 
were also used. TRAP and OSCAR were the genetic markers used to determine osteoclast 
differentiation. TRAP and OSCAR are both expressed in mature cells of the osteoclast 
differentiation pathway but are both also present in macrophages (Doster et al., 2018; 
Sinningen et al., 2013). After 8 days of culture, the expression of TRAP and OSCAR increased 
in a dose dependant manner with RANKL treatment. This validates that RANKL treatment for 
8 days is able to induce differentiation of RAW cells, and suggests that induction of 
differentiation may be proportional to the dose of RANKL given. However, it has been shown 
that multinucleated osteoclast number doesn’t necessarily increase dose dependently with 
RANKL (Nguyen & Nohe, 2017; Song et al., 2018). In these studies, it was seen that mature 
osteoclast number shows no increase at doses of RANKL >10ng/mL and >30ng/mL 
respectively. Therefore, as it was unknown whether PC3 sEVs would inhibit or induce 
osteoclast differentiation, for experiments combining RANKL and sEVs, a dose of 20ng/mL 
RANKL was used.  
Addition of sEVs alone resulted in no increase in OSCAR or TRAP expression, suggesting sEVs 
alone may be ineffective at stimulating osteoclast differentiation at the high doses used in 
this study. Conversely, when sEVs were given with RANKL, an increase in OSCAR and TRAP 
expression was seen. Similar to results seen in osteoblast stimulation, this collectively 
suggested that sEVs are more effective at synergistically increasing differentiation of 
osteoclasts with the aid of RANKL, rather than initiating differentiation when given alone.  
Given the increase in OSCAR and TRAP expression seen in RAW cells treated with sEVs + 
RANKL, it was expected that these wells would feature at least as many multinucleated cells 
as those treated with RANKL. However, upon visual inspection, it was clear that cells treated 
with sEVs + RANKL had a much higher proportion of floating dead cells. Visual assessment of 
the cells confirmed a decrease in cell number, consistent with the increased floating cells. 
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Furthermore, the remaining cells showed no distinct differentiation, collectively indicating 
that a combination of RANKL and sEVs not only prevents differentiation, but may in fact 
trigger apoptosis and/or be cytotoxic. Interestingly, when given alone, sEVs appeared to be 
able to induce very mild differentiation characteristics in some osteoclasts. Although fused 
cells were not clearly visible, some cells appeared elongated. As some of the RANKL treated 
cells also appeared elongated, it is possible that this represents cells that may have begun 
differentiation but have yet to undergo cellular fusion.  
As it was now suggested that sEVs + RANKL may affect the health of the RAW cells as well as 
their ability differentiate, cell viability assays were performed. Cytotoxicity (in the form of 
dead cell quantification), cell stress (in the form of H2O2 production) and cell viability (in the 
form of cellular metabolism level) were all measured to help build a well-rounded idea of the 
combined effects of sEVs + RANKL.  
When treated with sEVs alone, RAW cells showed no increase in dead cell number, but did 
show both an increase in cell stress and a decrease in cell metabolism. Combined with qPCR 
of osteoclastic markers and brightfield images, the data suggests that sEVs alone are not able 
to induce cell death, but may decrease proliferation and partially induce differentiation.  
Treatment of cells with RANKL resulted in a significant increase in both cell death and cell 
stress, an unexpected result. However, links between osteoclast differentiation and 
accelerated cell death in vitro have been made. For example, Akchurin et al. (2008) showed 
that when stimulated with RANKL, RAW cells produced multinucleated osteoclasts in a 
cyclical manner, displaying peaks of multinucleated cell number, followed by an increase in 
apoptosis, which then repeated. Furthermore, Ikeda and Takeshita (2016) found that plating 
bone marrow macrophages at too high confluency resulted in accelerated osteoclast 
formation but subsequently an acceleration in osteoclast death. These results may explain 
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why an increase in cell death and cellular stress can be seen in differentiating RAW cells 
following treatment with RANKL.  
Treatment of RAW cells with sEVs + RANKL resulted in a significant increase in both cell death 
and cell stress compared to sEVs or RANKL alone. Given the results seen with RANKL alone, 
this would suggest either a further increase in differentiation or a genuine cytotoxic effect 
when combining both treatments. However, combining these results with images of sEV + 
RANKL treated cells, it is clear that treatment of RAW cells with sEVs + RANKL is cytotoxic 
and results in an increase in cell death. Nevertheless, given the links between differentiation 
of RAW cells and subsequent apoptosis of these cells, the use of further viability assays, 
potentially looking at different mechanisms of cell death, may be better at distinguishing 
between differentiation and cytotoxicity induced cell death.  
Although sEV + RANKL treated cells displayed increased cell death, the increased expression 
of osteoclast markers in these cells would suggest that, despite what microscopy images may 
show, the surviving cells may have differentiated to a greater extent. This would show a 
synergistic effect of treatment with sEVs + RANKL. We then showed that PC3 sEVs carried 
additional RANKL, which may be driving the increased expression of these osteoclastic 
markers, as human RANKL is shown to be functional in mice (Rinotas et al., 2014).  
However, although RANKL has been extensively linked with apoptosis of osteoclasts as well 
as their differentiation (Bharti & Aggarwal, 2004), this effect is not thought to be dose 
dependant. Therefore, the cytotoxic effect of sEVs + RANKL is likely not due to excess 
stimulation from both sEV and soluble RANKL. Instead, regulation of apoptosis by RANKL is 
controlled by a number of downstream signalling networks within the osteoclasts, such as 
the PI3K/Akt/mTOR and JNK pathways (Bharti & Aggarwal, 2004). For example, activation of 
JNK by RANKL signalling may induce apoptosis of osteoclasts through inhibition of anti-
apoptotic molecules such as B-cell lymphoma 2 (Bcl-2) (Maundrell et al., 1997) or activation 
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of apoptotic molecules such as BCL-2-interacting mediator of cell death-extra long (BimEL) 
(Whitfield et al., 2001).  sEVs from multiple cell types, including cancer cells, have been 
shown to activate JNK (Blackwell et al., 2017; Li et al., 2018b; Yoon et al., 2014). Therefore, 
it is possible that activation of JNK by sEVs, combined with RANKL treatment, may shift the 
RANKL signalling pathway in the favour of apoptosis over differentiation. However, 
significant further analysis of these signalling pathways and the downstream effects is 
required.  
Finally, the effect of these treatments on the overall function of RAW cells was tested. 
Corning® osteo assay plates are coated with a layer of “inorganic crystalline calcium 
phosphate coating that mimics living bone material”. Upon differentiation, mature 
multinucleated osteoclasts begin to resorb the calcium phosphate layer, which can then be 
visualised, aided by staining with ARS. We saw that without RANKL, both control and sEV 
treated RAW cells formed no pits, indicating that both treatments were ineffective at 
initiating osteoclastogenesis, at least to the point of mature osteoclast formation. This data 
matches earlier microscopy images which showed a lack of multinucleated cells in RAW cells 
treated with sEVs alone. Compared to RANKL treated cells, RANKL + sEV treated RAW cells 
displayed a significant decrease in activity. Total resorbed area was used to determine 
osteoclast activity. Also analysing pit number would give details as to the number of cells 
undergoing differentiation, as opposed to resorption area, which may be a combination of 
osteoclast number and activity. However, there were difficulties determining the number of 
individual pits due to the close proximity and fusion of pits, combined with their often 
irregular shape. ImageJ software was used to automatically determine resorbed area based 
on a colorimetric threshold, detecting pits based on their lighter appearance. Identical 
threshold values were used for all images, to reduce variability and bias.  
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To conclude, the data from this chapter indicates that when given in combination with 
RANKL, PC3 sEVs reduce the function of RAW cells and may in fact be cytotoxic. However, 
this treatment is also associated with an increase in the expression of osteoclastic markers. 
Thus, a number of cellular responses may be occurring. The cytotoxicity witnessed may be 
associated with an over-activation of the RAW cells, although this process that is as yet not 
documented. Conversely, there may be 2 signalling pathways initiated, one driving further 
osteoclast differentiation, potentially as a result of the sEV RANKL, and another initiating 
cytotoxic cell death, through JNK related pathways discussed previously. Overall, the 
osteoclastic function of RAW cells was attenuated by sEV treatment, indicating a push 
towards bone formation rather than resorption.  
7.5 Summary of Key Points 
sEVs were able to induce increased expression of the osteoclastic markers TRAP and OSCAR 
in RANKL treated RAW cells, suggesting a pro-osteoclastic effect. However, visual assessment 
showed an anti-osteoclastic, and potentially cytotoxic effect of this treatment. Cell viability 
assays also pointed towards a cytotoxic effect of RANKL + sEV treatment. Finally, overall it 
was shown that RANKL + sEV treatment resulted in a decrease in RAW cell function, assessed 
by the ability of these cells to resorb bone. 
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8 General Discussion 
Bone metastases are the most common form of secondary tumour associated with PCa. The 
development of secondary tumours is associated with markedly higher levels of morbidity 
and mortality compared to primary disease (Sieh et al., 2013; Tangen et al., 2003). Currently, 
treatment options for skeletal metastases are limited, with bisphosphonates and the anti-
RANKL antibody denosumab representing the best existing treatments, both acting to reduce 
osteoclast activity (Smith et al., 2015; Woodward & Coleman, 2010). Once the secondary 
tumour has seeded within the bone, growth of the tumour is accompanied by the 
development of either an osteolytic (most common with metastatic breast cancer) or 
osteoblastic (most common with metastatic PCa) lesion. These lesions reflect direct changes 
in the function of osteoblasts and osteoclasts, with the dominance of a particular cell type 
resulting in excess bone formation or degradation. Given the significant increase in morbidity 
and mortality with bone metastases vs primary disease, recent studies have focussed on 
gaining an understanding of both the spread of cells as well as the signalling pathways 
responsible for altered bone cell function.   
Molecular signalling between metastatic cancer cells and bone cells has been extensively 
examined. A number of well characterised signalling molecules have been implemented in 
both the function of bone cells and the development of the secondary tumour, such as TGF-
β, VEGF, MMPs, ET-1 and many more (Kingsley et al., 2007). However, the lack of available 
treatment options for metastatic bone disease reflects a difficulty in manipulating these 
pathways in order to produce a therapeutic benefit. miRNAs have been linked to several 
classic aspects of cancer development, such as proliferation and apoptosis (Hwang & 
Mendell, 2006). Furthermore miRNAs have been implemented in the metastasis of certain 
cancers (Peng & Croce, 2016). sEVs, including exosomes, are significant carriers of miRNAs 
and are involved in extensive signalling between both nearby and distant cells (Falcone et 
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al., 2015). These sEV miRNAs have been implicated in signalling between PCa cells and bone 
cells, resulting in changes in the function of these cells that may drive the development of 
osteolytic/osteoblastic lesions. For example, miR-141-3p from PCa sEVs was shown to 
increase osteoblast activity and induce osteoblastic lesion development in mice (Ye et al., 
2017). Furthermore, inhibiting miRNA activity using antisense oligos is cheap, specific and 
fast. Thus, miRNA based treatment options have significant potential.  
The aim for this study was therefore, to further analyse signalling between PCa cells and 
bone cells via miRNAs, especially those carried by sEVs. By examining this signalling using a 
variety of techniques such as next generation sequencing, the hope was to uncover new 
signalling pathways that may contribute to bone metastatic lesions.  
As bone metastases associated with PCa are predominantly osteoblastic, the primary focus 
of this study was the effect of PCa sEV miRNA signalling on osteoblastogenesis and the 
associated function of mature osteoblasts. Due to the complexity of in vivo models, and the 
lack of available clinical bone metastatic samples including cadaver-derived samples 
currently available at Cardiff University, an in vitro model was utilised.  Before testing the 
effects of PCa sEVs, a model of osteoblastic differentiation and function was first 
characterised. 7F2 mouse osteoblasts, treated with osteogenic media, showed reproducible 
differentiation, culminating in the deposition of hydroxyapatite (HA). Manipulation of this 
process is a commonly used to study osteoblast differentiation (Gharibi et al., 2016), with 
the level of HA deposition being an easily and reliably measurable end point. To add validity 
to the osteoblast differentiation model, the expression levels of key osteoblastic genes are 
often measured, in tandem with HA staining. Commonly used markers of osteoblast 
differentiation such as RUNX2 and ALP could not be reproducibly induced in mineralising 7F2 
cells in this study. However, 4 other genes, linked with osteogenesis were found to be 
differentially expressed in mineralising vs non-mineralising 7F2 cells, COL1A1, MMP3, DLX5 
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and ACVR1. Although we recognise that using mouse osteoblasts as a model of human bone 
metastases offers a degree of limitation, the ability of human PCa cell xenografts to readily 
form bone metastases in mice displays a commonality across these two species. Thus, the 
ease of handling of the 7F2 cell line, combined with its well documented reliable 
mineralisation (Gharibi et al., 2016) was favoured over a human cell line equivalent.         
The ability of PCa cells to induce increased osteoblastogenesis and osteoblast function is well 
documented (Logothetis & Lin, 2005). However, PC3 cells form primarily osteolytic lesions 
following metastasis (Dai et al., 2016), and have displayed an ability to reduce the 
mineralisation of BMSCs (Alsulaiman et al., 2016). Although sub clones of PC3 cell lines have 
been developed that induce mixed lesions, thus demonstrating that PC3 cells may have the 
potential to form more than just purely osteolytic lesions (Fradet et al., 2013), the finding 
that PC3 cells induced an increase in mineralisation in 7F2 cells was interesting. This 
induction of mineralisation was validated by an associated increase in osteoblast 
differentiation genes. These findings suggest that PC3 cells may have different effects on 
osteoblast differentiation depending on cell line. Furthermore, PC3 cells were shown to 
induce mineralisation of 7F2 cells to a greater extent than DU145 cells, and both induced 
mineralisation to a greater extent than LNCaP cells. Given the tendency of LNCaP cells to 
form mixed lesions, as opposed to the osteolytic lesions seen with PC3 and DU145 cells, this 
pattern of 7F2 cell mineralisation was surprising. Instead, based on these results, it would 
appear that induction of mineralisation in 7F2 cells is directly linked to the aggressiveness of 
the PCa cell line. As studies directly comparing the effects of various PCa cell lines on 7F2 
mineralisation are lacking, this finding may in fact be novel. Given the aggressiveness of PC3 
cells, combined with their ability to induce osteoblastogenesis, this cell line was further 
explored.  
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We hypothesised that exported miRNAs from PC3 cells may be involved in this pro-
osteoblastic signalling. The various routes of miRNA export, i.e. EVs, HDL molecules and 
argonaute proteins, are well characterised (Boon & Vickers, 2013), although the exact 
mechanisms that govern these pathways are still being widely explored. Therefore, 
confirmation that various miRNAs were significantly raised in PC3 cell conditioned media 
compared to regular FCS containing media was of little surprise. Differential centrifugation 
of PC3 cell conditioned media revealed that although most miRNAs are essentially soluble, 
and in association with small molecules, a fraction are likely associated with small EVs. This 
result mirrors findings from Dr Alwyn Dart, who showed, using size exclusion 
chromatography, that a larger portion of miRNA is either free in solution or associated with 
smaller molecules compared to those associated with EVs. 
sEV associated miRNAs are of great interest in the field of intercellular signalling due to their 
innate ability to protect their miRNA cargo from RNase activity (Koga et al., 2011), a major 
hurdle in long range RNA based signalling. Furthermore sEVs are shown to be enriched in 
miRNAs (Goldie et al., 2014) and are shown to selectively package miRNAs (Guduric-Fuchs et 
al., 2012), also displaying an ability to alter this selective packaging in diseased states (Skog 
et al., 2008). sEVs also display a more specialised RNA profile than lEVs (also well known for 
transporting miRNA), containing a greater proportion of small RNAs whilst being absent of 
rRNA (Crescitelli et al., 2013; Ji et al., 2014).  
We therefore looked to isolate PCa sEVs and determine their miRNA content. NGS is 
frequently used to assess sEV miRNA profiles due to its high resolution and quantitative 
nature (Liu et al., 2018; Rodriguez et al., 2017). Combining sequencing results from PC3 and 
DU145 cells allowed for comparisons of miRNA expression across two aggressive PCa cell 
lines. Furthermore, cellular miRNAs from these cell lines were also sequenced to give insight 
into the selective packaging that may be at play. A number of miRNAs appeared highly 
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expressed in both cell lines and their associated sEVs. Let-7a-5p, highly expressed in both cell 
lines and their sEVs, was shown to be overexpressed in PCa vs non-malignant samples by 
Kristensen et al. (2016), although in general, expression of let-7 miRNAs is reduced in many 
cancer types (Ghanbari et al., 2015). miR-16-5p, was also shown to be highly expressed in all 
samples, a surprising finding given that miR-16-5p is often quoted as a tumour suppressor, 
with overexpression resulting in reduced proliferation and invasion of cancer cells (Qu et al., 
2017; Zhang et al., 2018). The high expression of miR-221-3p seen in PC3 samples in this 
study is consistent with the findings of Galardi et al. (2007), which may reflect the 
proliferative effects of miR-221 targeting of p27Kip1 (le Sage et al., 2007).  
After validating miRNA sequencing results by qPCR, the levels of highly expressed miRNAs 
such as miR-16-5p and miR-221-3p as well as miRNAs that showed lower expression were 
compared between cancerous PC3/DU145 cells and non-cancerous PZ-HPV-7 cells. All cells 
showed higher expression of miR-16-5p and miR-221 compared to other miRNAs. miR-221 
levels were similar in DU145 and PZ-HPV-7 cells. However, high expression of miR-16-5p 
appeared to be exclusive to the cancerous cell lines. Hessvik et al. (2012) found miR-16 to be 
among the 20 highest expressed miRNAs in PC3 cells. However, miR-16 was not found to be 
in the 20 highest expressed miRNAs in sEVs. Li et al. (2016b) showed that miR-16-5p was 
highly expressed in drug resistant PC3 and DU145 cells compared to wild types. Furthermore, 
they showed that miR-16-5p was higher in drug resistant DU145 sEVs compared to wild type 
sEVs. This further indicates that miR-16-5p expression is correlated with aggressive PCa cells. 
The high expression of miR-16-5p in PCa cells, combined with the known tumour suppressive 
characteristics of miR-16, suggest that high expression of miR-16-5p may be crucial for other 
aspects of PCa development, such as intercellular signalling at primary or secondary sites. 
This would explain why miR-16-5p levels appear to be high in the sEVs isolated from these 
cell types. Additionally, the presence of certain tumour suppressor miRNAs in EVs has been 
hypothesised as a mechanism of reducing their cellular levels, thus increasing a cancer cells 
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survival (Ohshima et al., 2010). This may offer another explination as to the high levels of 
miR-16-5p in PC3 cell sEVs.  
sEV to cellular ratio calculations for each miRNA suggest that selective packaging may be at 
play for PC3 cells, with some miRNAs expressed at higher levels in sEVs than cells. DU145 
cells show a different packaging pattern, with most miRNAs showing decreased expression 
in sEVs compared to cells. This suggests that PC3 sEVs may have a more specialised miRNA 
cargo, and thus these sEVs may represent a greater intercellular signalling potential. 
Correlation analysis shows that sEV miRNA levels are linked to cellular concentrations, 
suggesting the process is likely mediated by both cellular concentrations and selective 
packaging of particular miRNAs. Interestingly, correlation analysis also demonstrated that 
DU145 cells likely have a less selectively packaged sEV miRNA transcriptome than PC3 cells, 
mirroring results from ratio analysis.  
Although sEVs have been shown previously to protect encapsulated, intraluminal RNA from 
RNase degradation (Koga et al., 2011), miRNAs within the PC3 sEVs in this study could not be 
considered as mediators of long range communication without first displaying an ability to 
survive in an environment displaying RNase activity. Therefore, by showing that PC3 sEV 
miRNAs were largely protected from RNase activity, we indicate their potential as long range 
communicators. The small loss of miRNA seen with RNase treatment likely represents 
miRNAs associated with the sEV surface, especially as sEVs were pre-treated with proteinase 
K. These extracellular miRNAs may produce slightly misleading data in experiments such as 
NGS, especially when combined with the potential for contamination of sEV samples with 
co-isolates. However, the lack of rRNA in our sEV samples is evidence of a high quality, 
acellular RNA isolation.  
Addition of PC3 sEVs augmented 7F2 mineralisation in osteogenic media, confirmed by 
changes in expression of osteogenic genes. It was then shown that sEVs also induce 
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differentiation in regular media, and are able to induce mineralisation in the presence of a 
phosphate source. The ability of sEVs from other PCa cell lines to induce changes in the 
differentiation and mineralisation of osteoblasts has been demonstrated (Xu et al., 2018a). 
Furthermore, MVs from PC3 cells can induce osteoblast differentiation (Itoh et al., 2012), 
indicating that PC3 cells may also have osteoblastic properties, despite their typical osteolytic 
presentation, further validating the osteoblastic nature of PC3 sEVs seen in this study.  
For a deeper understanding of the effects of sEV communication between PC3 and 7F2 cells, 
sEV treated 7F2 cells were sequenced for their transcriptome. sEVs were given alongside 
osteogenic supplements, thus detailing the role sEVs play in addition to regular 
mineralisation, in an attempt to more accurately mimic the conditions of a metastatic lesion. 
Pathway analysis revealed a number of bone related development and disorder pathways 
were affected by PC3 sEV treatment. Furthermore, a number of upstream regulators were 
implicated in the gene changes seen in sEV treated cells. Within these upstream regulators, 
7 miRNAs were determined to be involved in this communication, including miR-16-5p. Given 
the high expression of miR-16-5p in PC3 cells and sEVs, combined with literature evidence 
suggesting a correlation between miR-16-5p and PCa cell aggressiveness (Hessvik et al., 
2012; Li et al., 2016b), miR-16-5p was further explored as a mediator of sEV communication 
between PC3 and 7F2 cells. 
To validate the previous findings, we confirmed both delivery, and increased functionality of 
miR-16-5p in sEV treated 7F2 cells using qPCR and a miR-16-5p reporter. In an exciting and 
novel finding, transfection of miR-16-5p alone, resulting in an increase in intracellular 7F2 
miR-16-5p levels of 50%, was able to stimulate a significant increase in osteoblast 
differentiation. Although the change in mineralisation was mild, reflected by a change in only 
2 of the 4 osteoblast differentiation genes, this finding highlights a new way of inducing 
osteoblast differentiation, and therefore may hold clinical significance within the field of 
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bone metastasis as well as other skeletal related disorders such as osteoporosis. Describing 
a model in which transfection of a single miRNA can increase osteoblastic function has the 
potential to inspire a range of clinical therapeutic agents in this area. As discussed, the clinical 
application of miRNA inhibitors hold great potential. Already, clinical trials involving miRNA 
inhibitors for conditions such as T-cell lymphoma (Seto et al., 2018) and Hepatitis C infection 
(van der Ree et al., 2017) are underway. However, as stated, the change in osteoblast 
function with miR-16-5p transfection was mild compared to sEV treatment. It is therefore 
recognised that the remaining osteoblast inducing capability of sEVs is either caused by 
additional miRNAs or by non-miRNA based signalling. 
To further explore the mechanism(s) by which miR-16-5p induces osteoblast differentiation, 
we re-analysed the sEV treated 7F2 sequencing data, specifically looking for altered targets 
of miR-16-5p. 3 individual miRNA target databases were used to compile a representative 
list of sequenced miR-16-5p targets. From which 4 genes, related to osteoblast function, and 
significantly reduced by sEV treatment, were selected; DLL1, PLSCR4, ADRB2 and AXIN2.   
A successful reduction in the exzpression of these genes was then confirmed following 
treatment with miR-16-5p or PCE sEVS, thus validating their potential involvement in the 
associated osteoblastic signalling. We therefore looked to analyse the effects of the 
overexpression of these genes on 7F2 differentiation and mineralisation.  
AXIN2 knockout has previously been shown to rescue the loss in mineralisation of BMSCs 
from RUNX2+/- mice, but produced a mild and insignificant increase in mineralisation alone 
(McGee-Lawrence et al., 2013). This contradicts our own data from 7F2 cells, which indicates 
that AXIN2 may augment osteoblastogenesis. However, the effect of AXIN2 KO shown by 
McGee-Lawrence et al (2013) was linked to the expression of RUNX2. As discussed, during 
the characterisation of mineralising 7F2 cells, RUNX2 was not reliably increased during 
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differentiation. This may explain why AXIN2 appeared to have a different effect in 7F2 cells 
compared to the other osteoblasts where RUNX2 induction has been reliably confirmed.  
The varying expression patterns of PLSCR4 in osteoblastic vs non-osteoblastic osteosarcomas 
and high vs low bone forming hBMSCs, suggests a role of PLSCR4 in bone formation 
(Andersen et al., 2015; Kubista et al., 2011). However, the functional role of PLSCR4 
expression in osteoblasts is yet to be explored. We present novel data showing a significant 
reduction in 7F2 mineralisation following PLSCR4 overexpression.  
Although not validated by protein overexpression, transcript overexpression of DLL1 and 
ADRB2 also lead to a decrease in 7F2 mineralisation. DLL1 expression was previously linked 
to decreased osteoblast differentiation (Muguruma et al., 2017), and thus our findings agree 
with these results. ADRB2 expression has been linked to osteoblast proliferation (Fu et al., 
2005), which is tightly linked to subsequent differentiation. Thus, the reduction in 
mineralisation seen in ADRB2 overexpressing 7F2 cells may be the result of increased 
proliferation, subsequently reducing the differentiation potential of these cells. Ma et al. 
(2011) showed that increased ADRB2 expression in osteoblasts is linked to the catabolic bone 
effects of glucocorticoids, further showing the treatment with the β-blocker propranolol as 
well as glucocorticoids prevented the loss of bone in mice. Thus, our data, showing reduced 
mineralisation in ADRB2 overexpression osteoblasts, is in keeping with these results.  
The dynamic restructuring of bone is a process reliant on the function of multiple cell types, 
primarily osteoblasts and osteoclasts. The balance of this process, as well as its aberrance 
during metastatic lesion formation, crucially depends on the functionality of both cell types. 
Therefore, the effect of sEVs on osteoclasts was assessed to build a more complete picture 
of the effects of PCa sEV signalling within the bone microenvironment.  
PC3 sEVs in combination with RANKL appeared cytotoxic to RAW cells, with cellular assays 
confirming an increase in cell stress and death. This effect ultimately lead to a decrease in 
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osteoclast formation and function. Thus the effects of sEVs appear to be linked to the effects 
of RANKL signalling in these cells. It has been shown that RANKL can induce apoptosis of 
osteoclasts, as opposed to differentiation depending on downstream signalling cascades, 
including JNK activation (Maundrell et al., 1997; Whitfield et al., 2001). sEVs have also 
displayed an ability to activate JNK (Blackwell et al., 2017; Li et al., 2018b; Yoon et al., 2014), 
thus based on the current data, sEV activation of JNK coupled with RANKL signalling may shift 
signalling from pro-osteoclastic to apoptotic. Karlsson et al. (2016) also demonstrated that 
sEVs from murine TRAMP-C1 PCa cells with RANKL impaired the formation of mature 
osteoclasts from RAW cells, whereas fibroblast sEVs had no effect. However, the levels of 
apoptotic markers in these cells showed no change with sEV treatment, indicating the 
reduction of osteoclastogenesis was occurring via another mechanism. Though apoptosis 
markers are tested, the study makes no mention of witnessing cell death in sEV treated cells. 
Therefore the action of PCa sEVs from these cells may well be inhibitory, but does not negate 
that PC3 sEVs may induce apoptosis of RAW cells, although further testing of apoptotic 
markers and pathways is necessary.  
In conclusion, although further assessment of the effects of PC3 sEVs on bone cells, 
particularly osteoclasts, is required, the combined pro-osteoblastic and anti-osteoclastic 
nature of PC3 sEVs seen in this thesis mirrors the common osteoblastic presentation of PCa 
metastatic bone disease. We show that PC3 sEV miR-16-5p is able to induce mineralisation 
of 7F2 cells and highlight key gene targets that may effect this process (figure 8.1A). We then 
show that PC3 sEVs reduce the osteoclastogenic signalling of RANKL and may induce 
apoptosis in these cells (figure 8.1B). However, as PC3 cells form predominantly osteolytic 
metastatic lesions, further testing of sEVs from other PCa cell types on osteoblasts and 
osteoclasts may help to build a more substantial picture as to the effects of local sEV 
signalling between PCa and bone cells within a metastatic lesion. 
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Figure 8.1: Schematic Summary of the Thesis Findings. (A) sEVs from metastatic PCa tumours deliver miR-16-5p to osteoblast precursor cells, reducing 
their expression of PLSCR4, ADRB2 and DLL1, which contribute to increased osteoblast differentiation and mineralisation. (B) The same sEVs impair RANKL 
induced differentiation of osteoclast precursors, and may induce apoptosis in these cells. The overall effect of this pro-osteoblastic and anti-osteoclastic 
signalling suggests that PCa sEVs may contribute to the osteoblastic presentation of PCa metastatic bone lesions.  
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Future Work 
The findings of this project detail mechanisms by which PCa sEVs may induce 
osteoblastogenesis, as well as highlighting the effect of these same sEVs on 
osteoclastogenesis, thus highlighting a “double-pronged” effect in driving bone formation. 
Future work, following on from these findings, should focus on expanding these assays into 
an ex vivo bone model system, which would encompass the multiple PCa, osteoblast and 
osteoclast cell types and capitulate the full complexity and heterogeneity of cells in this 
specialised environment. It would also facilitate detailed examination of vesicle-mediated 
manipulation of the bone niche, prior to the physical landing and engraftment of metastatic 
cells. This represents an important area of metastasis requiring greater insight, as the effect 
of EVs on this process has shown recent promise (Peinado et al., 2012). This would build a 
more representative idea as to the effects of PCa sEV signalling within the metastatic lesion. 
Furthermore, specific findings within the project, such as the ability of miR-16-5p to induce 
osteoblast differentiation, and PCa sEVs to alter RANKL signalling in osteoclasts, should be 
further examined, and the relative importance of vesicles in this complex system should be 
established 
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Appendix figure 1: qPCR of additional genes for 7F2 characterisation (unused): (A) ALP 
expression, (B) BGLAP expression, (C) RUNX2 expression and (D) SP7 expression in cells 
treated with regular or osteogenic media over a 12 day period. (n=4) 
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